Novel inhibitors of potassium channels
By developing small-conductance calcium-activated potassium (SK) channel inhibitors, especially 2-aminobenzimidazole derivatives, the limitations of existing drugs in regulating cardiac electrical activity have been overcome, achieving effective treatment of arrhythmias.
Patent Information
- Application Number
- CN202280036734.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-03-22
- Filing Date
- 2022-03-17
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-03-17
AI Technical Summary
Existing antiarrhythmic drugs have limitations in regulating cardiac electrical activity and synchronizing myocardial cell contraction, especially in their insufficient regulation of small-conductance calcium-activated potassium (SK) channels, resulting in limited therapeutic effects for arrhythmias.
A class of inhibitors or negative regulators of low-conductivity calcium-activated potassium (SK) channels have been developed, specifically certain 2-aminobenzimidazole derivatives with IC50 values below 30 μM, suitable as pharmaceutical formulations for the treatment of heart disease and disorders.
These compounds exhibit significant pharmacological selectivity and in vivo absorption, effectively inhibiting SK channels and improving symptoms of arrhythmias, such as arrhythmias and atrial fibrillation, providing a more effective treatment option for arrhythmias.
Smart Images

Figure QLYQS_1 
Figure BDA0004560631960000031 
Figure BDA0004560631960000061
Abstract
Description
Technical Field
[0001] This invention relates to novel compounds, the use of said compounds as pharmaceuticals, and their use in the preparation of pharmaceuticals for treating heart diseases, disorders, or conditions in mammals. The invention also relates to pharmaceutical compositions comprising said novel compounds. Background Technology
[0002] The heart is a muscle that pumps circulating blood by contracting 1-3 times per second. The heartbeat is caused by the simultaneous contraction of individual cardiac muscle cells (cardiac myocytes). The synchronization of cell contractions is controlled by cardiac electrical impulses (cardiac action potentials), which are generated in the pacemaker cells of the sinoatrial node and rapidly propagate to the heart via a specific conduction system.
[0003] Disorders in pulse generation and conduction can result from illness, medication, or electrolyte imbalance. These pulse disturbances are called arrhythmias or rhythm disorders, and they can lead to anxiety, embolism, syncope, or sudden death. In its simplest form, arrhythmia includes everything that deviates from the normal sinus rhythm of the heart.
[0004] Disorders can range from simple palpitations to devastating ventricular fibrillation, including bradycardia and tachycardia.
[0005] At the molecular level, a group of proteins called ion channels are fundamental to cardiac electrical activity because they are able to conduct electrical currents across cell membranes. Therefore, different types of ion channels play a role in the generation and conduction of cardiac action potentials, the regulation of heart rate by the autonomic nervous system, and the contraction of individual heart cells. Consequently, different types of ion channels are obvious targets for antiarrhythmic cardiac drugs, and many antiarrhythmic drugs on the market do indeed exert their effects by interacting with ion channels.
[0006] According to the so-called Singh Vaughan-Williams classification, antiarrhythmic drugs are generally divided into four classes: Class I compounds all inhibit cardiac voltage-dependent sodium channels. Some Class I compounds do have additional effects affecting cardiac action potentials, which forms the basis for further subdivision into three subclasses:
[0007] Class IA compounds are sodium channel inhibitors, such as quinidine, procainamide, or disopyramid, which prolong the action potential;
[0008] Class IB compounds are sodium channel inhibitors, such as lidocaine, mexiletine, tocainide, or phenytoin, which shorten action potentials; and
[0009] Class IC compounds are sodium channel inhibitors, such as flecainide, moricizine, or propafenone, which do not alter the duration of action potentials.
[0010] Class I compounds interact with sodium channels in their open or inactive state and dissociate from the channels in their closed state (diastole). The dissociation rate determines whether they exhibit frequency-dependent channel inhibition. In addition to sodium channel inhibition, some Class I compounds also inhibit subtypes of potassium or calcium osmotic channels.
[0011] Class II compounds are β-adrenergic receptor inhibitors, including drugs such as atenolol, metoprolol, timolol, or propranolol. β-adrenergic receptor inhibitors are selective for cardiac β1 receptors, or have affinity for both β1 and β2 receptors. Some compounds also possess inherent β-stimulatory effects.
[0012] Class III compounds are potassium channel inhibitors, such as amiodarone, dronedarone, sotalol, ibutilide, and dofetilide, which prolong action potentials.
[0013] Class IV compounds are inhibitors of L-type calcium channels, such as verapamil.
[0014] Small-conductance calcium-activated potassium (SK) channels belong to the Ca2+ family. 2+ Activate K 2+ Channel family. Three SK channel isoforms have been cloned: SK1, SK2, and SK3 (corresponding to KCNN1-3 using genomic nomenclature). The activity of these channels is regulated by calmodulin based on free intracellular calcium ([Ca2+]). 2+ The concentration of [i] determines the constitutive binding of calmodulin to the channel. Within physiological limits, the SK channel is affected by [Ca]... 2+ The strict regulation of i, in [Ca 2+ It shuts down when i reaches approximately 0.1 μM, but in [Ca 2+Fully activated at 1 μM. Due to their potassium selectivity, open or activated SK channels have a hyperpolarizing effect on the cell membrane potential. SK channels are widely expressed in the central nervous system (CNS) and peripheral tissues, including the heart.
[0015] Activation of SK channels and hyperpolarization play a crucial role in controlling the firing patterns and excitability of excitable cells. SK channel inhibitors (such as apamin and N-methyl bicuculline) have been shown to increase excitability, while the SK channel opener 1-EBIO reduces electrical activity. In non-excitable cells, Ca2+ flows into cells via a voltage-independent pathway. 2+ The content is highly sensitive to membrane potential. Activation of SK channels will increase the driving force, while inhibition of SK channels will have a depolarizing effect, thereby reducing the driving force of calcium.
[0016] SK channel inhibitors are drugs that weaken potassium ions (K+). + ) via Ca 2+ Activated small conductance K + Channel conduction. This damage can be achieved through any decrease in current or a decrease in calcium sensitivity, any decrease in current due to, for example, direct inhibition of ion conduction to prevent Ca2+ conduction. 2+ This is a necessary requirement for channel activation.
[0017] For reviews of SK channels and SK channel modulators, please refer to the following literature: Wulff H et al.: "Modulators of Small-and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications", Current Medicinal Chemistry 2007 14 1437-1457; and Liegeois JF et al.: "Modulation of small conductance calcium-activated potassium (SK) channels: a new challenge in medicinal chemistry", Current Medicinal Chemistry 2003 10 625-647.
[0018] Based on the SK channel in connecting [Ca 2+Given their important role in membrane potential, SK channels are an interesting target for developing novel therapeutics, and the potential of SK channel inhibitors for antiarrhythmic therapy has been identified, see, for example, Nattel S; J. Physiol. 2009 587 1385-1386 (doi:10.1113 / jphysiol.2009.170621); Xiao-Yan Qi et al, Circulation 2014 28 430-440 (doi:10.1161 / CIRCULATIONAHA.113.003019); and Diness et al; Circ. Arrhythm. Electrophysiol. 2017 10 1-13 (doi:10.1161 / CIRCEP.117.005125).
[0019] WO 2006 / 013210 describes certain 2-aminobenzimidazole derivatives and their use as regulators of low-conductivity calcium-activated potassium channels. Summary of the Invention
[0020] Exemplary compounds of the present invention are inhibitors or negative regulators of low-conductivity calcium-activated potassium (SK) channels (particularly (SK3)) and are considered effective drug candidates with IC50 values below 30 μM, as demonstrated in the automated patch-clamp system described herein. Certain selections of these compounds exhibit significantly improved IC50 values below 1 μM. Some of these compounds also possess physicochemical properties suitable for pharmaceutical substances and important for the preparation of pharmaceutical formulations, and may have beneficial properties in terms of pharmacological selectivity, in vivo absorption / bioavailability, toxicity and safety characteristics, and manufacturability. Furthermore, some of these compounds possess pharmacokinetic properties that make them suitable for use as drugs.
[0021] In a broad sense, the present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof;
[0022]
[0023] in
[0024] A is a 5- or 6-membered aromatic heterocycle containing at least one nitrogen atom and optionally one sulfur atom and optionally one oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Substitution with at least one group selected from alkoxy, C1-6 alkylthio, and cyano;
[0025] R1 is selected from hydrogen and C. 1-6 alkyl;
[0026] Alternatively, A and R1, together with the nitrogen atom to which they are attached, form a 5-6 membered aromatic or non-aromatic heterocycle containing 1-2 nitrogen atoms, optionally 1 oxygen atom, and optionally 1 sulfur atom, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio, =NH, =O, -OH and cyano groups;
[0027] R2-R3 are independently selected from hydrogen and C. 1-6 Alkyl groups;
[0028] Or R2 and R3 together with the carbon atoms they are attached to form C 3-4 cycloalkyl;
[0029] R4-R6 are independently selected from hydrogen, halogens, and C. 1-4 Alkyl groups;
[0030] R7-R8 are independently selected from hydrogen, C 1-4 Alkyl group, C substituted with an OH group 1-4 Alkyl group, with an OC 1-3 Alkyl-substituted C 1-4 Alkyl groups, C substituted with at least one halogen 1-4 Groups in alkyl groups,
[0031] Or R7 and R8 together with the carbon atoms they are attached to form C 3-4 cycloalkyl;
[0032] R9-R13 are independently selected from hydrogen, halogens, and C atoms substituted with at least one halogen. 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 Groups in alkylthio and cyano groups.
[0033] In one embodiment, A is a 5-membered aromatic heterocycle containing 1-3 nitrogen atoms and optionally 1 oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 At least one of the groups selected from alkylthio and cyano is substituted.
[0034] In another embodiment, A is a 6-membered aromatic heterocycle containing 1-3 nitrogen atoms, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 At least one of the groups selected from alkylthio and cyano is substituted.
[0035] In another embodiment, A is selected from imidazole, pyrazol, oxazol, isoxazol, oxadiazol, and pyrimidinyl, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 At least one of the groups selected from alkylthio and cyano is substituted.
[0036] In a specific embodiment of the AN bond in a compound of Formula I, A comprises a carbon atom bonded to a N atom. Therefore, the case where A comprises nitrogen, oxygen, or sulfur bonded to N is excluded.
[0037] Furthermore, when a halogen is a substituent in ring A, it is attached to a carbon atom in ring A. Specifically, halogen substituents are not attached to a nitrogen atom in ring A.
[0038] In another embodiment, R1 is selected from hydrogen (H) and methyl, typically H.
[0039] In another embodiment, A and R1, together with the nitrogen atom to which they are attached, form a 5-membered aromatic or non-aromatic heterocycle containing 1-2 nitrogen atoms, optionally 1 oxygen atom, and optionally 1 sulfur atom, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio, =NH, OH, =O and cyano groups.
[0040] In another embodiment, A and R1, together with the nitrogen atom to which they are attached, form a 5-membered non-aromatic heterocycle containing one nitrogen atom and one oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6The alkylthio, =NH, -OH, =O and cyano groups are substituted. Typically, the 5-membered nonaromatic heterocycle is substituted with one, two or three groups selected from methyl and =NH, such as 2,3-dihydro-1,3-oxazol-2-imine optionally substituted with one or two methyl groups.
[0041] In another implementation, R2-R3 are independently selected from H and C. 1-3 The alkyl group typically has R2-R3 all being H. In another embodiment, R2 is H and R3 is C. 1-3 Alkyl groups, such as methyl groups.
[0042] In another embodiment, R2 and R3 together with the carbon atoms to which they are attached form a cyclopropyl group.
[0043] In another embodiment, R4-R6 are independently selected from H, F, Cl, and methyl groups, for example, R4-R6 are all H.
[0044] In yet another implementation, R7 is selected from H and C. 1-3 An alkyl group. Typically, R7 is H. In another embodiment, R7 is methyl.
[0045] In another implementation, R8 is selected from C 1-4 Alkyl group, C substituted with an OH group 1-4 Alkyl and by an OC 1-3 Alkyl-substituted C 1-4 An alkyl group. In one embodiment, R8 is CH2OH.
[0046] In another embodiment, R7 and R8 together with the carbon atoms to which they are attached form a cyclopropyl group.
[0047] In yet another embodiment, R9-R13 are independently selected from H, halogens, and C substituted with at least one halogen. 1-6 Alkyl groups and C groups substituted with at least one halogen 1-6 An alkoxy group.
[0048] In another embodiment, R9, R12, and R13 are all H, and R10-R11 are independently selected from H, halogens, and C substituted with at least one halogen. 1-6 Alkyl groups and C groups substituted with at least one halogen 1-6 An alkoxy group; provided that R10 and R11 are not both H.
[0049] In another embodiment, the compound of formula (I) is selected from any of the exemplary compounds of Examples 1-30b; or a pharmaceutically acceptable salt thereof.
[0050] In another embodiment, the compound of formula (I) is selected from any of the exemplary compounds of Examples 1-49b; or a pharmaceutically acceptable salt thereof.
[0051] In another aspect, the present invention relates to the use of compounds of formula (I) as defined above as pharmaceuticals.
[0052] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) as defined above and optional pharmaceutically acceptable additives, such as carriers or excipients.
[0053] In another aspect, the present invention relates to compounds of formula (I) as defined above, in methods of treating cardiac diseases, disorders, or conditions in mammals (e.g., humans). In one embodiment, the cardiac disease, disorder, or condition is selected from cardiac diseases, disorders, or conditions associated with arrhythmias or variations and exercise-induced angina. In another embodiment, the cardiac disease, disorder, or condition is selected from arrhythmias, atrial arrhythmias, ventricular arrhythmias, atrial fibrillation, ventricular fibrillation, tachyarrhythmias, atrial tachyarrhythmias, ventricular tachyarrhythmias, bradycardia, and arrhythmias occurring after cardiac surgery or cardiac ablation.
[0054] According to another aspect of this specification, a pharmaceutical composition is provided comprising a compound of formula (I) as defined herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0055] According to another aspect of this specification, a pharmaceutical composition is provided comprising a compound of formula (I) as defined herein or a pharmaceutically acceptable salt thereof, for treating cardiac disease, disorder, or condition in mammals (e.g., humans). In one embodiment, the cardiac disease, disorder, or condition is selected from cardiac diseases, disorders, or conditions associated with arrhythmias or variations and exercise-induced angina. In another embodiment, the cardiac disease, disorder, or condition is selected from arrhythmias, atrial arrhythmias, ventricular arrhythmias, atrial fibrillation, ventricular fibrillation, tachyarrhythmias, atrial tachyarrhythmias, ventricular tachyarrhythmias, bradycardia, and arrhythmias occurring after cardiac surgery or cardiac ablation.
[0056] According to another aspect of this specification, compounds of formula (I) as defined herein or pharmaceutically acceptable salts thereof are provided for use as medicines.
[0057] According to another aspect of this specification, compounds of formula (I) or pharmaceutically acceptable salts thereof for treatment are provided as defined herein.
[0058] According to another aspect of this specification, methods are provided for using compounds of formula (I) as defined herein or pharmaceutically acceptable salts thereof for therapeutic treatment of human or animal bodies.
[0059] According to another aspect of this specification, compounds of formula (I) as defined herein or pharmaceutically acceptable salts thereof are provided for the prevention or treatment of mammals (e.g., humans).
[0060] According to another aspect of this specification, the use of compounds of formula (I) as defined herein or pharmaceutically acceptable salts thereof in the preparation of medicaments for the prevention or treatment of mammals (e.g., humans) is provided.
[0061] According to another aspect of this specification, methods for preventing or treating cardiac diseases, disorders, or conditions in mammals (e.g., humans) are provided. In one embodiment, the cardiac disease, disorder, or condition is selected from cardiac diseases, disorders, or conditions associated with arrhythmias or variations and exercise-induced angina. In another embodiment, the cardiac disease, disorder, or condition is selected from arrhythmias, atrial arrhythmias, ventricular arrhythmias, atrial fibrillation, ventricular fibrillation, tachyarrhythmias, atrial tachyarrhythmias, ventricular tachyarrhythmias, bradycardia, and arrhythmias occurring after cardiac surgery or cardiac ablation in mammals (e.g., humans) requiring such treatment, said treatment comprising administering to said animal an effective dose of a compound of formula (I) as defined herein or a pharmaceutically acceptable salt thereof.
[0062] In another aspect, the present invention relates to a method of treating cardiac diseases, disorders, or conditions in mammals (e.g., humans), wherein a therapeutically effective dose of at least one compound of formula (I) as defined above is administered to the mammal requiring said treatment. In one embodiment, the cardiac disease, disorder, or condition in the mammal is selected from arrhythmias, atrial arrhythmias, ventricular arrhythmias, atrial fibrillation, ventricular fibrillation, tachyarrhythmias, atrial tachyarrhythmias, ventricular tachyarrhythmias, bradycardia, and arrhythmias occurring after cardiac surgery or cardiac ablation.
[0063] In another aspect, the present invention relates to a method for preparing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and intermediates, the method comprising the steps described in combination with reaction schemes 1-9. Detailed Implementation
[0064] In a broad sense, this invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof:
[0065]
[0066] A and R1-R13 are defined as above.
[0067] In some implementations, when C 1-6 Alkyl or C 1-6 When the alkoxy group is substituted with at least one halogen, this C is preferred. 1-6 Alkyl or C 1-6 The alkoxy group is replaced by one to three halogens, such as one to three F atoms, preferably CF3 and OCF3.
[0068] In another embodiment, A is selected from any one of pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, furazanyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, pyridinyl, diazinyl, pyridazinyl, triazinyl, and tetrazinyl.
[0069] In another implementation, A is selected from C. 1-6 The alkyl group is substituted with any one of the following: pyrrole, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, furazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyrimidinyl, pyridinyl, diazinyl, pyridazinyl, triazinyl, and tetraazinyl.
[0070] In one embodiment, A is a 5-membered aromatic heterocycle containing 1-2 nitrogen atoms and optionally 1 oxygen atom, such as imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, or oxadiazolyl.
[0071] In another embodiment, A is a 5-membered aromatic heterocycle containing 1-2 nitrogen atoms and optionally 1 oxygen atom, selected from 1 or 2 atoms selected from C. 1-6 Imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, and oxadiazolyl groups substituted with alkyl (e.g., methyl) groups.
[0072] In another embodiment, A is a 6-membered aromatic heterocycle containing 1-2 nitrogen atoms, such as pyrimidine.
[0073] In another embodiment, A is selected from at least one of C. 1-6Alkyl groups are substituted with imidazole, pyrazol, oxazol, isoxazol, oxadiazol, and pyrimidinyl groups.
[0074] In one embodiment, R1 is H. In another embodiment, R1 is methyl.
[0075] In another embodiment, A and R1, together with the nitrogen atom to which they are attached, form a 5-membered aromatic heterocycle containing 1-2 nitrogen atoms and 1 oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio, =NH, -OH, =O and cyano groups.
[0076] In another embodiment, A and R1 together with the nitrogen atom to which they are attached form a 5-membered aromatic heterocycle containing 2 nitrogen atoms, said heterocycle being substituted with a group selected from =O, for example 2,3-dihydro-1H-imidazol-2-one.
[0077] In another embodiment, A and R1 together with the nitrogen atom to which they are attached form a 5-membered aromatic heterocycle containing one nitrogen atom and one oxygen atom, the heterocycle being substituted with a group selected from =NH, for example 2-imino-2,3-dihydro-1,3-oxazol-3-yl.
[0078] In another embodiment, A and R1 together with the nitrogen atom to which they are attached form a 5-membered aromatic heterocycle containing one nitrogen atom and one sulfur atom, said heterocycle being substituted with a group selected from =NH, for example 2-imino-2,3-dihydro-1,3-thiazolyl.
[0079] In another embodiment, A and R1, together with the nitrogen atom to which they are attached, form a 5-membered non-aromatic heterocycle containing one nitrogen atom and one oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 The alkylthio, =NH, -OH; =O and cyano groups are substituted. Typically, the 5-membered nonaromatic heterocycle is substituted by one or more (e.g., 1-3) groups selected from methyl and =NH, such as 2,3-dihydro-1,3-oxazol-2-imine optionally substituted by one or two methyl groups.
[0080] In another embodiment, A and R1, together with the nitrogen atom to which they are attached, form a 5-membered non-aromatic heterocycle containing 1-2 nitrogen atoms and 1 oxygen atom, optionally selected from halogens, C1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 The groups in the alkylthio, =NH, -OH, =O, and cyano groups are substituted. Typically, the 5-membered non-aromatic heterocycle is substituted with one or more (e.g., 1-3) methyl groups and =NH groups.
[0081] In another embodiment, A and R1 together with the nitrogen atoms to which they are attached form a 5-membered non-aromatic heterocycle containing 2 nitrogen atoms, said heterocycle being substituted with =O and optionally a methyl group, such as imidazolidin-2-one or methylimidazolidin-2-one.
[0082] In another embodiment, A and R1 together with the nitrogen atom to which they are attached form a 5-membered non-aromatic heterocycle (substituted with =O) containing one nitrogen atom and one sulfur atom, for example, 1,3-thiazolidin-2-one.
[0083] In another embodiment, A and R1 together with the nitrogen atom to which they are attached form a 5-membered non-aromatic heterocycle containing one nitrogen atom (substituted with =O), for example, pyrrolidone-2-one.
[0084] In another embodiment, A and R1, together with the nitrogen atoms they are attached to, form a 6-membered aromatic heterocycle containing 1-2 nitrogen atoms, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl groups, halogenated C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio, =NH, -OH, =O and cyano groups.
[0085] In another embodiment, A and R1, together with the nitrogen atoms to which they are attached, form a 6-membered non-aromatic heterocycle containing 1-2 nitrogen atoms, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl groups, halogenated C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio, =NH, -OH, =O and cyano groups; for example, 3,4-dihydropyrimidine-4-imine.
[0086] In another implementation, R2 is selected from H and C. 1-3 Alkyl groups, such as H.
[0087] In yet another implementation, R3 is selected from H and C. 1-3Alkyl group, typically R3 is H. In one embodiment, R3 is methyl.
[0088] In another embodiment, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group. In another embodiment, R2 and R3 together with the carbon atom to which they are attached form a cyclobutyl group.
[0089] In yet another embodiment, R4 is selected from H, F, Cl, methyl, for example, H.
[0090] In another embodiment, R5 is selected from H, F, Cl, methyl, for example, H.
[0091] In yet another embodiment, R6 is selected from H, F, Cl, methyl, for example, H.
[0092] In another embodiment, R7 is H. In another embodiment, R7 is C. 1-3 Alkyl groups, such as methyl or ethyl.
[0093] In another implementation, R8 is C 1-4 Alkyl, for example, methyl.
[0094] In yet another implementation, R8 is a C substituted with an OH group. 1-4 Alkyl groups, such as CH2OH or CH2CH2OH.
[0095] In another implementation, R8 is controlled by an OC. 1-3 Alkyl-substituted C 1-4 Alkyl groups, such as C substituted with at least one methoxy or ethoxy group. 1-3 Alkyl groups, typically CH2OCH3 or CH2CH2OCH3.
[0096] In another embodiment, R7 and R8 together with the carbon atom to which they are attached form a cyclopropyl group. In another embodiment, R7 and R8 together with the carbon atom to which they are attached form a cyclobutyl group.
[0097] In yet another embodiment, R9 is H. In yet another embodiment, R9 is a halogen, such as F or Cl. In yet another embodiment, R9 is C substituted with at least one halogen. 1-6 Alkyl group, such as CF3. In another embodiment, R9 is a C group substituted with at least one halogen. 1-6 Alkyl groups, such as OCF3.
[0098] In yet another embodiment, R10 is a halogen, such as F or Cl. In another embodiment, R10 is H. In yet another embodiment, R10 is C substituted with at least one halogen. 1-6Alkyl group, such as CF3. In another embodiment, R10 is a C group substituted with at least one halogen. 1-6 Alkyl groups, such as OCF3.
[0099] In yet another embodiment, R11 is H. In another embodiment, R11 is a halogen, such as F or Cl. In yet another embodiment, R11 is C substituted with at least one halogen. 1-6 Alkyl, for example, CF3. In another embodiment, R11 is a C substituted with at least one halogen. 1-6 Alkyl groups, such as OCF3.
[0100] In yet another embodiment, R12 is H. In another embodiment, R12 is a halogen, such as F or Cl. In yet another embodiment, R12 is C substituted with at least one halogen. 1-6 Alkyl, for example, CF3. In another embodiment, R12 is a C substituted with at least one halogen. 1-6 Alkyl groups, such as OCF3.
[0101] In yet another embodiment, R13 is H. In another embodiment, R13 is a halogen, such as F or Cl. In yet another embodiment, R13 is C substituted with at least one halogen. 1-6 Alkyl, for example, CF3. In another embodiment, R13 is a C substituted with at least one halogen. 1-6 Alkyl groups, such as OCF3.
[0102] In another embodiment, R9, R12, and R13 are all H, and R10 is a C selected from halogens and substituted with at least one halogen. 1-6 Alkyl groups and C groups substituted with at least one halogen 1-6 The alkoxy group, R11 is selected from H, halogen, or C substituted with at least one halogen. 1-6 Alkyl groups and C groups substituted with at least one halogen 1-6 An alkoxy group.
[0103] In another embodiment, R9, R12, and R13 are all H, R10 is a group selected from F, Cl, CF3, and OCF3, and R11 is a group selected from H, F, Cl, CF3, and OCF3.
[0104] In another embodiment, R9, R10, R11, and R12 are each selected from H and halogens, and R13 is H. Preferably, R9, R10, R11, and R12 are each selected from H, Cl, and F, and R13 is H, provided that at least two of R9-R12 are halogens, such as halogens selected from F and Cl.
[0105] Each compound described in the experimental section constitutes an embodiment of the invention in any form, such as a salt or a free base, and protection may be claimed for such compound or its salt.
[0106] In yet another embodiment, the compound of formula (I) is selected from the trifluoroacetate of any of the compounds in Examples 1-30b.
[0107] In another embodiment, the compound of formula (I) is selected from the trifluoroacetate of any of the compounds in Examples 1-49b.
[0108] In yet another embodiment, the compound of formula (I) is selected from the trifluoroacetate of any of the compounds in Examples 31-49b.
[0109] heart disease
[0110] In the context of this invention, cardiac disease, disorder, or condition is any cardiac disease, disorder, or condition, including but not limited to arrhythmias or variations and exercise-induced angina.
[0111] In a more specific implementation, cardiac disease, disorder, or condition is any disease, disorder, or condition associated with abnormal or variable heart rhythms and exercise-induced angina.
[0112] In a more specific implementation, heart disease, disorder, or condition is any disease, disorder, or condition associated with an abnormal heart rhythm.
[0113] In a more specific implementation, the cardiac disease, disorder, or condition associated with arrhythmia is selected from arrhythmias, atrial arrhythmias, ventricular arrhythmias, atrial fibrillation, ventricular fibrillation, tachyarrhythmias, atrial tachyarrhythmias, ventricular tachyarrhythmias, and bradycardia.
[0114] In another embodiment, the heart disease, disorder, or ailment of the present invention is an arrhythmia caused by myocardial ischemia, myocardial infarction, cardiac hypertrophy, or cardiomyopathy.
[0115] In another embodiment, the cardiac disease, disorder, or symptom of the present invention is a rhythm abnormality that occurs after cardiac surgery or cardiac ablation.
[0116] In another specific implementation, the heart disease, disorder, or condition associated with the arrhythmia is an arrhythmia caused by a genetic disease.
[0117] In another preferred embodiment, the cardiac disease, disorder, or condition associated with the arrhythmia is arrhythmia.
[0118] In a preferred embodiment, the cardiac disease, disorder, or condition associated with the arrhythmia is atrial fibrillation.
[0119] In one specific embodiment, the compound of formula (I) of the present invention can be used to treat atrial fibrillation by acute cardiac cardioversion to normal sinus rhythm.
[0120] In another specific embodiment, the compound of formula (I) of the present invention can be used to treat atrial fibrillation by maintaining normal sinus rhythm and avoiding or reducing new episodes of atrial fibrillation.
[0121] Drug treatment for atrial fibrillation
[0122] In the context of this invention, as understood by those skilled in the art, treatment for atrial fibrillation is acute cardioversion or maintenance of sinus rhythm, or both. Acute cardioversion is defined as the application of a compound capable of converting atrial fibrillation to a normal sinus rhythm. A normal sinus rhythm is defined as a regular, stable heartbeat in an adult at rest with a normal frequency of 40 to 100 regular P waves on a standard 12-lead electrocardiogram. Maintaining sinus rhythm is defined as the ability of a compound to maintain a normal, stable sinus rhythm for a period of time without recurrence of atrial fibrillation, or the ability of a compound to significantly reduce the incidence of recurrence from atrial fibrillation to a normal sinus rhythm compared to an untreated control.
[0123] Overall Process Description
[0124] Schemes 1-9 summarize some synthetic methods that can be used to prepare compounds of general formula (I).
[0125] Option 1
[0126]
[0127] Option 1: A large number of ketones and aldehydes (1) are commercially available or readily prepared by many routes described in the literature. Ketones and aldehydes (1) can be converted into hydantoin derivatives (2) by various methods, such as reacting (1) with potassium cyanide in the presence of ammonium salts (such as ammonium carbonate), in solvents such as water and alcohols (such as ethanol), and under heating (50°C to 100°C). Hydantoin derivatives (2) can be hydrolyzed into amino acid derivatives (3) in the presence of strong bases (such as sodium hydroxide), in water, and under heating (100°C). Many other well-established methods for preparing amino acids are described in the literature. Many amino acid derivatives are also readily available commercially. Amino acids (3) can be protected as N-(tert-butoxy)carbonyl derivatives (4) by treatment with di-tert-butyl dicarbonate and a base (such as sodium bicarbonate) in a suitable solvent (e.g., tetrahydrofuran / water) at 0°C to ambient temperature. Intermediate (4) can be reduced to alcohol derivative (5) by a variety of methods, including by hydride reducing agents (e.g., sodium borohydride or lithium aluminum hydride). This can be achieved by directly reducing the acid group at ambient temperature (e.g., using lithium aluminum hydride (in a solvent such as tetrahydrofuran)) or by first converting (4) to a mixed anhydride (e.g., using isobutyl chloroformate and triethylamine in tetrahydrofuran) at 0°C, and then reducing it with sodium borohydride (e.g., in water) at 0°C to ambient temperature. Alcohol derivative (5) may require protection, for example, by reacting it with 2,2-dimethylpropionyl chloride and a base (e.g., triethylamine) to convert it to an ester (e.g., 2,2-dimethylpropionate) in a solvent (e.g., dichloromethane) at 0°C to ambient temperature. Intermediate (6) can be deprotected to an amine derivative (7) by treatment with an acid (e.g., hydrochloric acid or trifluoroacetic acid) in a suitable solvent (e.g., dioxane or dichloromethane) at 0°C to ambient temperature. Under the influence of an alkali (e.g., sodium bicarbonate) and at temperatures from 0°C to ambient, the intermediate (7) can be converted into an isothiocyanate derivative (8) by reacting it with sulfur phosgene in a suitable solvent (e.g., dichloromethane).
[0128] Option 2
[0129]
[0130] Scheme 2: Ketones and aldehydes (1) can be converted into sulfinamide derivatives (9) by reaction with 2-methylpropane-2-sulfinamide under the influence of Lewis acids (e.g., titanium ethoxide (IV)), in a suitable solvent (e.g., tetrahydrofuran) and at 70°C. Under the influence of zinc and copper iodide (I), in a solvent (e.g., tetrahydrofuran) at 0-5°C, sulfinamide derivatives (9) can be converted into β-amino acid esters (10) by reaction with methyl 2-bromoacetate. Many other well-established methods for preparing β-amino acids are also described in the literature. Some β-amino acid derivatives are also readily available commercially. β-amino acid esters (10) can be reduced to alcohol derivatives (11) by various methods, including reduction with a hydride reducing agent (e.g., lithium aluminum hydride) in a suitable solvent (e.g., tetrahydrofuran) at 0°C. The alcohol derivative (12) may require protection, for example, by reacting it with 2,2-dimethylpropionyl chloride and a base (e.g., triethylamine) at 0°C in a solvent (e.g., dichloromethane) to convert it into an ester (e.g., 2,2-dimethylpropionate). In a suitable solvent (e.g., dioxane or dichloromethane) at 0°C, the intermediate (12) can be deprotected by treatment with an acid (e.g., hydrochloric acid or trifluoroacetic acid) to obtain the free derivative (13). Under the influence of a base (e.g., sodium bicarbonate) at ambient temperature in a suitable solvent (e.g., dichloromethane), the intermediate (13) can be reacted with phosgene to convert it into an isothiocyanate derivative (14).
[0131] Option 3
[0132]
[0133] Option 3: At room temperature, in a solvent (e.g., acetonitrile), and under the influence of a metal oxide (e.g., silver oxide), the alcohol derivative (5) can be alkylated at the oxygen atom of the alcohol by reacting with methyl iodine, transforming it into intermediate (15). In a suitable solvent (e.g., dioxane or dichloromethane), at 0°C to ambient temperature, intermediate (15) can be deprotected by acid (e.g., hydrochloric acid or trifluoroacetic acid) to amine derivative (16). Under the influence of a base (e.g., sodium bicarbonate), in a suitable solvent (e.g., dichloromethane), at 0°C to ambient temperature, intermediate (16) can be reacted with phosgene to transform it into isothiocyanate derivative (17).
[0134] Option 4 (where R7 and R8 together form a small ring or R7 and R8 are H or alkyl groups)
[0135]
[0136] Option 4: There are many intermediates (18) that are readily available commercially or can be prepared by methods described in the literature. Under the influence of a base (e.g., sodium bicarbonate), at ambient temperature, and in a suitable solvent (e.g., dichloromethane), the intermediate (18) can react with phosgene to convert into an isothiocyanate derivative (19).
[0137] Option 5
[0138]
[0139] Option 5: There are many phenyl-1,2-diamine intermediates (20), which are readily available commercially or can be prepared by methods described in the literature. In pyridine (at temperatures from 0°C to 45°C), intermediate (20) can react with thionyl chloride to convert to a 2,1,3-benzothiadiazole derivative (21). Upon heating at reflux temperature, under the influence of a free radical initiator (e.g., benzoyl peroxide), intermediate (21) can be converted to a benzyl bromide derivative (22) by reaction with N-bromosuccinimide in a solvent (e.g., chloroform). Upon heating in a solvent (e.g., acetonitrile) at 60°C, intermediate (22) can react with various amino heterocycles to give intermediate (23). Upon desulfurization with hydrogen in a suitable solvent (e.g., methanol) at ambient temperature under the influence of a metal catalyst (e.g., ragnet), intermediate (23) can be converted to a phenyl-1,2-diamine derivative (24).
[0140] Option 6
[0141]
[0142] Option 6: In a suitable solvent (e.g., dioxane / water) at reflux temperature, intermediate (22) can be converted into an alcohol derivative (25) by reaction with a metal carbonate (e.g., potassium carbonate). At ambient temperature in a solvent (e.g., dichloromethane), alcohol derivative (25) can be oxidized to an aldehyde or ketone derivative (26) by an oxidant (e.g., Dess-Martin periodinane). At ambient temperature in a solvent (e.g., dichloromethane) under the influence of tetrabutylammonium tribromide, intermediate (26) can be protected as a 1,3-dioxolane-2-yl derivative (27) by reaction with 1,2-ethylene glycol.
[0143] At ambient temperature, in a suitable solvent (e.g., methanol), and under the influence of a metal catalyst (e.g., Ramane nickel), the intermediate (27) can be converted into a phenyl-1,2-diamine derivative (28) by desulfurization with hydrogen.
[0144] Option 7
[0145]
[0146] Scheme 7, Route 1 of Example (I): In a suitable solvent (e.g., dichloromethane) at ambient temperature, a benzene-1,2-diamine derivative (24) can be reacted with isothiocyanate (8) or (14) to give a mixture of thiourea products (29) and (30). Many other benzene-1,2-diamine derivatives are commercially available or readily prepared by well-established methods described in the literature (e.g., by nitration and subsequent reduction of commercially substituted benzene starting materials). Thiourea derivatives (29) and (30) can be converted to 2-aminobenzimidazole derivatives (31) by a cyclization reaction in the presence of iodoacetic acid at ambient temperature in a suitable solvent (e.g., methanol or acetonitrile). Cyclization of (29) and (30) to (31) can also be carried out in the presence of a mercury salt (e.g., mercuric oxide) in a suitable solvent (e.g., acetonitrile) under heating. 2-Aminobenzimidazole ester derivatives (31) can be converted into compounds of formula (I) by deprotection of the ester under the influence of a base (e.g., sodium hydroxide), in a suitable solvent (e.g., methanol), and at ambient temperature. The 2-aminobenzimidazole derivative of formula (I) can be a racemic mixture, which can be separated into two enantiomers A and B by a series of methods, including chromatography using a chiral stationary phase. This can be normal-phase or reversed-phase chromatography, using a suitable solvent mixture as eluent (e.g., chloroform, dichloromethane, ethanol, ethyl acetate, methanol, ethanol), and sometimes additives (e.g., ammonia, triethylamine, trifluoroacetic acid, acetic acid).
[0147] Option 8
[0148]
[0149] Scheme 8, Route 2 of Example (I): In a suitable solvent (e.g., dichloromethane) at ambient temperature, a benzene-1,2-diamine derivative (28) can be reacted with isothiocyanate (8) or (14) to give a mixture of thiourea products (32) and (33). Many other benzene-1,2-diamine derivatives are commercially available or readily prepared by well-established methods described in the literature (e.g., by nitration and subsequent reduction of commercially substituted benzene starting materials). Thiourea derivatives (32) and (33) can be converted to 2-aminobenzimidazole derivatives (34) by a cyclization reaction in the presence of iodoacetic acid at ambient temperature in a suitable solvent (e.g., methanol or acetonitrile). In a suitable solvent (e.g., acetone) at ambient temperature, intermediate (34) can be deprotected by reaction with an acid (e.g., p-toluenesulfonic acid) to yield ketone and aldehyde derivatives (35). Under the influence of a dehydrating agent (e.g., titanium isopropoxide (IV)) and under reflux, the derivative (35) can react with various amino heterocycles in tetrahydrofuran, and then, at ambient temperature, in tetrahydrofuran, with a reducing agent (e.g., sodium cyanoborohydride) to give intermediate (36). Under the influence of a base (e.g., sodium hydroxide) and in a suitable solvent (e.g., methanol) at ambient temperature, the 2-aminobenzimidazole ester derivative (36) can be converted to the compound of formula (I) by ester deprotection. The 2-aminobenzimidazole derivative of formula (I) can be a racemic mixture, which can be separated into two enantiomers A and B by a series of methods, including chromatography using a chiral stationary phase. This can be normal-phase or reversed-phase chromatography, which uses a suitable solvent mixture as eluent (e.g., chloroform, dichloromethane, ethanol, ethyl acetate, methanol, ethanol), and sometimes additives (e.g., ammonia, triethylamine, trifluoroacetic acid, acetic acid).
[0150] Option 9
[0151]
[0152] Scheme 9, Route 3 of Example (I): Benzene-1,2-diamine derivative (24) can be reacted with isothiocyanate (17) or (19) at ambient temperature in a suitable solvent (e.g., dichloromethane) to yield a mixture of thiourea products (37) and (38). Thiourea derivatives (37) and (38) can be converted to the 2-aminobenzimidazole derivative of formula (I) via a cyclization reaction under the influence of iodoacetic acid at ambient temperature in a suitable solvent (e.g., methanol or acetonitrile). The cyclization of (37) and (38) to the derivative of formula (I) can also be carried out under the influence of a mercury salt (e.g., mercuric oxide) in a suitable solvent (e.g., acetonitrile) and under heating. The 2-aminobenzimidazole derivative of formula (I) can be a racemic mixture that can be separated into two enantiomers A and B by a series of methods, including chromatography using a chiral stationary phase. This can be normal-phase or reversed-phase chromatography, which uses a suitable solvent mixture as an eluent (e.g., chloroform, dichloromethane, ethanol, ethyl acetate, methanol, ethanol), and sometimes additives (e.g., ammonia, triethylamine, trifluoroacetic acid, acetic acid).
[0153] Those skilled in the art will understand that it may be necessary to adjust or change the order of steps in the above methods, and such changes include aspects of the methods described in the above reaction scheme and accompanying method steps.
[0154] Furthermore, those skilled in the art will understand that the functional groups of the methods described above and the intermediate compounds described below may need to be protected by protecting groups.
[0155] The functional groups requiring protection include hydroxyl, amino, and carboxylic acids. Suitable hydroxyl protecting groups include optionally substituted and / or unsaturated alkyl groups (e.g., methyl, allyl, benzyl, or tert-butyl), trialkylsilyl or diarylalkylsilyl (e.g., tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or trimethylsilyl), AcO (acetoxy), TBS (tert-butyldimethylsilyl), TMS (trimethylsilyl), PMB (p-methoxybenzyl), and tetrahydropyranyl. Suitable carboxylic acid protecting groups include (C1-C6)-alkyl esters or benzyl esters. Suitable amino protecting groups include tert-butoxycarbonyl, benzyloxycarbonyl, 2-(trimethylsilyl)-ethoxy-methyl, or 2-trimethylsilylethoxycarbonyl (Teoc). Suitable S protecting groups include SC(=N)NH2, TIPS.
[0156] The protection and deprotection of functional groups can be performed before or after any of the reactions described above.
[0157] Furthermore, those skilled in the art will understand that, in order to obtain the compounds of the present invention in an alternative and, in some cases, more convenient manner, the various method steps mentioned above may be carried out in a different order, and / or the various reactions may be carried out at different stages of the entire route (i.e., substituents may be added to and / or chemically transformed to those different intermediates mentioned above associated with a particular reaction). This may negate the necessity of a protecting group, or make it necessary.
[0158] Compounds of formula (I) have at least one asymmetric center and may have additional asymmetric centers, and any optical isomers (i.e., enantiomers or diastereomers), in the form of isolated, pure, or partially purified optical isomers and any mixtures thereof (including racemic mixtures, i.e., mixtures of stereoisomers), are intended to be included within the scope of this invention. In particular, the carbon atom of formula (I), wherein four valence bonds are attached to R7, R8, NH, and phenyl, and is the asymmetric center that produces two optical isomers, the R-type and the S-type. In one embodiment, the compound of the present invention has the S-form. In another embodiment, the compound of the present invention has the R-form. In yet another embodiment, the compound of the present invention is a racemic mixture.
[0159] In this document, it should be understood that when an enantiomeric form is specified, the compound is in enantiomeric excess, for example, substantially pure monoenantiomeric form. Therefore, one embodiment of the invention relates to compounds of the invention in an enantiomeric excess of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, preferably at least 98%.
[0160] The racemic form can be resolved into optical enantiomers by known methods, such as by separating its diastereomer salts with an optically active acid and by releasing the optically active amine compound through treatment with a base. Another method for resolving the racemic form into optical enantiomers is chromatography based on an optically active matrix. The compounds of the present invention can also be resolved by forming diastereomer derivatives.
[0161] Other methods known to those skilled in the art for resolving optical isomers can be used. These methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions," John Wiley and Sons, New York (1981). Optically active compounds can also be prepared from optically active starting materials.
[0162] Furthermore, geometric isomers may form when double bonds or fully or partially saturated ring systems are present in the molecule. Any geometric isomer, such as isolated, pure, or partially purified geometric isomers or mixtures thereof, is intended to be included within the scope of this invention. Similarly, molecules with restricted rotational bonds can form geometric isomers. These are also intended to be included within the scope of this invention.
[0163] Furthermore, the compounds of general formula I of the present invention have a benzimidazole structure in the form of tautomers, and as used herein, all tautomers are included in the compounds of formula I, even if only one is shown.
[0164] The tautomer of equation (I) is:
[0165]
[0166] The benzimidazole tautomers of Formula I above refer to the back-and-forth conversion of hydrogen from one nitrogen atom to another, and the double bond thus converts back and forth between the nitrogen and carbon atom and the NH- group. Furthermore, when a structure is defined as benzimidazole as part of a general structure or as a separate specific compound, it should be understood that benzimidazole encompasses all tautomers; therefore, even if only one tautomer is shown, all tautomers are included.
[0167] Unless otherwise stated herein or clearly contradicted by the context, “compound of formula (I)” as used herein means any form of compound of formula (I), including its free form or salts, such as pharmaceutically acceptable salts.
[0168] Whenever a substituent is disclosed as R1-R13, it means that the individual and successive possibilities of each are disclosed; for example, R2-R4 represents R2, R3, and R4, and R9-R13 represents R9, R10, R11, R12, and R13. In another embodiment, compound I is in its free form. In one embodiment, the free form is an anhydrous compound. In another embodiment, the free form is a solvate, such as a hydrate.
[0169] In another embodiment, the compound is in crystalline form. Those skilled in the art can experiment to identify polymorphs, and such polymorphs are intended to be included in the term "crystalline form" as used herein.
[0170] When the compounds and pharmaceutical compositions disclosed herein are used for the above treatment, a therapeutically effective dose of at least one compound is administered to the mammal in need of the treatment.
[0171] As used herein, the term "free form" refers to the compound of formula (I), which, as the case may be, is a free base or a free acid, and not in the form of any salt.
[0172] The term "C" used in this article 1-x "Alkyl" refers to an alkyl group containing 1 to x carbon atoms, such as C 1-3 C 1-4 C 1-5 Or C 1-6 Examples include methyl, ethyl, propyl, butyl, pentyl, or hexyl, and also branched C. 3-6 Alkyl groups, such as isopropyl, isobutyl, tert-butyl, isopentyl, 3-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. When C 1-x Alkyl (e.g., C10) 1-6 When an alkyl group is replaced by a group (e.g., a halogen, such as F), it means that the F (e.g., 3F) is attached to one carbon (CF3), two carbons (CF2-CF), or even three carbons (CF-CF-CF).
[0173] The term "C" used in this article 1-x "alkylene" refers to an alkylene group containing 1 to x carbon atoms, such as C1. 1-3 C 1-4 C 1-5 Or C 1-6 Examples include methylene, ethylene, propylene, butylene, pentylene, or hexylene, and also branched C-terminals. 3-6 Alkylenes, such as isopropylene, isobutylene, tert-butylene, isopentene, 3-methylbutene, 2,2-dimethylpropene, n-hexene, 2-methylpentene, 2,2-dimethylbutene, and 2,3-dimethylbutene.
[0174] The term "C" used in this article 1-x "alkoxy" or "OC" 1-x Alkyl (used interchangeably) refers to an alkyl group containing 1 to x carbon atoms, where one oxygen atom is covalently attached, for example, C0. 1-5 Or C 1-6 For example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy, or hexoxy.
[0175] The term "C" used in this article 1-x "alkylthio" or "SC" 1-x Alkyl (used interchangeably) refers to an alkyl group containing 1 to x carbon atoms, where one sulfur atom is covalently attached, for example, C0. 1-5 Or C 1-6 For example, methylthio, ethylthio, and n-propylthio.
[0176] The term "C" used in this article 3-4 "Cycloalkyl" refers to a cyclic alkyl group containing 3-4 carbon atoms, such as cyclopropyl or cyclobutyl.
[0177] As used in this article, the term "CN" refers to a cyano or nitrile group (C and N linked by a triple bond).
[0178] The term "C substituted with at least one halogen" as used in this article 1-6 "Alkyl" refers to one or more halogen atoms as defined herein attached to a C atom as defined herein. 1-6 On one or more carbon atoms of an alkyl group, such as CHFCF3 or CF3.
[0179] The term "C substituted with at least one halogen" as used in this article 1-6 "Alkoxy" refers to one or more halogen atoms as defined herein attached to a C atom as defined herein. 1-6 On one or more carbon atoms of the alkoxy group, such as OCH2CHF2 or OCF3.
[0180] The term "C replaced by an OH group" is used in this article. 1-4 "alkyl" refers to an OH group connected to a C group as defined herein via an oxygen atom. 1-4 On a carbon atom of an alkyl group, for example, CH2OH, CH2CH2OH or CHOHCH3.
[0181] The term "by an OC" used in this article 1-3 Alkyl-substituted C 1-4 "alkyl" refers to an OC 1-3 Alkyl groups are attached to C as defined herein via oxygen. 1-4 On a carbon atom of an alkyl group, for example, CH2OCH3 or CH2CH2OCH3.
[0182] As used herein, the term "halogen" refers to an atom selected from chlorine (Cl), fluorine (F), iodine (I), and bromine (Br). When a halogen is disclosed in any embodiment herein, F or Cl is preferred.
[0183] As used herein, the term "a 5- or 6-membered aromatic heterocycle containing at least one nitrogen atom and optionally one oxygen atom and optionally one sulfur atom" refers to a chemically stable monoaromatic ring system containing at least one nitrogen atom, preferably 1-3 N atoms, no more than 5 carbon atoms, and may contain 1 oxygen atom and / or 1 sulfur atom, for example including but not limited to pyrrole, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, furazolyl, oxadiazolyl, thiazolyl, tetrazolyl, pyrimidinyl, pyridinyl, diazinyl, pyridazinyl, triazinyl, and tetraazinyl.
[0184] As used herein, the terms "treatment" and "treating" refer to the management and care of a patient in order to combat a condition (e.g., disease or disorder). The term is intended to encompass all treatment of a given condition, such as the administration of active compounds to alleviate symptoms or complications, slow the progression of the disease, disorder, or symptom, reduce or alleviate symptoms and complications, and / or cure or eliminate the disease, disorder, or symptom, as well as prevention of the condition, including the administration of active compounds to prevent the onset of symptoms or complications, where prevention should be understood as the management and care of the patient for the purpose of combating the disease, symptom, or disorder. Treatment can be administered in an acute or chronic manner. Patients to be treated are preferably mammals; particularly humans, but may also include animals such as dogs, cats, cattle, sheep, and pigs.
[0185] The term “pharmaceutically acceptable salt” as used herein is used to describe a salt suitable for use in humans or animals. A list of examples of pharmaceutically acceptable salts is provided in the Handbook of Pharmaceutical Salts: Properties, Selection and Use, PHStahl and CGWermuth, editors, Weinheim / Zurich: Wiley-VCH / VHCA, 2002. Pharmaceutically acceptable salts of compounds of formula (I) include salts formed in the human or animal body after the compound has been administered to the human or animal.
[0186] As used herein, the term "therapeutic effective dose" of the compound of formula (I) refers to an amount sufficient to cure, alleviate, or partially suppress the clinical manifestations of a given disease and its complications. A dose sufficient to achieve this purpose is defined as a "therapeutic effective dose." The effective dose for each purpose will depend on the severity of the disease or injury, as well as the subject's weight and overall condition. It should be understood that appropriate doses can be determined using routine experiments, by constructing a numerical matrix and testing the differences in the matrix, which falls within the general skill scope of an experienced physician or veterinarian.
[0187] In another aspect, the present invention relates to pharmaceutical compositions comprising a compound of formula (I) and optionally pharmaceutically acceptable additives, such as carriers or excipients. Generally, the present invention relates to pharmaceutical compositions comprising a compound of formula (I) and pharmaceutically acceptable additives (e.g., carriers or excipients).
[0188] The term "pharmaceuticalally acceptable additives" as used herein includes, but is not limited to, carriers, excipients, diluents, adjuvants, colorants, flavorings, and preservatives. Those skilled in the art will consider using these additives when formulating the compounds of this invention to prepare pharmaceutical compositions.
[0189] The adjuvants, diluents, excipients, and / or carriers that can be used in the compositions of the present invention must be pharmaceutically acceptable, i.e., compatible with the compound of formula (I) and other components of the pharmaceutical composition, and harmless to the recipient. Preferably, the composition should not contain any substances that may cause adverse reactions (e.g., allergic reactions). The adjuvants, diluents, excipients, and carriers that can be used in the pharmaceutical compositions of the present invention are well known to those skilled in the art.
[0190] As described above, in addition to the compounds disclosed herein, the compositions disclosed herein, especially pharmaceutical compositions, may also contain at least one pharmaceutically acceptable adjuvant, diluent, excipient, and / or carrier. In some embodiments, the pharmaceutical composition comprises 1 to 99% by weight of the at least one pharmaceutically acceptable adjuvant, diluent, excipient, and / or carrier, and 1 to 99% by weight of the compounds disclosed herein. The total amount of the active ingredient and the pharmaceutically acceptable adjuvant, diluent, excipient, and / or carrier does not exceed 100% by weight of the composition, particularly the pharmaceutical composition.
[0191] In some implementations, only one compound disclosed herein is used for the above purposes.
[0192] In some embodiments, two or more compounds disclosed herein are combined for the above-described purposes.
[0193] The compositions, particularly pharmaceutical compositions comprising the compounds described herein, are suitable for oral, intravenous, topical, intraperitoneal, intranasal, oral, sublingual, or subcutaneous administration, or for administration via the respiratory tract, for example, in the form of aerosols or air-suspended fine powders. Therefore, the pharmaceutical compositions may be in the form of, for example, tablets, capsules, powders, nanoparticles, crystals, amorphous substances, solutions, transdermal patches, or suppositories.
[0194] Other implementations of the method are described in the experimental section of this paper, and each individual method and each starting material constitutes an implementation that can form part of the implementation.
[0195] The above embodiments should be considered as relating to any aspect described herein (e.g., "treatment method", "pharmaceutical composition", "compound used as a medicine" or "compound used in a method"), and any embodiment described herein, unless specifically stated that the embodiments relate to one or more aspects of the invention.
[0196] All references cited in this article, including publications, patent applications and patents, are incorporated herein by reference as if each reference were individually and specifically indicated as incorporated herein by reference and fully elaborated upon herein.
[0197] All headings and subheadings used herein are for convenience only and should not be construed as limiting the invention in any way.
[0198] This invention includes any combination of all possible variations of the above elements, unless otherwise stated herein or clearly contradicted by the context.
[0199] The terms “a,” “an,” and “the,” as used in the context of describing this invention, and similar designations, shall be interpreted to cover both the singular and the plural, unless otherwise stated herein or clearly contradicted by the context.
[0200] Unless otherwise stated herein, the descriptions of numerical ranges herein are intended only as a shorthand for individually referring to each individual value falling within the range, and each individual value is incorporated into the specification as if it were described separately herein. Unless otherwise stated, all precise values provided herein represent corresponding approximations (e.g., all precise exemplary values provided with respect to a particular factor or measurement may also be considered as providing corresponding approximate measurements, modified with "about" where appropriate).
[0201] Unless otherwise stated in this document or clearly contradicted by the context, all methods described herein may be performed in any suitable order.
[0202] Unless otherwise stated, the use of any and all instances or exemplary language (e.g., “for example”) provided herein is merely for the purpose of better illustrating the invention and does not constitute a limitation on the scope of the invention. No language in the specification should be construed as indicating that any element is essential to the implementation of the invention unless equally expressly stated otherwise.
[0203] The patent documents cited and incorporated in this article are for convenience only and do not reflect any opinion on the validity, patentability and / or enforceability of these patent documents.
[0204] In the description of any aspect or embodiment of the invention, terms such as “comprising,” “having,” “including,” or “containing” are used to refer to one or more elements, intended to support similar aspects or embodiments of the invention, namely “composed of a particular element,” “consistently composed of a particular element,” or “substantially comprising” that particular element, unless otherwise stated or obviously contradicted by the context (e.g., a composition described herein as comprising a particular element should be understood to also describe a composition composed of that element, unless otherwise stated or obviously contradicted by the context).
[0205] To the fullest extent permitted by applicable law, this invention includes all modifications and equivalents of the subject matter set forth herein or in the claims.
[0206] The present invention is further illustrated by the following embodiments; however, these embodiments should not be construed as limiting the scope of protection. The features disclosed in the foregoing description and the embodiments below, whether individually or in any combination, are important for implementing the invention in different forms.
[0207] Experimental Procedure
[0208] Automatic Patch Clamp
[0209] The human SK3 channel (hK) was stably expressed using the QPatch 16HT system and single-well Qplates (Sophion, Denmark). Ca 2.3) Automated whole-cell patch-clamp recording was performed on HEK-293 cells. Cells were cultured and prepared for experiments using standard cell culture procedures. A total of 4-5 million cells were used per experiment. Qpatch automatically generated gigabyte seals, whole-cell formation, compound application, and current recording. In symmetrical K... + Record hK in solution Ca 2.3 Current. The intracellular / pipette solution contained 154 mM KCl, 10 mM HEPES, and 10 mM EGTA. CaCl2 was added... 2+ The free concentration was calculated to be 0.4 μM; after adding MgCl2, the free concentration was calculated to be 1 mM. To maintain the total [K]... + The concentration was 156 mM (corresponding to the concentration in the extracellular Ringer), and a fixed amount of KOH (15 mM) was added, followed by pH adjustment to 7.2 with HCl. Expected osmolarity: 275 mOsm. Sucrose was added until the final osmolarity was approximately 295 mosm. The extracellular solution consisted of the following (mM): CaCl₂ 0.1, MgCl₂ 3, KCl 150, HEPES 10, and glucose 10, adjusted to pH 7.4 with KOH. The osmolarity was between 285 and 295 mosm. Cells were maintained at 0 mV, and a linear voltage ramp from -80 MV to +80 mV was applied every 5 seconds (duration 200 ms) to induce hK. Ca 2.3 Current.
[0210] The compound application protocol consists of 12 recording cycles lasting 200 seconds: 1) Record the extracellular solution baseline; 2) Apply the positive control N-methylpastoside (100 μM), which is characterized by its high potency and rapid on / off rate; 3-4) Elute; 5-10) Increase the concentration of the test compound to establish the IC50 value; 11-12) Elute; 13) Use compound NS8593 (N-[(1R)-1,2,3,4-tetrahydro-1-naphthyl]-1H-benzimidazole-2-amine) (1M) or the positive control N-methylpastoside (100 μM).
[0211] Data was sampled at 10 kHz using a 4th-order Bessel filter with a cutoff frequency of 3 kHz. Current compensation was applied to mitigate the drop in current. The effectiveness was quantified as the concentration required to suppress half the activity of the SK channels and reported as IC50 values.
[0212] All effects of the tested compounds of the present invention were normalized relative to the observed inhibitory effect of N-methylpalmitin. Current was measured at -80 mV.
[0213] result
[0214] The embodiments described above are all effective inhibitors of the SK3 channel, and they demonstrated the following IC in the aforementioned automated patch-clamp experiments. 50 :
[0215] Examples: 1, 3b, 6, 8b, 10, 11, 12b, 14, 15, 16, 17, 18b, 19b, 21, 22, 24a, 25, 26, 27b, 28, 31, 33, 34, 35, 36, 37, 38, 39b, 40a, 40b, 41b, 42a, 42b, 43a, 43b, 44a, 44b, 45b, 46a, 46b, 47b, 48a, 48b, 49a, and 49b all have ICs below 30μM. 50 .
[0216] Examples: 2, 3, 3a, 4, 5, 7, 8, 8a, 9, 12, 12a, 13, 13a, 13b, 18, 18a, 19, 19a, 20, 23, 23a, 23b, 24, 24b, 27, 27a, 29, 30, 30a, 30b, 32, 32a, 32b, 39a, 41a, 45a, and 47a all have IC values below 1 μM. 50 .
[0217] Materials and methods
[0218] Unless otherwise specified, use commercially available reagents; no further purification is required. Store in silica gel at 60-F. 254TLC analysis was performed on a Merck spectrometer, with detection by fluorescence and immersion in KMnO4 solution (KMnO4 solution formulation: 1.5 g KMnO4, 10 g K2CO3, and 1.25 mL 10% NaOH dissolved in 200 mL water), followed by carbonization. The compound was purified by column chromatography on silica gel (60-120 mesh, Swambe Chemicals, India). NMR was performed at ambient temperature using a Bruker AV 400 MHz spectrometer (400 MHz for...) using deuterated DMSO-d6, CDCl3, CD3CO2D (AcOH-d4), or CD3OD as solvents. 1 H, 100MHz is used for 13 C) Record NMR spectra, for example 1 H, 13 C and 2D COSY. Chemical shifts are reported as δ (ppm). ESI-MS was recorded on an Agilent LC1200 Series MS single quadrupole 6130 mass spectrometer.
[0219] Abbreviations used in the experimental section:
[0220] BOP = hexafluorophosphate (benzotriazol-1-yloxy)tris(dimethylamino)phosphine
[0221] PyBOP = Hexafluorophosphate (benzotriazol-1-yloxy)tripyrrolidinylphosphide
[0222] EDC.HCl = N-(3-Dimethylaminopropyl)-N′-Ethylcarbodiimide hydrochloride
[0223] HBTU = N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)urea hexafluorophosphate.
[0224] DCM = dichloromethane; DMF = N,N-dimethylformamide; TEA = triethylamine
[0225] TFA = trifluoroacetic acid; Boc-anhydride = di-tert-butyl dicarbonate; THF = tetrahydrofuran; t-BuOH = 2-methylpropane-2-ol; DEA = diethylamine; DIEA = ethylbis(propane-2-yl)amine; IPA = propylene glycol; Pd / C = palladium on carbon; RT = ambient temperature; MeOH = methanol.
[0226] Grace rapid chromatography system:
[0227] Grace Prep purification system (Grace) The Prep Purification System is used for sample purification via rapid chromatography, utilizing a pre-packed silica gel column.
[0228] Columns used:
[0229] High-purity, high-speed silica gel column (normal phase);
[0230] 12g, 60A, maximum pressure 350 psi (24 bar),
[0231] 24g, 60A, maximum pressure 350 psi (24 bar),
[0232] 40g, 60A, maximum pressure 350 psi (24 bar),
[0233] 80g, 60A, maximum pressure 350 psi (24 bar).
[0234] Solvents: hexane, EtOAc, CHCl3, and MeOH.
[0235] Example 1:
[0236] N-[1-(3-chlorophenyl)cyclopropyl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0237]
[0238] Example 1, Step 1: Preparation of 1-chloro-3-(1-isothiocyanocyclopropyl)benzene
[0239]
[0240] Add 10% sodium bicarbonate solution (50 mL) to an ice-cold solution of 1-(3-chlorophenyl)cyclopropaneamine (commercially available) (1.00 g, 5.97 mmol) in dichloromethane (50 mL), then add phosgene (1.14 mL, d = 1.50 g / cm³). 3 The mixture was stirred at ambient temperature for 30 min (14.90 mmol). The organic layer was separated, washed with brine (15 mL), dried over sodium sulfate, filtered and concentrated to give a pale yellow liquid 1-chloro-3-(1-isothiocyanocyclopropyl)benzene (1.00 g), which could be used in the next step without further purification.
[0241] 1 H NMR (400MHz, DMSO-d6) δ7.44(s,1H),7.39(d,J=8.00Hz,1H),7.34(t,J=7.20H z, 1H), 7.31 (d, J = 7.60Hz, 1H), 1.67 (t, J = 4.80Hz, 2H), 1.51 (t, J = 6.00Hz, 2H).
[0242] Example 1, Step 2: Preparation of 4-methyl-2,1,3-benzothiadiazole
[0243]
[0244] At 0℃, thionyl chloride (500.0 mL, d = 1.64 g / cm³) was added over a 60-minute period. 3 3-Methylphenyl-1,2-diamine (commercially available) (330.0 g, 2700.0 mmol) was added dropwise to a solution of 3-methylphenyl-1,2-diamine (commercially available) (330.0 g, 2700.0 mmol) in anhydrous pyridine (1800 mL). During the addition, the internal temperature was kept below 45 °C, and the reaction mixture was stirred at ambient temperature for 3 h. The reaction mixture was quenched by adding concentrated hydrochloric acid (1300 mL) dropwise until the pH of the reaction was adjusted to between pH 2 and 3, during which the internal temperature was kept below 65 °C. The reaction mixture was diluted with water (1500 mL) and ethyl acetate (2000 mL) and stirred for 2 h. The organic layer was then separated by filtration through a diatomaceous earth bed, and the aqueous layer was further extracted with ethyl acetate (3 × 1500 mL). The combined organic layers were washed with a brine solution (300 mL), dried over sodium sulfate, filtered, and concentrated to give a brown liquid, 4-methyl-2,1,3-benzothiadiazole (380.0 g), which could be used in the next step without further purification.
[0245] 1 H NMR (400MHz, DMSO-d6) δ7.90(d,J=8.80Hz,1H),7.61(t,J=8.80Hz,1H),7.51(d,J=6.80Hz,1H),2.69(s,3H);
[0246] MS: m / z 151.2 (M+1).
[0247] Example 1, Step 3: Preparation of 4-(bromomethyl)-2,1,3-benzothiadiazole
[0248]
[0249] Under a nitrogen atmosphere, benzoyl peroxide (3.23 g, 13.30 mmol) was added to a stirred solution of 4-methyl-2,1,3-benzothiadiazole (from Example 1, Step 2) (100.0 g, 666.0 mmol) in anhydrous chloroform (1200 mL), followed by N-bromosuccinimide (118.0 g, 666.0 mmol). The reaction mixture was refluxed for 28 h. The reaction mixture was cooled, and the succinimide solidified and was removed by filtration. The filtrate was concentrated to give a brown semi-solid crude substance (170.0 g), which was dissolved in methanol (1000 mL) and stirred for 30 min. The solid was filtered and dried under high vacuum to give a yellow solid of 4-(bromomethyl)-2,1,3-benzothiadiazole (110.0 g), which could be used in the next step without further purification.
[0250] 1 H NMR (400MHz, DMSO-d6) δ8.09 (d, J = 8.60 Hz, 1H), 7.87 (d, J = 8.80 Hz, 1H), 7.71 (t, J = 8.40 Hz, 1H), 5.13 (s, 2H).
[0251] Example 1, Step 4: Preparation of 3-[(2,1,3-benzothiadiazol-4-yl)methyl]2,3-dihydro-1,3-oxazol-2-imine hydrobromide
[0252]
[0253] 2-aminooxazole (22.00 g, 262.00 mmol) was added to a solution of 4-(bromomethyl)-2,1,3-benzothiadiazole (Example 1, Step 3) (30.00 g, 131.00 mmol) in acetonitrile (300 mL), and the mixture was stirred at 60 °C for 16 h. The solid formed in the reaction mixture was filtered and dried to give a crude substance (33.00 g) of a grayish-white solid. It was dissolved in a mixture of acetonitrile and water (1:1; 60 mL), and the solvent volume was reduced to about 40 mL at 40 °C and kept overnight at ambient temperature. The resulting crystals were filtered and dried under high vacuum at 40 °C to give a grayish-white solid 3-[(2,1,3-benzothiadiazole-4-yl)methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide (21.00 g).
[0254] 1H NMR (400MHz, DMSO-d6) δ9.86 (bs, 2H), 8.13 (d, J = 8.40Hz, 1H), 7.93 (d, J = 2.00Hz, 1H) ,7.77(t,J=9.20Hz,1H),7.69(d,J=9.20Hz,1H),7.60(d,J=2.40Hz,1H),5.62(s,2H);
[0255] MS: m / z 233.2 [(M+1)-HBr].
[0256] Example 1, Step 5: Preparation of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine
[0257]
[0258] To a degassed solution of 3-[(2,1,3-benzothiadiazol-4-yl)methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide (from Example 1, Step 4) (12.00 g, 38.34 mmol) in anhydrous methanol (1200 mL), 36.00 g of riconene nickel (300% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was subjected to a hydrogen atmosphere and a pressure of approximately 1.5 kg / cm². 2 The mixture was stirred at ambient temperature for 24 h. The reaction mixture was filtered through a diatomaceous earth bed, which was then washed with methanol (1000 mL). The combined filtrates were concentrated to give a gray colloidal substance, 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (10.00 g), which could be used in the next step without further purification.
[0259] MS: m / z 205.2(M+1).
[0260] Example 1, Step 6: Preparation of 1-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-3-[1-(3-chlorophenyl)cyclopropyl]thiourea and 1-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-3-[1-(3-chlorophenyl)cyclopropyl]thiourea (a mixture of regioisomers)
[0261]
[0262] 1-Chloro-3-(1-isothiocyanocyclopropyl)benzene (from Example 1, Step 1) (0.200 g, 0.954 mmol) was added to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, Step 5) (0.192 g, 0.954 mmol) in a dichloromethane:methanol (4:1; 10 mL) mixture, and the mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated in a water bath at 30°C to give a yellow gel-like substance 1-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-3-[1-(3-chlorophenyl)cyclopropyl]thiourea and 1-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-3-[1-(3-chlorophenyl)cyclopropyl]thiourea (as a mixture of inseparable regioisomers) (0.395 g), which can be used in the next step without further purification.
[0263] MS: m / z 414.1(M+1).
[0264] Example 1: N-[1-(3-chlorophenyl)cyclopropyl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0265]
[0266] Iodoacetic acid (0.274 g, 1.45 mmol) was added to a solution of 1-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-3-[1-(3-chlorophenyl)cyclopropyl]thiourea and 1-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-3-[1-(3-chlorophenyl)cyclopropyl]thiourea (as a mixture of inseparable regioisomers) (from Example 1, Step 6) (0.390 g, 0.660 mmol). The mixture was stirred at 65 °C for 1 h. The reaction mixture was concentrated at 30°C to remove the solvent methanol, yielding a crude brown gelatinous substance (0.320 g). This crude substance was purified by preparative HPLC using the TFA method to obtain a yellow solid N-[1-(3-chlorophenyl)cyclopropyl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine (0.275 g), which was then separated as a trifluoroacetate.
[0267] 1H NMR (400MHz, AcOH-d4) δ7.58(s,1H),7.53(d,J=7.60Hz,1H),7.36(d,J=8.00Hz,2H),7.31(d,J=7 .20Hz,3H),7.25(t,J=6.00Hz,2H),5.44(s,2H),1.67(t,J=4.80Hz,2H),1.51(t,J=6.00Hz,2H);
[0268] MS: m / z 380.2(M+1).
[0269] Example 2: Preparation of N-[2-(3-chlorophenyl)propane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0270]
[0271] Example 2, Step 1: Preparation of 1-chloro-3-(2-isothiocyanopropane-2-yl)benzene
[0272]
[0273] Add 10% sodium bicarbonate solution (40 mL) to an ice-cold solution of 2-(3-chlorophenyl)propane-2-amine (commercially available) (1.00 g, 5.89 mmol) in dichloromethane (40 mL), then add phosgene (0.452 mL, d = 1.50 g / cm³). 3 The mixture was stirred at ambient temperature for 30 min. The organic layer was separated, washed with brine (25 mL), dried over sodium sulfate, filtered and concentrated to give a pale yellow liquid 1-chloro-3-(2-isothiocyanopropane-2-yl)benzene (0.800 g), which can be used in the next step without further purification.
[0274] 1 H NMR (400MHz, DMSO-d6) δ7.54 (d, J = 8.40Hz, 1H), 7.45 (t, J = 8.00Hz, 1H), 7.43 (s, 1H), 7.41 (dd, J = 2.00, 5.20Hz, 1H), 1.77 (s, 6H).
[0275] Example 2, Step 2: Preparation of 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)propane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl]-1-[2-(3-chlorophenyl)propane-2-yl]thiourea (a mixture of regioisomers)
[0276]
[0277] 1-Chloro-3-(2-isothiocyanopropane-2-yl)benzene (from Example 2, Step 1) (0.300 g, 1.42 mmol) was added to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, Step 5) (0.289 g, 1.42 mmol) in dichloromethane (6 mL), and the mixture was stirred at ambient temperature for 48 h. The reaction mixture was concentrated in a water bath at 30°C to give a yellow gel-like substance 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)propane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl)-1-[2-(3-chlorophenyl)propane-2-yl]thiourea (as a mixture of inseparable regioisomers) (0.500 g), which can be used in the next step without further purification.
[0278] MS: m / z 416.1 (M+1).
[0279] Example 2: Preparation of N-[2-(3-chlorophenyl)propane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0280]
[0281] Iodoacetic acid (0.089 g, 0.481 mmol) was added to a solution of 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)propane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl]-1-[2-(3-chlorophenyl)propane-2-yl]thiourea (as a mixture of inseparable regioisomers) (from Example 2, Step 2) (0.200 g, 0.481 mmol) in methanol (20 mL), and the mixture was stirred at 65 °C for 1 h. The reaction mixture was concentrated at 30°C to remove the solvent methanol, yielding a crude brown gelatinous substance (0.240 g). This crude substance was purified by preparative HPLC using the TFA method to obtain a brown gelatinous substance N-[2-(3-chlorophenyl)propane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine (0.040 g), which was then separated as a trifluoroacetate.
[0282] 1 H NMR (400MHz, AcOH-d4) δ7.58(d,J=7.12Hz,2H),7.50(d,J=7.44Hz,1H),7.40(d,J=7.92Hz,1H),7.37(d,J=7. 68Hz,1H),7.33(d,J=7.96Hz,1H),7.30(t,J=7.56Hz,1H),7.26(d,J=7.04Hz,2H),5.40(s,2H),1.87(s,6H);
[0283] MS: m / z 381.2(M+1).
[0284] Example 3: Preparation of 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0285]
[0286] Example 3, Step 1: Preparation of 5-(3-chlorophenyl)-5-methylimidazolidine-2,4-dione
[0287]
[0288] Ammonium carbonate (448.00 g, 4660.00 mmol) was added to a stirred solution of 1-(3-chlorophenyl)ethane-1-one (commercially available) (120.00 g, 776.00 mmol) in an ethanol / water (1:1; 2400 mL) mixture, followed by potassium cyanide (45.60 g, 931.00 mmol). The mixture was stirred at 60 °C for 16 h. The reaction mixture was then poured into ice-cold water (1500 mL) and stirred for 30 min. The resulting solid was filtered off and dried to give a grayish-white solid, 5-(3-chlorophenyl)-5-methylimidazolidine-2,4-dione (160.00 g), which could be used in the next step without further purification.
[0289] 1 H NMR (400MHz, DMSO-d6) δ10.87 (bs, 1H), 8.63 (s, 1H), 7.50 (d, J = 1.60Hz, 1H), 7.47 (d,J=4.80Hz,1H),7.45(t,J=2.40Hz,1H),7.42(dd,J=2.40Hz,1H),1.65(s,3H);
[0290] MS: m / z 225.2(M+1).
[0291] Example 3, Step 2: Preparation of 2-amino-2-(3-chlorophenyl)propionic acid
[0292]
[0293] 160.00 g (712.00 mmol) of 5-(3-chlorophenyl)-5-methylimidazolidine-2,4-dione (from Example 3, Step 1) was added to a 10% sodium hydroxide aqueous solution (1200 mL), and the mixture was stirred at 110 °C for 72 h. The reaction mixture was neutralized with 6.0 N HCl (500 mL) (adjusting pH to 7), and the resulting solid was filtered and dried to give a white solid of 2-amino-2-(3-chlorophenyl)propionic acid (205.00 g), which could be used in the next step without further purification.
[0294] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.56(s,1H),7.46(d,J=7.60Hz,1H),7.37(t,J=7.60Hz,1H),7.35(d,J=7.60Hz,1H),1.65(s,3H);
[0295] MS: m / z 200.1(M+1).
[0296] Example 3, Step 3: Preparation of 2-((tert-butoxycarbonyl)amino)-2-(3-chlorophenyl)propionic acid
[0297]
[0298] Sodium bicarbonate (842.00 g, 10000.0 mmol) was added to a suspension of 2-amino-2-(3-chlorophenyl)propionic acid (from Example 3, Step 2) (286.00 g, 1430.00 mmol) in a tetrahydrofuran:water (1:1; 5000 mL) mixture, followed by di-tert-butyl dicarbonate (658.00 mL, d: 0.950 g / cm³). 3 The mixture was stirred at ambient temperature for 15 days (2870.00 mmol). The reaction mixture was diluted with water (2000 mL) and extracted with ethyl acetate (4 × 5000 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a colorless colloidal 2-((tert-butoxycarbonyl)amino)-2-(3-chlorophenyl)propionic acid (410.00 g), which could be used in the next step without further purification.
[0299] 1 H NMR (400MHz, DMSO-d6) δ7.23 (dd, J = 6.40Hz, 2H), 7.16 (t, J = 6.40Hz, 2H), 1.70 (s, 3H), 1.34 (s, 9H);
[0300] MS: m / z 200.1[(M+1)-Boc].
[0301] Example 3, Step 4: Preparation of tert-butyl N-[2-(3-chlorophenyl)-1-hydroxypropane-2-yl]carbamate
[0302]
[0303] At 0°C, triethylamine (349.0 mL, d = 0.726 g / cm³) was added to a solution of 2-((tert-butoxycarbonyl)amino)-2-(3-chlorophenyl)propionic acid (from Example 3, step 3) (250.00 g, 834.00 mmol) in anhydrous tetrahydrofuran (2000 mL). 3 2500.0 mmol), then add isobutyl chloroformate (130.0 mL, d = 1.053 g / cm). 3The mixture was stirred at the same temperature for 4 h. The solid formed was filtered off at 0 °C, and the residue was washed with tetrahydrofuran (400 mL). The combined filtrates were added to a mixture cooled with sodium borohydride (221.00 g, 5840.00 mmol) in water (500 mL). The reaction mixture was slowly heated to ambient temperature and stirred for 48 h. The reaction mixture was quenched with ice-cold water (1000 mL), extracted with ethyl acetate (4 × 5000 mL), washed with brine (300 mL), dried over sodium sulfate, filtered, and concentrated to give a pale yellow liquid (250.00 g). This was purified by gravity column chromatography on silica gel of 60-120, and the product was eluted with 30-35% ethyl acetate in petroleum ether to give a colorless liquid tert-butyl N-[2-(3-chlorophenyl)-1-hydroxypropane-2-yl]carbamate (95.00 g).
[0304] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.34(s,1H),7.32(d,J=7.60Hz,1H),7.28(t,J=7.40 Hz,1H),7.25(d,J=7.20Hz,1H),3.57(d,J=6.40Hz,2H),1.52(s,3H),1.34(s,9H);
[0305] MS: m / z 186.1[(M+1)-Boc].
[0306] Example 3, Step 5: Preparation of 2-{[(tert-butoxy)carbonyl]amino}-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate
[0307]
[0308] Under a nitrogen atmosphere and at 0°C, triethylamine (250.00 mL, d = 0.726 g / cm³) was added to a solution of tert-butyl (2-(3-chlorophenyl)-1-hydroxypropane-2-yl)carbamate (from Example 3, Step 4) (170.00 g, 595.00 mmol) in anhydrous dichloromethane (1500 mL). 3 ,1780.00mmol), then add neopentanoyl chloride (145.50mL, d=0.985g / cm) dropwise. 3The reaction mixture was stirred at ambient temperature for 48 h. The reaction mixture was quenched with ice-cold water (1000 mL) and extracted with dichloromethane (4 × 2500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown liquid (200.00 g). This liquid was purified by chromatography on a Grace instrument using a 330.0 g rapid column pre-packed with 60-120 silica gel. The product was eluted with 20% ethyl acetate in hexane to give a yellow liquid 2-{[(tert-butoxy)carbonyl]amino}-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate (218.00 g).
[0309] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.35(d,J=8.00Hz,1H),7.32(s,1H),7.30(d,J=7.20Hz,1H),7.28(t,J=6 .80Hz,1H),4.30(d,J=10.40Hz,1H),4.21(d,J=10.80Hz,1H),1.50(s,3H),1.31(s,9H),1.10(s,9H);
[0310] MS: m / z 270.2[(M+1)-Boc].
[0311] Example 3, Step 6: Preparation of 2-amino-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate hydrochloride
[0312]
[0313] Under a nitrogen atmosphere and at 0°C, a 4M HCl solution (442.00 mL, 1770.00 mmol) in dioxane was added dropwise to a solution of 2-{[(tert-butoxy)carbonyl]amino}-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate (from Example 3, Step 5) (218.00 g, 589.00 mmol) in anhydrous dichloromethane (1200 mL), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under high vacuum to give a yellow gel-like substance, 2-amino-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate hydrochloride, which could be used in the next step without further purification.
[0314] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.64(s,1H),7.51-7.47(m,3H),4.44(d,J=11.60Hz,1H),4.26(d,J=11.60Hz,1H),1.69(s,3H),1.04(s,9H);
[0315] MS: m / z 270.1 [(M+1)-HCl].
[0316] Example 3, Step 7: Preparation of 2-(3-chlorophenyl)-2-isothiocyanopropyl 2,2-dimethylpropionate
[0317]
[0318] At 0°C, a 10% sodium bicarbonate aqueous solution (900 mL) was added to a solution of 2-amino-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate hydrochloride (from Example 3, step 6) (90.00 g, 294.00 mmol) in anhydrous dichloromethane (900 mL). After 30 minutes, phosgene (33.80 mL, d = 1.5 g / cm³) was added. 3 The mixture was stirred at the same temperature for 1 h. The reaction mixture was extracted with dichloromethane (3 × 2000 mL), the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a yellow liquid (95.00 g), which was purified by gravity column chromatography on 60-120 mesh silica gel using 3-5% ethyl acetate in hexane as eluent to give a yellow liquid 2-(3-chlorophenyl)-2-isothiocyanopropyl 2,2-dimethylpropionate (75.00 g).
[0319] 1 H NMR (400MHz, DMSO-d6) δ7.55 (s, 1H), 7.55-7.45 (m, 3H), 4.45 (dd, J = 11.20Hz, 2H), 1.79 (s, 3H), 1.11 (s, 9H).
[0320] Example 3, Step 8: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0321]
[0322] Add [2-(3-chlorophenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 3, step 7) (3.56 g, 11.40 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5) (4 g, 13.70 mmol) in a dichloromethane:methanol (1:1; 70 mL) mixture and stir at room temperature for 20 h. The reaction mixture was concentrated in a water bath at 30°C to give a yellow gel-like substance 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2(3-chlorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (7.00 g), which can be used in the next step without further purification.
[0323] MS: m / z 516.2 / 517.4 (M+1).
[0324] Example 3, Step 9: Preparation of 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate
[0325]
[0326] Iodoacetic acid (3.78 g, 20.30 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2(3-chlorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 3, Step 8) (7.00 g, 13.60 mmol) in methanol (40 mL), and the mixture was refluxed for 1 h. The reaction mixture was concentrated at 30°C to remove the solvent methanol, yielding a red gel (6.50 g), which was purified by preparative HPLC (TFA / acetonitrile) to give a yellow gel 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (0.800 g), which was separated as a trifluoroacetate.
[0327] 1 H NMR(400MHz,AcOH-d4)δ7.59(s,2H),7.52-7.50(m,1H),7.4 4-7.38(m,2H),7.34(d,J=8.00Hz,1H),7.26(t,J=8.00Hz,1H),7.22(d,J=1.60Hz,1H),7.17(d,J=7. 60Hz,1H),5.40(s,2H),4.55(d,J=11.60Hz,1H),4.46(d,J=11.60Hz,1H),1.96(s,3H),1.18(s,9H);
[0328] MS: m / z 482.4 / 484.1(M+1).
[0329] The above product was resolved into its two enantiomers by chiral SFC using the following method: column: YMC cellulose-SB; mobile phase: 0.5% isopropylamine in isopropanol; cosolvent: 30% CO2; flow rate: 3 mL / min; pressure: 100 bar; temperature: 35 °C.
[0330] Examples 3-9a: 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (enantiomer A)
[0331] Enantiomer A is the first enantiomer eluted from the column:
[0332]
[0333] 1 H NMR (400MHz, AcOH-d4) δ7.59(s,2H),7.52-7.50(m,1H),7.44-7.38(m,2H),7.34(d,J=8.00Hz,1H),7.26(t,J=8.00Hz,1H),7.22(d ,J=1.60Hz,1H),7.17(d,J=7.60Hz,1H),5.40(s,2H),4.55(d,J=11.60Hz,1H),4.46(d,J=11.60Hz,1H),1.96(s,3H),1.18(s,9H);
[0334] MS: m / z 482.4 / 484.1(M+1).
[0335] Examples 3-9b: 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (enantiomer B)
[0336] Enantiomer B is the second enantiomer eluted from the column.
[0337]
[0338] 1 H NMR (400MHz, AcOH-d4) δ7.59(s,2H),7.52-7.50(m,1H),7.44-7.38(m,2H),7.34(d,J=8.00Hz,1H),7.26(t,J=8.00Hz,1H),7.22(d ,J=1.60Hz,1H),7.17(d,J=7.60Hz,1H),5.40(s,2H),4.55(d,J=11.60Hz,1H),4.46(d,J=11.60Hz,1H),1.96(s,3H),1.18(s,9H);
[0339] MS: m / z 482.4 / 484.1(M+1).
[0340] Example 3: Preparation of 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol)
[0341]
[0342] 0.5 M sodium hydroxide was added dropwise to a solution of 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate trifluoroacetate (Example 3, step 9) (0.090 g, 0.151 mmol) in methanol (0.900 mL, 0.453 mmol), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (1 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.070 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown gel 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.040 g), which was separated as a trifluoroacetate.
[0343] 1 H NMR(400MHz,AcOH-d4)δ7.57(d,J=2.88Hz,2H),7.50-7.48(m,1H),7.41-7.35(m,3H),7.31-7.24(m,2H),7. 20(d,J=1.48Hz,1H),5.40(d,J=5.64Hz,2H),4.36(d,J=12.04Hz,1H),4.08(d,J=11.96Hz,1H),1.76(s,3H);
[0344] MS: m / z 398.1 (M+1).
[0345] Example 3a: Preparation of (-)-2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0346]
[0347] 0.5 M sodium hydroxide was added dropwise to a solution of 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (Examples 3-9a, enantiomer A) (0.180 g, 0.302 mmol) in methanol (2.42 mL, 1.21 mmol), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (2 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.15 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown gel (-)-2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.065 g), which was separated as trifluoroacetate.
[0348] 1 H NMR(400MHz,AcOH-d4)δ7.57(d,J=2.88Hz,2H),7.50-7.48(m,1H),7.41-7.35(m,3H),7.31-7.24(m,2H),7. 20(d,J=1.48Hz,1H),5.40(d,J=5.64Hz,2H),4.36(d,J=12.04Hz,1H),4.08(d,J=11.96Hz,1H),1.76(s,3H);
[0349] MS: m / z 398.1(M+1);
[0350] SOR:[α]D 22.9 (-)9.12, (MeOH, c=0.5).
[0351] Example 3b: Preparation of (+)-2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0352]
[0353] 0.5N sodium hydroxide was added dropwise to a solution of 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (Examples 3-9b, enantiomer B) (0.170 g, 0.285 mmol) in methanol (2.28 mL, 1.14 mmol), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (2 mL) and concentrated under reduced pressure at 30 °C to obtain a brown gel (0.15 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to obtain a brown gel (+)-2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.060 g), which was separated as trifluoroacetate.
[0354] 1 H NMR(400MHz,AcOH-d4)δ7.58-7.57(m,2H),7.50-7.47(m,1H),7.41-7.36(m,3H),7.32-7.26(m,2H),7.21 (d,J=1.60Hz,1H),5.40(d,J=4.56Hz,2H),4.36(d,J=12.08Hz,1H),4.08(d,J=12.08Hz,1H),1.77(s,3H);
[0355] MS: m / z 398.1(M+1);
[0356] SOR:[α]D 22.9 (+)9.20, (MeOH, c=0.5).
[0357] Example 4: Preparation of 4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-N-{1-[3-(trifluoromethyl)phenyl]ethyl}-1H-1,3-benzodiazole-2-amine
[0358]
[0359] Example 4, Step 1: Preparation of 1-(1-isothiocyanoethyl)-3-(trifluoromethyl)benzene
[0360]
[0361] Add 10% sodium bicarbonate solution (200 mL) to an ice-cold solution of 1-[3-(trifluoromethyl)phenyl]ethylamine (commercially available) (10.0 g, 52.86 mmol) in dichloromethane (200 mL), then add phosgene (10.10 mL, d = 1.50 g / cm³). 3 The mixture (132.15 mmol) was stirred at ambient temperature for 30 min. The organic layer was separated, washed with brine (80 mL), dried over sodium sulfate, filtered, and concentrated to give a yellow gel (11.00 g). This gel was then placed on a Grace instrument using 60.0 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm, and the product was eluted with 8-12% ethyl acetate in hexane to give a pale yellow liquid 1-(1-isothiocyanoethyl)-3-(trifluoromethyl)benzene (12.00 g).
[0362] 1 H NMR (400MHz, DMSO-d6) δ7.65-7.77 (m, 4H), 5.41 (q, J = 5.40Hz, 1H), 1.65 (d, J = 8.80Hz, 3H).
[0363] Example 4, Step 2: Preparation of 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-{1-[3(trifluoromethyl)phenyl]ethyl}thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-{1-[3-(trifluoromethyl)phenyl]ethyl}thiourea (a mixture of regioisomers)
[0364]
[0365] Add 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, Step 5) (0.414 g, 1.791 mmol) to a solution of 1-(1-isothiocyanoethyl)-3-(trifluoromethyl)benzene (from Example 4, Step 1) in a dichloromethane:methanol (4:2; 6 mL) mixture, and stir the mixture at ambient temperature for 16 h. The reaction mixture was concentrated to give a brown gel-like substance 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-{1-[3(trifluoromethyl)phenyl]ethyl}thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-{1-[3-(trifluoromethyl)phenyl]ethyl}thiourea (as a mixture of inseparable regioisomers) (0.750 g), which can be used in the next step without further purification.
[0366] MS: m / z 436.1 (M+1).
[0367] Example 4: Preparation of 4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-N-{1-[3(trifluoromethyl)phenyl]ethyl}-1H-1,3-benzodiazole-2-amine
[0368]
[0369] Iodoacetic acid (0.288 g, 1.55 mmol) was added to a solution of 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-{1-[3-(trifluoromethyl)phenyl]ethyl}thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-{1-[3-(trifluoromethyl)phenyl]ethyl}thiourea (as a mixture of inseparable regioisomers) (from Example 4, Step 2) (0.450 g, 1.03 mmol). The mixture was stirred at 65 °C for 1.5 h. The reaction mixture was concentrated at 25 °C to give a yellow gel (0.500 g). The substance was purified by preparative HPLC using the TFA method to obtain a grayish-white solid 4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-N-{1-[3(trifluoromethyl)phenyl]ethyl}-1H-1,3-benzodiazole-2-amine (0.300 g), which was then separated as a trifluoroacetate.
[0370] 1H NMR(400MHz,AcOH-d4)δ7.78(t,J=1.00Hz,2H),7.63-7.53(m,4H),7.32(t,J=7.92Hz,1H),7. 18(t,J=1.44Hz,2H),5.42(d,J=4.60Hz,2H),5.21(d,J=7.64Hz,1H),1.73(d,J=7.72Hz,3H);
[0371] MS: m / z 402.1(M+1).
[0372] Example 5: Preparation of 2-(3-chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0373]
[0374] Example 5, Step 1: 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-4-methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide
[0375]
[0376] 4-Methyloxazol-2-amine (10.30 g, 105.00 mmol) was added to a solution of 4-(bromomethyl)-2,1,3-benzothiadiazole (Example 1, Step 3) (20.00 g, 87.30 mmol) in N,N-dimethylformamide (100 mL), and the mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated to give a yellow gel (22.00 g). This gel was then subjected to a Grace instrument using 120.00 g of normal-phase silica gel. Purification was performed by pre-packed rapid column chromatography at 40-63 μm, and the product was eluted with 25-30% ethyl acetate in hexane to give a yellow solid 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-4-methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide (15.20 g).
[0377] 1 H NMR (400MHz, DMSO-d6) δ9.74 (bs, 2H), 8.13 (dd, J = 3.60, 8.20Hz, 1H), 7.95 (s, 1H) ,7.76(dd,J=2.00,6.60Hz,1H),7.68(t,J=6.00Hz,1H),5.63(s,2H),1.86(s,3H);
[0378] MS: m / z 247.1 [(M+1)-HBr].
[0379] Example 5, Step 2: Preparation of 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine
[0380]
[0381] To a degassed solution of 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-4-methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide (from Example 5, Step 1) (1.00 g, 3.08 mmol) in anhydrous methanol (100 mL), 3.00 g of riconene nickel (3.00 g, 300% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was subjected to a hydrogen atmosphere and a pressure of approximately 1.5 kg / cm². 2 The mixture was stirred at ambient temperature for 16 h. The reaction mixture was filtered through a diatomaceous earth bed, which was then washed with methanol (750 mL). The combined filtrates were concentrated to give a black gel-like substance, 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (0.650 g), which could be used in the next step without further purification.
[0382] MS: m / z 219.2 (M+1).
[0383] Example 5, Step 3: Preparation of 2-[({2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)]
[0384]
[0385] Add [2-(3-chlorophenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 3, Step 7) (0.300 g, 0.962 mmol) to a solution of 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 5, Step 2) (0.210 g, 0.962 mmol) in a mixed solvent of dichloromethane:methanol (4:1; 6 mL), and stir the mixture at ambient temperature for 48 h. The reaction mixture was concentrated in a water bath at 30°C to give a brown gel-like substance 2-[({2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (0.510 g), which can be used in the next step without further purification.
[0386] MS: m / z 531.1(M+1).
[0387] Example 5, Step 4: Preparation of 2-(3-chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate
[0388]
[0389] Iodoacetic acid (0.126 g, 0.679 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)-2-(3-chlorophenyl)propyl 2,2-dimethylpropionate (from Example 5, Step 3) (0.300 g, 0.566 mmol) in methanol (15 mL), and the mixture was stirred at 65 °C for 1 h. The reaction mixture was concentrated under high vacuum, and the residue was diluted with 10% sodium bicarbonate aqueous solution (25 mL) and extracted with a mixed solvent of dichloromethane / methanol (9:1) (3 × 75 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown gel (0.280 g), which was purified by preparative HPLC using the TFA method to give a brown gel 2-(3-chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (0.090 g), which was separated as a trifluoroacetate.
[0390] MS: m / z 497.2 (M+1).
[0391] Example 5: Preparation of 2-(3-chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0392]
[0393] To a solution of 2-(3-chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate trifluoroacetate (from Example 5, Step 4) (0.090 g, 0.147 mmol) in methanol (0.400 mL, 0.590 mmol), the mixture was added and stirred at ambient temperature for 2 h. The reaction mixture was quenched with 1.5 N hydrochloric acid (2 mL) and the resulting reaction mixture was concentrated under high vacuum to give a brown gel (0.100 g). The product was purified by preparative HPLC using the TFA method to obtain a brown solid 2-(3-chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.020 g), which was then separated as a trifluoroacetate.
[0394] 1 H NMR (400MHz, AcOH-d4) δ7.59(s,1H),7.50(d,J=6.76Hz,1H),7.44(s,1H),7.40(t,J=7.32Hz,1H),7.35(d,J=8.00Hz,2H),7.24(t ,J=7.96Hz,1H),6.86(d,J=7.68Hz,1H),5.46(s,2H),4.36(d,J=12.08Hz,1H),4.09(d,J=12.12Hz,1H),2.09(s,3H),1.77(s,3H);
[0395] MS: m / z 412.2(M+1).
[0396] Example 6: Preparation of N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0397]
[0398] Example 6, Step 1: Preparation of tert-butyl (2-(3-chlorophenyl)-1-methoxypropane-2-yl)carbamate
[0399]
[0400] Under a nitrogen atmosphere, silver oxide (24.30 g, 105.00 mmol) was added to a solution of tert-butyl (2-(3-chlorophenyl)-1-hydroxypropane-2-yl)carbamate (from Example 3, step 4) (6.00 g, 21.00 mmol) in acetonitrile (150 mL), followed by the addition of iodomethane (12.00 mL, d = 2.28 g / cm³). 3 The mixture was stirred at ambient temperature for 48 h (0.189 mmol). The reaction mixture was filtered through a diatomaceous earth bed and the bed was washed with ethyl acetate (3 × 500 mL). The combined filtrates were concentrated under vacuum to give a brown gel (6.00 g). This gel was then processed on a Grace instrument using 80.00 g of normal-phase silica gel. Purification was performed by pre-packed rapid column chromatography at 40-63 μm, and the product was eluted with 18% ethyl acetate in petroleum ether to give a yellow gelatinous tert-butyl (2-(3-chlorophenyl)-1-methoxypropane-2-yl)carbamate (4.50 g).
[0401] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.35(s,1H),7.32(d,J=7.96Hz,2H),7.27(t,J=6.76Hz,1H),3.47(s,2H),3.22(s,3H),1.53(s,3H),1.19(s,9H);
[0402] MS: m / z 200.1[(M+1)-Boc].
[0403] Example 6, Step 2: Preparation of 2-(3-chlorophenyl)-1-methoxypropane-2-amine hydrochloride
[0404]
[0405] Under a nitrogen atmosphere and at 0°C, a 4M HCl solution (11.25 mL, 45.00 mmol) in dioxane was added dropwise to a solution of tert-butyl(2-(3-chlorophenyl)-1-methoxypropane-2-yl)carbamate (from Example 6, Step 1) (4.50 g, 15.00 mmol) in anhydrous dichloromethane (50 mL), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under high vacuum to give a pale yellow gel-like 2-(3-chlorophenyl)-1-methoxypropane-2-amine hydrochloride (3.50 g), which could be used in the next step without further purification.
[0406] 1H NMR(400MHz, DMSO-d6:D2O)δ7.50(s,1H),7.46(t,J=7.60Hz,1H),7.43-7.39(m, 2H),3.67(d,J=10.40Hz,1H),3.56(d,J=10.40Hz,1H),3.27(s,3H),1.54(s,3H);
[0407] MS: m / z 200.1 [(M+1)-HCl].
[0408] Example 6, Step 3: Preparation of 1-chloro-3-(2-isothiocyano-1-methoxypropane-2-yl)benzene
[0409]
[0410] Add 10% sodium bicarbonate solution (50 mL) to an ice-cold solution of 2-(3-chlorophenyl)-1-methoxypropane-2-amine hydrochloride (from Example 6, Step 2) (3.00 g, 12.70 mmol) in dichloromethane (50 mL), then add phosgene (1.20 mL, d = 1.50 g / cm³). 3 15.20 mmol), and the entire mixture was stirred at ambient temperature for 30 min. The organic layer was separated, washed with brine (25 mL), dried over sodium sulfate, filtered and concentrated to give a pale yellow liquid 1-chloro-3-(2-isothiocyano-1-methoxypropane-2-yl)benzene (2.10 g), which could be used in the next step without further purification.
[0411] 1 H NMR (400MHz, DMSO-d6) δ7.46 (s, 1H), 7.45 (t, J = 7.20Hz, 1H), 7.41 (dd, J = 2.40, 9.80Hz, 2H), 3.68 (q, J = 10.40Hz, 2H), 3.33 (s, 3H), 1.58 (s, 3H).
[0412] Example 6, Step 4: Preparation of 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea (a mixture of regioisomers)
[0413]
[0414] 1-Chloro-3-(2-isothiocyano-1-methoxypropane-2-yl)benzene (from Example 6, step 3) (0.400 g, 1.96 mmol) was added to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5) (0.400 g, 1.96 mmol) in dichloromethane:methanol (4:2; 6 mL), and the mixture was stirred at ambient temperature for 96 h. The reaction mixture was concentrated under high vacuum at 25°C to give a brown gel-like substance 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea (as a mixture of inseparable regioisomers) (0.850 g), which can be used in the next step without further purification.
[0415] MS: m / z 446.2 (M+1).
[0416] Example 6: Preparation of N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0417]
[0418] Iodoacetic acid (0.250 g, 1.34 mmol) was added to a solution of 3-{2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea (as a mixture of inseparable regioisomers) (0.400 g, 0.896 mmol) in methanol (5 mL), and the mixture was stirred at 60 °C for 1 h. The reaction mixture was concentrated to obtain a dark brown gel (0.450 g), which was purified by preparative HPLC using the TFA method to obtain a brown gel N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine (0.060 g), which was separated as a trifluoroacetate.
[0419] 1 H NMR(400MHz,AcOH-d4)δ7.58(d,J=1.00Hz,1H),7.54(s,1H),7.46-7.44(m,1H),7.39-7.37(m,3H),7.29(d,J=4.60Hz,2H), 7.24(d,J=7.64Hz,1H),5.42(d,J=7.72Hz,2H),4.03(d,J=10.40Hz,1H),3.79(d,J=10.0Hz,1H),3.49(s,3H),1.81(s,3H);
[0420] MS: m / z 412.2(M+1).
[0421] Example 7: Preparation of 4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-N-{2-[3(trifluoromethyl)phenyl]propane-2-yl}-1H-1,3-benzodiazole-2-amine]
[0422]
[0423] The title compound was prepared from commercially available 2-[3-(trifluoromethyl)phenyl]propane-2-amine by the method described in Example 2 and isolated as a trifluoroacetate.
[0424] 1 H NMR (400MHz, AcOH-d4) δ7.86 (s, 1H), 7.84 (d, J = 8.40Hz, 1H), 7.67 (dd, J = 7.60Hz, 2H), 7.60 (dd, J = 1 .60,8.20Hz,1H),7.33(t,J=7.60Hz,1H),7.27(dd,J=1.60,8.80Hz,3H),5.40(s,2H),1.92(s,6H);
[0425] MS: m / z 416.1 (M+1).
[0426] Example 8: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0427]
[0428] Example 8, Step 1: Preparation of 5-(3-chloro-4-fluorophenyl)-5-methylimidazolidine-2,4-dione
[0429]
[0430] Ammonium carbonate (125.00 g, 1300.00 mmol) was added to a stirred solution of 1-(3-chloro-4-fluorophenyl)ethane-1-one (commercially available) (45.00 g, 261.00 mmol) in a 1:1; 1200 mL ethanol / water mixture, followed by potassium cyanide (20.40 g, 313.00 mmol). The mixture was stirred at 65 °C for 18 h. The reaction mixture was then poured into ice-cold water (1500 mL) and stirred for 30 min. The resulting solid was filtered and dried to give a grayish-white solid, 5-(3-chloro-4-fluorophenyl)-5-methylimidazolidine-2,4-dione (55.00 g), which could be used in the next step without further purification.
[0431] 1 H NMR (400MHz, DMSO-d6) δ10.89(bs,1H),8.65(s,1H),7.65(d,J=6.80Hz,1H),7.52(s,1H,),7.50(d,J=6.80Hz,1H),1.65(s,3H);
[0432] MS: m / z 243.0 (M+1).
[0433] Example 8, Step 2: Preparation of 2-amino-2-(3-chloro-4-fluorophenyl)propionic acid
[0434]
[0435] 5-(3-chloro-4-fluorophenyl)-5-methylimidazolidine-2,4-dione (from Example 8, Step 1) (55.00 g, 227.00 mmol) was dissolved in 10% sodium hydroxide aqueous solution (600 mL), and the mixture was stirred at 110 °C for 120 h. The reaction mixture was neutralized with 6.0 N HCl (500 mL) (adjusting pH to 7), the resulting solid was filtered, washed with petroleum ether (2 × 150 mL), and dried to give a white solid 2-amino-2-(3-chloro-4-fluorophenyl)propionic acid, which could be used in the next step without further purification.
[0436] 1 H NMR (400MHz, DMSO-d6) δ8.06(bs,2H),7.69(d,J=6.80Hz,1H),7.48(s,1H),7.37(d,J=7.38Hz,1H),1.61(s,3H);
[0437] MS: m / z 218.1 (M+1).
[0438] Example 8, Step 3: Preparation of 2-((tert-butoxycarbonyl)amino)-2-(3-chloro-4-fluorophenyl)propionic acid
[0439]
[0440] Sodium bicarbonate (29.00 g, 345.00 mmol) was added to a suspension of 2-amino-2-(3-chloro-4-fluorophenyl)propionic acid (from Example 8, Step 2) (75.00 g, 345.00 mmol) in a tetrahydrofuran:water (1:1; 1500 mL) mixture, followed by di-tert-butyl dicarbonate (158.00 mL, d: 0.950 g / cm³). 3 The mixture was stirred at ambient temperature for 72 h. The reaction mixture was diluted with water (750 mL) and extracted with ethyl acetate (4 × 1500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a colorless colloidal 2-((tert-butoxycarbonyl)amino)-2-(3-chloro-4-fluorophenyl)propionic acid (100.00 g), which could be used in the next step without further purification.
[0441] 1 H NMR (400MHz, DMSO-d6) δ7.36(d,J=7.80Hz,1H),7.25(d,J=7.60Hz,1H),7.23(s,1H),7.12(s,1H),1.71(s,3H),1.33(s,9H);
[0442] MS: m / z 316.0 (M-1).
[0443] Example 8, Step 4: Preparation of tert-butyl N-[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]carbamate
[0444]
[0445] At 0°C, triethylamine (92.10 mL, d = 0.726 g / cm³) was added to a solution of 2-((tert-butoxycarbonyl)amino)-2-(3-chloro-4-fluorophenyl)propionic acid (from Example 8, step 3) (70.00 g, 220.00 mmol) in anhydrous tetrahydrofuran (500 mL). 3 661.00 mmol), then add isobutyl chloroformate (34.25 mL, d = 1.053 g / cm). 3, 263.00 mmol), and stirred at the same temperature for 4 h. The solid formed was filtered off at 0 °C, and the residue was washed with tetrahydrofuran (100 mL). The combined filtrates were added to a mixture cooled with sodium borohydride (58.30 g, 1540.00 mmol) in water (75 mL). The reaction mixture was slowly heated to ambient temperature and stirred for 30 h. The reaction mixture was quenched with ice-cold water (500 mL), extracted with ethyl acetate (4 × 2000 mL), washed with brine (75 mL), dried over sodium sulfate, filtered and concentrated to give a pale yellow liquid (70.00 g). It was purified by gravity column chromatography on silica gel of 60-120, and the product was eluted with 25-30% ethyl acetate in petroleum ether to give a colorless liquid tert-butyl N-[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]carbamate (32.50 g).
[0446] 1 H NMR(400MHz,DMSO-d6)δ7.43(d,J=6.80Hz,1H),7.34(d,J=8.40Hz,1H),7.30(s,1H),6 .85(bs,1H),4.56(t,J=5.20Hz,1H),3.45(d,J=6.00Hz,2H),1.55(s,3H),1.26(s,9H);
[0447] MS: m / z 304.0 (M+1).
[0448] Example 8, Step 5: Preparation of 2-{[(tert-butoxy)carbonyl]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate
[0449]
[0450] At 0°C, triethylamine (75.50 mL, 543.00 mmol) was added to a solution of tert-butyl N-[1-(3-chloro-4-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]carbamate (from Example 8, Step 4) (55.0 g, 181.00 mmol) in anhydrous dichloromethane, followed by the addition of 2,2-dimethylpropionyl chloride (33.40 mL, 272.00 mmol), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with water (500 mL), and the aqueous layer was extracted with dichloromethane (4 × 1000 mL). The combined organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered, and concentrated to obtain a crude yellow liquid (70.50 g). This crude liquid was purified by gravity column chromatography using 601-20 silica gel. The product was eluted with a petroleum ether solution of 30% ethyl acetate to give a yellow oily 2-{[(tert-butoxy)carbonyl]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate.
[0451] 1 H NMR (400MHz, DMSO-d6) δ7.47(dd,J=1.60,7.00Hz,1H),7.36-7.32(m,2H),4.32-4.23(m,2H),1.55(s,3H),1.18(s,9H),1.17(s,9H);
[0452] MS: m / z 288.2[(M+1)-Boc].
[0453] Example 8, Step 6: Preparation of 2-amino-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate hydrochloride
[0454]
[0455] At 0°C, 4M HCl in dioxane (103.00 mL, 413.00 mmol) was added to a stirred solution of 2-{[(tert-butoxy)carbonyl]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (from Example 8, Step 5) (40.0 g, 103.00 mmol) in dichloromethane (300 mL), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated to give a brown gel-like substance, 2-amino-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate hydrochloride, which could be used in the next step without further purification.
[0456] 1H NMR(400MHz, DMSO-d6)δ7.87(d,J=8.80Hz,1H),7.63-7.60(m,1H),7.55-7.49(m, 1H),4.44(d,J=15.60Hz,1H),4.29(d,J=15.20Hz,1H),1.70(s,3H),1.11(s,9H);
[0457] MS: m / z 288.2 [(M+1)-HCl].
[0458] Example 8, Step 7: Preparation of [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate
[0459]
[0460] At 0°C, 10% sodium bicarbonate aqueous solution (300 mL) was added to a stirred solution of 2-amino-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate hydrochloride (from Example 8, Step 6) (30.0 g, 92.50 mmol) in dichloromethane (300 mL), followed by the addition of phosgene (14.2 mL, 185.00 mmol), and the mixture was stirred at the same temperature for 1 h. The reaction mixture was diluted with water (100 mL), extracted with dichloromethane (3 × 1000 mL), and the combined organic layers were dried over sodium sulfate, filtered, and concentrated to a yellow liquid (33.5 g). This was purified by gravity column chromatography on silica gel at 60–120 °C, eluting the product with 10% ethyl acetate in petroleum ether to give a yellow oily [2-(3-chloro-4-fluorophenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (18.20 g).
[0461] 1 H NMR (400MHz, DMSO-d6) δ7.73(dd,J=2.00,7.00Hz,1H),7.54-7.50(m,2H),4.44(dd,J=11.20,17.20Hz,2H),1.80(s,3H),1.11(s,9H);
[0462] Example 8, Step 8: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0463]
[0464] Add [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7) (1.50 g, 3.18 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5) (1.70 g, 8.32 mmol) in a dichloromethane:methanol (1:1; 40 mL) mixture, and stir at ambient temperature for 20 h. The reaction mixture was concentrated in a water bath at 30°C to give a yellow gel-like substance 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (3.20 g), which can be used in the next step without further purification.
[0465] MS: m / z 534.2 / 536.2(M+1).
[0466] Example 8, Step 9: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate
[0467]
[0468] Iodoacetic acid (1.67 g, 8.99 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 8, Step 8) (3.20 g, 5.99 mmol) in methanol (25 mL), and the mixture was refluxed for 1 h. The reaction mixture was concentrated to remove the solvent methanol, yielding a red gel (3 g), which was purified by preparative HPLC (TFA: acetonitrile) to give a yellow gel 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (0.800 g), which was separated as a trifluoroacetate.
[0469] 1 H NMR(400MHz,AcOH-d4)δ7.70(dd,J=6.84,2.36Hz,1H),7.59(d,J=1.68Hz,1H),7.56-7.53(m,1H),7.37(dd,J=7.22,1.88Hz,1H),7 .33-7.26(m,3H),7.24(d,J=1.64Hz,1H),5.40(s,2H),4.54(d,J=11.64Hz,1H),4.46(d,J=11.60Hz,1H),1.99(s,3H),1.19(s,9H);
[0470] MS: m / z 500.1 / 502.1[(M+1)-TFA].
[0471] Example 8: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0472]
[0473] 0.5N sodium hydroxide was added dropwise to a solution of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate trifluoroacetate (Example 8, Step 9) (0.780 g, 1.27 mmol) in methanol (10.20 mL, 5.08 mmol), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (4 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.7 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown gel 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.180 g), which was then separated by trifluoroacetate.
[0474] 1 H NMR(400MHz,AcOH-d4)δ7.67(dd,J=6.80,2.36Hz,1H),7.57(s,1H),7.53-7.49(m,1H),7.40(d,J=7.48Hz,1H),7.31-7.22(m ,3H),7.21(d,J=1.52Hz,1H),5.37(dd,J=21.86,7.16Hz,2H),4.32(d,J=12.08Hz,1H),4.07(d,J=12.08Hz,1H),1.77(s,3H);
[0475] MS:m / z 416.1 / 418.1(M+1).
[0476] The above product was separated into two enantiomers by chiral SFC using the following method: column: Chiralcel OZ-H, mobile phase: 0.5% isopropylamine in methanol, co-solvent: 30% CO2; flow rate: 3 mL / min, pressure: 100 bar, temperature: 35 °C, to obtain two enantiomers.
[0477] Example 8a: (-)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0478] The (-) enantiomer is the first compound eluted from the column, separated as a trifluoroacetate.
[0479]
[0480] 1 H NMR(400MHz,AcOH-d4)δ7.67(dd,J=6.80,2.36Hz,1H),7.57(s,1H),7.53-7.49(m,1H),7.40(d,J=7.48Hz,1H),7.31-7.22(m ,3H),7.21(d,J=1.52Hz,1H),5.37(dd,J=21.86,7.16Hz,2H),4.32(d,J=12.08Hz,1H),4.07(d,J=12.08Hz,1H),1.77(s,3H);
[0481] MS: m / z 416.1 / 418.1(M+1);
[0482] SOR:[α]D 24.2 (-)7.80,(MeOH,c=1.0).
[0483] Example 8b: (+)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0484] The (+) enantiomer is the second compound eluted from the column, separated as a trifluoroacetate.
[0485]
[0486] 1 H NMR(400MHz,AcOH-d4)δ7.67(dd,J=6.80,2.36Hz,1H),7.57(s,1H),7.53-7.49(m,1H),7.40(d,J=7.48Hz,1H),7.31-7.22(m ,3H),7.21(d,J=1.52Hz,1H),5.37(dd,J=21.86,7.16Hz,2H),4.32(d,J=12.08Hz,1H),4.07(d,J=12.08Hz,1H),1.77(s,3H);
[0487] MS: m / z 416.1 / 418.1(M+1).
[0488] Example 9: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[0489]
[0490] Example 9, Step 1: Preparation of 2,1,3-benzothiadiazole-4-ylmethanol
[0491]
[0492] Potassium carbonate (177.0 g, 1280.0 mmol) was added to a stirred solution of 4-(bromomethyl)-2,1,3-benzothiadiazole in a 1:1 dioxane / water (300 mL) mixture (Example 1, Step 3) and refluxed for 48 h. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 × 750 mL). The combined organic layers were washed with a brine solution (75 mL), dried over sodium sulfate, filtered, and concentrated to give a dark brown liquid (31.0 g). This liquid was then transferred to a Grace instrument using 220.0 g of normal-phase silica gel. The product was purified by chromatography using a pre-packed rapid column of 40-63 μm and eluted with 30-40% ethyl acetate in hexane to give a yellow solid 2,1,3-benzothiadiazole-4-ylmethanol (20.0 g).
[0493] 1 H NMR (400MHz, DMSO-d6) δ7.95 (d, J = 8.40Hz, 1H), 7.72 (t, J = 10.00Hz, 2H), 5.52 (t, J = 4.80Hz, 1H), 5.02 (d, J = 4.00Hz, 2H);
[0494] Example 9, Step 2: Preparation of 2,1,3-benzothiadiazole-4-carboxaldehyde
[0495]
[0496] Dess-Martin Periodinane (30.60 g, 72.20 mmol) was added to a stirred solution of 2,1,3-benzothiadiazol-4-ylmethanol (from Example 9, Step 1) in dichloromethane (150 mL). The mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with 10% sodium bicarbonate aqueous solution (100 mL) and extracted with dichloromethane (3 × 500 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated to give a yellow gel (10.00 g). This gel was then subjected to an Isolera instrument using 120.0 g of silica gel packed with normal phase. The product was purified by chromatography using a pre-packed rapid column of 40-63 μm and eluted with 30-40% ethyl acetate in hexane to give 8.20 g of pale yellow solid 2,1,3-benzothiadiazole-4-carboxaldehyde.
[0497] 1 H NMR (400MHz, DMSO-d6) δ10.62(s,1H),8.47(dd,J=0.80,8.80Hz,1H),8.30(dd,J=0.80,6.80Hz,1H),7.95(t,J=6.80Hz,1H);
[0498] MS: m / z 165.0 (M+1).
[0499] Example 9, Step 3: Preparation of 4-(1,3-dioxolane-2-yl)-2,1,3-benzothiadiazole
[0500]
[0501] 1,2-ethylene glycol (6.80 mL, d = 1.11 g / cm³) was added to a stirred solution of 2,1,3-benzothiadiazole-4-carboxaldehyde (from Example 9, Step 2) in dichloromethane (100 mL) (5.00 g, 30.50 mmol). 3 122.0 mmol), then tetrabutylammonium tribromide (1.47 g, 30.5 mmol), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was cooled to 0 °C, diluted with ethyl acetate (500 mL), and solid sodium bicarbonate (3.00 g) was added and stirred for 30 min. The mixture was filtered and concentrated to give a yellow gel (6.50 g), which was purified by gravity column chromatography on neutral silica gel at 60–120 °C. The product was eluted with 10–12% ethyl acetate in hexane to give a colorless gel 4-(1,3-dioxolane-2-yl)-2,1,3-benzothiadiazole (4.80 g).
[0502] 1 H NMR (400MHz, DMSO-d6) δ8.14 (dd, J=1.20, 8.80Hz, 1H), 7.81 (d, J=6.00Hz, 1H), 7. 75(t,J=6.80Hz,1H),6.44(s,1H),4.17(t,J=2.00Hz,2H),4.07(t,J=2.00Hz,2H);
[0503] MS: m / z 209.1 (M+1).
[0504] Example 9, Step 4: Preparation of 3-(1,3-dioxolane-2-yl)phenyl-1,2-diamine
[0505]
[0506] To a degassed solution of 4-(1,3-dioxolane-2-yl)-2,1,3-benzothiadiazole (from Example 9, Step 3) (1.50 g, 7.20 mmol) in anhydrous methanol (75 mL), 4.50 g of nickel lanthanum (300% w / w, pre-washed five times with dry methanol) was added, and the resulting reaction mixture was incubated under a hydrogen atmosphere at a pressure of approximately 1.5 kg / cm². 2 The mixture was stirred at ambient temperature for 48 h. The reaction mixture was filtered through a diatomaceous earth bed, which was then washed with methanol (500 mL). The combined filtrates were concentrated to give a brown gelatinous substance, 3-(1,3-dioxolane-2-yl)phenyl-1,2-diamine (1.10 g), which could be used in the next step without further purification.
[0507] 1 H NMR (400MHz, CD3OD) δ6.77(dd,J=2.80,8.20Hz,2H),6.61(t,J=7.60Hz,1H),5.75(s,1H),4.13(t,J=3.20Hz,2H),4.04(t,J=1.60Hz,2H);
[0508] MS: m / z 181.2(M+1).
[0509] Example 9, Step 5: Preparation of 2-({[2-amino-3-(1,3-dioxolane-2-yl)phenyl]carbamoylthio)amino)-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-({[2-amino-6-(1,3-dioxolane-2-yl)phenyl]carbamoylthio)amino)-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0510]
[0511] To a solution of [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7) (1.50 g, 4.55 mmol) in an acetonitrile / dichloromethane / methanol (3:1:1; 50 mL) mixture, 3-(1,3-dioxolane-2-yl)phenyl-1,2-diamine (from Example 9, step 4) (0.820 g, 4.55 mmol) was added, and the mixture was stirred at ambient temperature for 48 h. The reaction mixture was then evaporated under vacuum at 20 °C to give a brown gel (2.40 g). This gel was then applied to a Grace instrument using 60.0 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm, and the product was eluted with 3% methanol in chloroform to give a brown solid 2-({[2-amino-3-(1,3-dioxolane-2-yl)phenyl]carbamoylthio)amino)-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-({[2-amino-6-(1,3-dioxolane-2-yl)phenyl]carbamoylthio)amino)-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (1.80 g).
[0512] MS: m / z 511.2(M+1).
[0513] Example 9, Step 6: Preparation of 2-(3-chloro-4-fluorophenyl)-2-{[4-(1,3-dioxolane-2-yl)-1H-1,3-benzodiazol-2-yl]amino}propyl 2,2-dimethylpropionate
[0514]
[0515] Iodoacetic acid (0.294 g, 1.58 mmol) was added to a solution of 2-({[2-amino-3-(1,3-dioxolane-2-yl)phenyl]carbamoylthio)amino)-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-({[2-amino-6-(1,3-dioxolane-2-yl)phenyl]carbamoylthio)amino)-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (from Example 9, Step 5) (0.620 g, 1.22 mmol) in methanol (20 mL). The mixture was stirred at ambient temperature for 3 h. The reaction mixture was concentrated under vacuum at 25 °C, diluted with 10% sodium bicarbonate aqueous solution (75 mL), and then extracted with ethyl acetate (3 × 150 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to obtain a brown solid, 2-(3-chloro-4-fluorophenyl)-2-{[4-(1,3-dioxolane-2-yl)-1H-1,3-benzodiazol-2-yl]amino}propyl 2,2-dimethylpropionate (0.550 g), which can be used in the next step without further purification.
[0516] MS: m / z 476.1 (M+1).
[0517] Example 9, Step 7: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-formyl-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate
[0518]
[0519] To a solution of 2-(3-chloro-4-fluorophenyl)-2-{[4-(1,3-dioxolane-2-yl)-1H-1,3-benzodiazol-2-yl]amino)propyl 2,2-dimethylpropionate (from Example 9, Step 5) (0.550 g, 0.573 mmol) in acetone (30 mL), p-toluenesulfonic acid monohydrate (0.164 g, 0.860 mmol) was added, and the mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under vacuum at 25 °C and diluted with 10% sodium bicarbonate aqueous solution (30 mL). Extracted with ethyl acetate (3 × 75 mL), the combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown solid (0.500 g). This solid was then subjected to a Grace instrument using 24.0 g of normal-phase silica gel. The product was purified by chromatography using a pre-packed rapid column of 40-63 μm and eluted with 21% ethyl acetate in hexane to give 0.120 g of 2-(3-chloro-4-fluorophenyl)-2-[(4-formyl-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate as a yellow solid.
[0520] 1 H NMR (400MHz, DMSO-d6) δ11.34(s,1H),10.04(s,1H),7.65(dd,J=2.00,7.00Hz,1H),7.49(dd,J=3.20,7.20Hz,2H),7.46(dd,J=3.60 ,7.40Hz,1H),7.38(t,J=9.20Hz,1H),7.11(t,J=8.00Hz,1H),6.97(s,1H),4.48(dd,J=2.40,8.40Hz,2H),1.86(s,3H),1.06(s,9H);
[0521] MS: m / z 432.1(M+1).
[0522] Example 9: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[0523]
[0524] At 0°C, titanium isopropoxide (IV) (0.35 g, 1.25 mmol) was added to a solution of 2-(3-chloro-4-fluorophenyl)-2-[(4-formyl-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (0.18 g, 0.41 mmol) (from Example 9, step 7) and isoxazol-3-amine (0.042 g, 0.50 mmol) in anhydrous tetrahydrofuran (20 mL), and the reaction mixture was refluxed for 16 h. The reaction mixture was cooled, sodium cyanoborohydride (0.26 g, 4.17 mmol) was added, and the mixture was stirred at ambient temperature for 16 h. The mixture was filtered through a diatomaceous earth bed, washed with tetrahydrofuran (10 mL), and concentrated to give a yellow gel (0.350 g). The product was purified by preparative HPLC to obtain a colorless gel-like substance, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol (0.103 g), which was then separated as a trifluoroacetate.
[0525] 1H NMR(400MHz,AcOH-d4)δ8.20(d,J=1.60Hz,1H),7.68(dd,J=2.40,6.80Hz,1H),7.55-7.51(m,1H),7.32(t,J=2.40Hz,1H) ,7.31-7.24(m,3H),6.03(d,J=2.00Hz,1H),4.59(s,2H),4.17(d,J=11.60Hz,1H),4.02(d,J=12.00Hz,1H),1.87(s,3H);
[0526] MS: m / z 416.0 [(M+1)-TFA].
[0527] Example 10: Preparation of N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0528]
[0529] Example 10, Step 1: 3-{2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea (a mixture of regioisomers)
[0530]
[0531] 1-Chloro-3-(2-isothiocyano-1-methoxypropane-2-yl)benzene (from Example 6, step 3) (0.300 g, 1.24 mmol) was added to a solution of 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 5, step 2) (0.271 g, 1.24 mmol) in a dichloromethane:methanol (4:1; 8 mL) mixed solvent. The mixture was stirred at ambient temperature for 48 h. The reaction mixture was concentrated in a water bath at 30°C to give a brown gel-like substance 3-{2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea (as a mixture of inseparable regioisomers) (0.300 g), which can be used in the next step without further purification.
[0532] MS: m / z 461.1(M+1).
[0533] Example 10: N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0534]
[0535] Iodoacetic acid (0.121 g, 0.652 mmol) was added to a solution of 3-{2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea and 3-{2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}-1-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]thiourea (as a mixture of inseparable regioisomers) (from Example 10, Step 4) (0.300 g, 0.652 mmol) in methanol (15 mL), and the mixture was stirred at 65 °C for 1 h. The reaction mixture was concentrated under high vacuum, and the residue was diluted with 20 mL of 10% sodium bicarbonate aqueous solution. Extraction was performed using a mixed solvent of dichloromethane / methanol (9:1) (2 × 100). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a crude, brown, gelatinous substance (0.360 g). This crude substance was purified by preparative HPLC using the TFA method to give a brown solid N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine (0.050 g), which was separated as a trifluoroacetate.
[0536] 1 H NMR (400MHz, AcOH-d4) δ7.55(s,1H),7.47(dd,J=2.00,6.60Hz,2H),7.38(t,J=8.80Hz,1H),7.33(d,J=8.40Hz,2H),7.24(t,J=8.00H z,1H),6.86(d,J=7.60Hz,1H),5.46(s,2H),4.05(d,J=10.40Hz,1H),3.80(d,J=10.00Hz,1H),3.49(s,3H),2.11(s,3H),1.82(s,3H);
[0537] MS: m / z 426.1 [(M+1)].
[0538] Example 11: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(pyrimidin-4-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[0539]
[0540] The title product was prepared from commercially available pyrimidine-4-amine according to the method described in Example 16 and isolated as a trifluoroacetate.
[0541] 1 H NMR(400MHz,AcOH-d4)δ8.94(d,J=1.20Hz,1H),8.22-8.19(m,1H),7.68-7.65(m,1H),7.52-7.49(m,1H),7.41-7.36(m,2H),7. 32-7.22(m,2H),7.01(d,J=7.72Hz,1H),5.65(t,J=5.20Hz,2H),4.31(d,J=12.0Hz,1H),4.06(d,J=11.92Hz,1H),1.76(s,3H);
[0542] MS: m / z 427.1 (M+1).
[0543] Example 12: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl]amino]propane-1-ol
[0544]
[0545] Add 3-methylisoxazole-5-amine (0.218 g, 2.22 mmol) to a solution of 2-(3-chloro-4-fluorophenyl)-2-[(4-formyl-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (from Example 9, step 7) (0.800 g, 1.85 mmol) in anhydrous tetrahydrofuran (30 mL), then add titanium isopropoxide (10.80 mL, d = 0.937 kg / cm²). 3 The mixture was heated at 72°C for 48 h. Anhydrous methanol (20 mL) was added to the reaction mixture, followed by sodium cyanoborohydride (0.582 g, 9.26 mmol) at 0°C, and stirred at ambient temperature for 24 h. The reaction mixture was concentrated, the residue was quenched with ice-cold water (50 mL), diluted with a dichloromethane / methanol (9:1; 200 mL) mixture, and filtered through a diatomaceous earth bed. The two-phase filtrates were separated, and the aqueous layer was further extracted with dichloromethane (2 × 200 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown gel (1.10 g). The product was purified by preparative HPLC using the TFA method to obtain a grayish-white solid 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl]amino]propane-1-ol (0.360 g), which was then separated as a trifluoroacetate.
[0546] 1 H NMR(400MHz,AcOH-d4)δ7.68(dd,J=2.40,7.00Hz,1H),7.53-7.50(m,1H),7.30(t,J=8.40Hz,1H),7.24(d,J=8.00Hz,2H),7. 21(t,J=7.60Hz,1H),5.60(s,1H),4.52(s,2H),4.25(d,J=12.00Hz,1H),4.04(d,J=12.00Hz,1H),2.29(s,3H),1.78(s,3H);
[0547] MS: m / z 430.0 (M+1).
[0548] The above product was resolved into its two enantiomers by a chiral SFC using the following method: column: chiral Pak OX-H; flow rate: 3.0 mL / min; co-solvent: 40%; co-solvent name: 0.5% isopropylamine in isopropanol; injection volume: 15.0 μL; outlet pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 12a and 12b.
[0549] Example 12a: (-)-2-(3-chloro-4-fluorophenyl)-2-((4-(((5-methylisoxazol-3-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol
[0550] The (-) enantiomer is the first compound eluted from the column, separated as a trifluoroacetate.
[0551]
[0552] 1 H NMR (400MHz, AcOH-d4) δ7.67(dd,J=2.40,6.80Hz,1H),7.52-7.49(m,1H),7.30(t,J=7.40Hz,1H),7.23(t,J=8.80Hz,1H),7. 19(d,J=7.80Hz,2H),5.63(s,1H),4.51(s,2H),4.25(d,J=12.00Hz,1H),4.04(d,J=12.00Hz,1H),2.29(s,3H),1.77(s,3H);
[0553] MS: M / z 430.0(M+1);
[0554] [α]D 22.7 (-)2.64(MeOH,c=1.0).
[0555] Example 12b: (+)-2-(3-chloro-4-fluorophenyl)-2-((4-(((5-methylisoxazol-3-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol
[0556] The (+) enantiomer is the second compound eluted from the column, separated as a trifluoroacetate.
[0557]
[0558] 1 H NMR (400MHz, AcOH-d4) δ7.67(dd,J=2.00,7.00Hz,1H),7.52(dd,J=2.80,7.40Hz,1H),7.30(t,J=4.40Hz,1H),7.23(t,J=9.20Hz,1 H),7.20(d,J=4.80Hz,2H),5.63(s,1H),4.51(s,2H),4.25(d,J=12.00Hz,1H),4.04(d,J=12.00Hz,1H),2.29(s,3H),1.77(s,3H);
[0559] MS: M / z 430.0(M+1);
[0560] [α]D 22.6 (+)2.92(MeOH,c=1.0).
[0561] Example 13: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0562]
[0563] The title compound was prepared using the methods described in steps 8, 9, and 10 of Example 8, starting with 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 5, step 2) and [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7), and isolated as a trifluoroacetate.
[0564] 1H NMR(400MHz,AcOH-d4)δ7.68(dd,J=6.80,2.40Hz,1H),7.52-7.52(m,1H),7.45(d,J=1.60Hz,1H),7.36(d,J=8.00Hz,1H),7.28 -7.24(m,2H),6.87(d,J=7.60Hz,1H),5.46(s,2H),4.33(d,J=12.40Hz,1H),4.08(d,J=12.00Hz,1H),2.10(s,3H),1.79(s,3H);
[0565] MS: m / z 430.2 / 431.2(M+1).
[0566] The above product was resolved into its two enantiomers by a chiral SFC using the following method: column: Lux C4, mobile phase: 0.5% isopropylamine in methanol solvent, co-solvent: 40% CO2; flow rate: 3 mL / min, pressure: 100 bar; temperature: 35 °C, yielding two enantiomers 13a and 13b.
[0567] Example 13a: (-)-2(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl]methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0568] The (-) enantiomer is the first compound eluted from the column, separated as a trifluoroacetate.
[0569]
[0570] 1 H NMR(400MHz,AcOH-d4)δ7.68(dd,J=6.80,2.40Hz,1H),7.52-7.52(m,1H),7.45(d,J=1.60Hz,1H),7.36(d,J=8.00Hz,1H),7.28 -7.24(m,2H),6.87(d,J=7.60Hz,1H),5.46(s,2H),4.33(d,J=12.40Hz,1H),4.08(d,J=12.00Hz,1H),2.10(s,3H),1.79(s,3H);
[0571] MS: M / z 430.2 / 431.2(M+1);
[0572] SOR:[α]D 23.0 (-)7.60, (MeOH, c=0.5).
[0573] Example 13b: (+)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0574] The (+) enantiomer is the second compound eluted from the column, separated as a trifluoroacetate.
[0575]
[0576] 1 H NMR(400MHz,AcOH-d4)δ7.68(dd,J=6.80,2.40Hz,1H),7.52-7.52(m,1H),7.45(d,J=1.60Hz,1H),7.36(d,J=8.00Hz,1H),7.28 -7.24(m,2H),6.87(d,J=7.60Hz,1H),5.46(s,2H),4.33(d,J=12.40Hz,1H),4.08(d,J=12.00Hz,1H),2.10(s,3H),1.79(s,3H);
[0577] MS: m / z 430.2 / 431.2(M+1);
[0578] SOR:[α]D 23.5 (+)8.40, (MeOH, c=0.5).
[0579] Example 14: Preparation of N-[2-(3-chloro-4-fluorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine
[0580]
[0581] The title compound was prepared using tert-butyl (2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl)carbamate (from Example 8, step 4) and 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5) by the method described in Example 6, and then isolated as a trifluoroacetate.
[0582] 1H NMR (400MHz, AcOH-d4) δ7.64(dd,J=2.36,6.84Hz,1H),7.59(s,1H),7.51-7.48(m,1H),7.39(dd,J=2.48,6.54Hz,1H),7.31(t,J =7.64Hz,1H),7.24(d,J=8.52Hz,3H),5.41(s,2H),3.99(d,J=10.12Hz,1H),3.78(d,J=10.12Hz,1H),3.49(s,3H),1.83(s,3H);
[0583] MS: m / z 430.1n(M+1).
[0584] Example 15: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[0585]
[0586] Add 5-methyl-1,2,4-oxadiazol-3-amine (0.033 g, 0.333 mmol) to a solution of 2-(3-chloro-4-fluorophenyl)-2-[(4-formyl-1H-1,3-benzodiazol-2-yl)amino]propyl-2,2-dimethylpropionate (from Example 9, step 7) (0.120 g, 0.278 mmol) in anhydrous tetrahydrofuran (5 mL), then add titanium isopropoxide (1.23 mL, d = 0.937 kg / cm²). 3 The mixture was heated at 72°C for 48 h. Anhydrous methanol (5 mL) was added to the reaction mixture, followed by sodium cyanoborohydride (0.087 g, 1.39 mmol) at 0°C, and stirred at ambient temperature for 24 h. The reaction mixture was concentrated, the residue was quenched with ice-cold water (25 mL), diluted with a dichloromethane / methanol (9:1; 50 mL) mixture, and filtered through a diatomaceous earth bed. The two-phase filtrates were separated, and the aqueous layer was further extracted with dichloromethane (2 × 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown gel (0.100 g). The substance was purified by preparative HPLC using the TFA method to obtain a light brown gelatinous substance, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol (0.070 g), which was then separated as a trifluoroacetate.
[0587] 1H NMR(400MHz,AcOH-d4)δ7.69(dd,J=2.00,7.00Hz,1H),7.53(d,J=7.60Hz,1H),7.30(d,J=7.60Hz,1H),7.25(t,J=6.40Hz,1H), 7.22(s,1H),7.20(d,J=7.60Hz,1H),4.55(s,2H),4.27(d,J=12.00Hz,1H),4.06(d,J=12.00Hz,1H),2.49(s,3H),1.79(s,3H);
[0588] MS: m / z 431.1(M+1).
[0589] Example 16: Preparation of 2-(3-chloro-4-fluorophenyl)-2-((4-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol
[0590]
[0591] Example 16, Step 1: Preparation of N-[(2,1,3-benzothiadiazol-4-yl)methyl]5-methyl-1,3,4-oxadiazol-2-amine hydrobromide
[0592]
[0593] Under a nitrogen atmosphere, 5-methyl-1,3,4-oxadiazol-2-amine (1.98 g, 20.00 mmol) was added to a stirred solution of 4-(bromomethyl)-2,1,3-benzothiadiazole (from Example 1, Step 3) (4.00 g, 17.4 mmol) in anhydrous acetonitrile (20 mL), and the resulting reaction mixture was stirred at 70 °C for 16 h. The solid formed in the reaction mixture was filtered off, washed with hexane (2 × 100 mL), and dried under high vacuum to give a grayish-white solid N-[(2,1,3-benzothiadiazol-4-yl)methyl]-5-methyl-1,3,4-oxadiazol-2-amine hydrobromide (1.80 g), which could be used in the next step without further purification.
[0594] 1 H NMR (400MHz, DMSO-d6:D2O) δ8.14(t,J=8.40Hz,1H),7.77(d,J=6.80Hz,2H),5.65(s,2H),2.39(s,3H);
[0595] MS: m / z 248.2 (M+1).
[0596] Example 16, Step 2: Preparation of 3-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)phenyl-1,2-diamine
[0597]
[0598] To a degassed solution of N-[(2,1,3-benzothiadiazol-4-yl)methyl]-5-methyl-1,3,4-oxadiazol-2-amine hydrobromide (from Example 16, Step 1) (1.50 g, 4.60 mmol) in anhydrous methanol (100 mL), 3.00 g of riconene nickel (200% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was incubated under a hydrogen atmosphere at a pressure of approximately 1.5 kg / cm². 2 The mixture was stirred at ambient temperature for 16 h. The reaction mixture was filtered through a diatomaceous earth bed, which was then washed with methanol (1000 mL). The combined filtrates were concentrated to give a light brown solid, 3-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)phenyl-1,2-diamine (1.00 g), which could be used in the next step without further purification.
[0599] 1 H NMR (400MHz, DMSO-d6:D2O) δ6.87(t,J=7.60Hz,1H),6.70(d,J=8.00Hz,1H),6.45(d,J=7.20Hz,1H),4.58(s,2H),1.97(s,3H);
[0600] MS: m / z 220.2(M+1).
[0601] Example 16, Step 3: Preparation of 2-{[(2-amino-3-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)-propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)-propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0602]
[0603] Add [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7) (0.376 g, 11.40 mmol) to a solution of 3-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)phenyl-1,2-diamine (from Example 16, step 2) (0.250 g, 11.40 mmol) in a dichloromethane:methanol (4:1, 12 mL) mixture, and stir the mixture at ambient temperature for 16 h. The reaction mixture was concentrated in a water bath at 30°C to give a yellow gel-like substance 2-{[(2-amino-3-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (0.650 g), which can be used in the next step without further purification.
[0604] MS: m / z 550.1 (M+1).
[0605] Example 16, Step 4: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl-2,2-dimethylpropionate
[0606]
[0607] Iodoacetic acid (0.447 g, 2.36 mmol) was added to a solution of 2-{[(2-amino-3-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (from Example 16, Step 3) (0.650 g, 1.18 mmol) in methanol (40 mL), and the mixture was stirred at 65 °C for 1 h. The reaction mixture was concentrated to remove the solvent methanol, and the residue was collected on a Grace instrument using 24.00 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm. The product was eluted with 40-45% ethyl acetate in hexane to give a white gelatinous product 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl-2,2-dimethylpropionate (0.120 g).
[0608] 1 H NMR (400MHz, DMSO-d6) δ10.24(s,1H),9.38(s,1H),7.64(d,J=5.20Hz,1H),7.46(d,J=4.80Hz,1H),7.39(t,J=8.80Hz,1H),7.19(s,1H),7.03(d ,J=8.00Hz,2H),6.81(d,J=6.00Hz,1H),4.80(s,2H),4.40(d,J=10.80H z,1H),4.50(d,J=11.20Hz,1H),2.00(s,3H),1.92(s,3H),1.06(s,9H);
[0609] MS: m / z 515.1 (M+1).
[0610] Example 16: Preparation of 2-(3-chloro-4-fluorophenyl)-2-((4-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol
[0611]
[0612] Sodium hydroxide granules (0.038 g, 0.912 mmol) were added to a solution of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,3,4-oxadiazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (from Example 16, Step 4) (0.120 g, 0.228 mmol) in methanol (10 mL), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was quenched with 1.5 N hydrochloric acid (2 mL), and the resulting reaction mixture was concentrated under high vacuum to give a brown gel (0.100 g). The product was purified by preparative HPLC to obtain a grayish-white solid 2-(3-chloro-4-fluorophenyl)-2-((4-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol (0.060 g).
[0613] 1H NMR(400MHz,AcOH-d4)δ7.61(s,1H),7.41(d,J=10.40Hz,2H),7.41(d,J=10.40Hz,2H),7.25 (t,J=8.80Hz,1H),5.00(d,J=8.80Hz,2H),4.94(d,J=9.20Hz,2H),2.21(s,3H),1.89(s,3H);
[0614] MS: m / z 431.2(M+1).
[0615] Example 17: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(3-methyl-1,2,4-oxadiazol-5-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[0616]
[0617] The title compound was prepared using commercially available 3-methyl-1,2,4-oxadiazole-5-amine by the method described in Example 8, and isolated as a trifluoroacetate salt, which was a white solid.
[0618] 1 H NMR (400MHz, AcOH-d4) δ7.75 (dd, J = 2.40, 6.80Hz, 1H), 7.59-7.56 (m, 1H), 7.39 (d, J = 8.00Hz, 1H), 7.28 (t, J = 7.60Hz, 1H), 7.26 (d, J = 10. 40Hz,1H),7.22(t,J=7.60Hz,1H),4.69(q,J=15.32Hz,2H),4.25(d,J=11.60Hz,1H),4.06(d,J=12.00Hz,1H),2.74(s,3H),1.85(s,3H);
[0619] MS: m / z 431.1(M+1).
[0620] Example 18: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0621]
[0622] Example 18, Step 1: Preparation of 5-methyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione
[0623]
[0624] Ammonium carbonate (115.00 g, 1200.00 mmol) was added to a stirred solution of 3-trifluoromethylacetophenone (commercially available) (45.00 g, 239.00 mmol) in a 1:1; 1000 mL ethanol / water mixture, followed by potassium cyanide (18.70 g, 287.00 mmol). The mixture was stirred at 60 °C for 16 h. The reaction mixture was poured into ice-cold water (1500 mL) and stirred for 30 min. The resulting solid was filtered and dried to give a grayish-white solid, 5-methyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione (61.00 g), which could be used in the next step without further purification.
[0625] (400MHz, DMSO-d6:D2O) δ7.78(d,J=7.70Hz,1H),7.72(d,J=8.90Hz,2H),7.65(t,J=7.70Hz,1H),1.69(s,3H);
[0626] MS: m / z 259.0 (M+1).
[0627] Example 18, Step 2: Preparation of 2-amino-2-(3-(trifluoromethyl)phenyl)propionic acid
[0628]
[0629] 110.0 g (426.0 mmol) of 5-methyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione (from Example 18, Step 1) was added to a 10% sodium hydroxide aqueous solution (600 mL), and the mixture was refluxed for 48 h. The reaction mixture was neutralized with 6.0 N HCl (250 mL) (adjusting pH to 7), and the resulting solid was filtered and dried to give a white solid of 2-amino-2-(3-(trifluoromethyl)phenyl)propionic acid (100.0 g), which could be used in the next step without further purification.
[0630] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.85(s,1H),7.79(d,J=8.00Hz,1H),7.65(d,J=7.60Hz,1H),7.60(t,J=7.60Hz,1H),1.68(s,3H);
[0631] MS: m / z 234.1(M+1).
[0632] Example 18, Step 3: Preparation of 2-((tert-Butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)propionic acid
[0633]
[0634] Sodium bicarbonate (216.00 g, 2570.00 mmol) was added to a suspension of 2-amino-2-(3,4-dichlorophenyl)propionic acid (from Example 18, Step 2) (100.00 g, 429.00 mmol) in a tetrahydrofuran:water (1:1; 1400 mL) mixture, followed by di-tert-butyl dicarbonate (148.00 mL, d = 0.95 g / cm³). 3 The mixture was stirred at ambient temperature for 72 h. The reaction mixture was diluted with water (1000 mL) and extracted with ethyl acetate (4 × 2000 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a yellow gel-like substance, 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)propionic acid (140.00 g), which could be used in the next step without further purification.
[0635] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.64 (s, 1H), 7.57 (s, 1H), 7.47 (d, J = 4.40Hz, 2H), 1.47 (s, 3H), 1.35 (s, 9H);
[0636] MS: m / z 234.1[(M+1)-Boc].
[0637] Example 18, Step 4; Preparation of tert-butyl N-{1-hydroxy-2-[3-(trifluoromethyl)phenyl]propane-2-yl}carbamate
[0638]
[0639] At 0°C, triethylamine (158.00 mL, d = 0.726 g / cm³) was added to a solution of 2-((tert-butoxycarbonyl)amino)-2-(3-(trifluoromethyl)phenyl)propionic acid (from Example 18, step 3) (140.0 g, 378.0 mmol) in anhydrous tetrahydrofuran (1000 mL). 3 1130.00 mmol), then add isobutyl chloroformate (68.8 mL, d = 1.053 g / cm). 3The mixture was stirred at the same temperature for 4 h. The solid formed was filtered off at 0 °C, and the residue was washed with anhydrous tetrahydrofuran (400 mL). The combined filtrates were added to a mixture cooled with sodium borohydride (85.8 g, 2270.00 mmol) in water (200 mL). The reaction mixture was slowly heated to ambient temperature and stirred for 30 h. The reaction mixture was quenched with ice-cold water (1000 mL) and extracted with ethyl acetate (4 × 2000 mL). The combined organic layers were washed with brine (250 mL), dried over sodium sulfate, filtered, and concentrated to give a pale yellow liquid (200 g). It was purified by chromatography on a Grace instrument using a 330 g rapid column pre-packed with 60-120 silica gel, and the product was eluted with 30-35% ethyl acetate in petroleum ether to give a colorless liquid tert-butyl N-{1-hydroxy-2-[3-(trifluoromethyl)phenyl]propane-2-yl}carbamate (63.0 g).
[0640] 1 H NMR (400MHz, DMSO-d6) δ7.61(t,J=6.80Hz,2H),7.57(s,1H),7.53(t,J=7.20Hz,1H),6 .92(bs,1H),4.98(t,J=5.20Hz,1H),3.50(d,J=6.00Hz,2H),1.59(s,3H),1.35(s,9H);
[0641] MS: m / z 221.2[(M+1)-Boc].
[0642] Example 18, Step 5: Preparation of 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethyl)phenyl]propyl-2,2-dimethylpropionate
[0643]
[0644] Under a nitrogen atmosphere and at 0°C, triethylamine (96.2 mL, d = 0.726 g / cm³) was added to a solution of tert-butyl N-{1-hydroxy-2-[3-(trifluoromethyl)phenyl]propane-2-yl}carbamate (from Example 18, step 4) (63.0 g, 197.0 mmol) in anhydrous dichloromethane (800 mL). 3 691.0 mmol), then add neopentanoyl chloride (36.4 mL, d = 0.985 g / cm). 3The reaction mixture was stirred at ambient temperature for 36 h. The reaction mixture was quenched with ice-cold water (500 mL) and extracted with dichloromethane (4 × 1000 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a crude product (110.0 g) as a brown liquid. It was purified by chromatography on a Grace instrument using 330 g of pre-packed 60-120 silica gel, and the product was eluted with 20% ethyl acetate in hexane to give a pale yellow liquid 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethyl)phenyl]propyl-2,2-dimethylpropionate (70.00 g).
[0645] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.61(d,J=6.80Hz,2H),7.55(t,J=7.60Hz,1H), 7.51(s,1H),4.26(q,J=10.40Hz,2H),1.52(s,3H),1.35(s,9H),1.05(s,9H);
[0646] MS: m / z 304.1[(M+1)-Boc].
[0647] Example 18, Step 6: Preparation of 2-amino-2-[3-(trifluoromethyl)phenyl]propyl-2,2-dimethylpropionate hydrochloride
[0648]
[0649] Under a nitrogen atmosphere, a 4M HCl solution (127.0 mL, 521.0 mmol) in dioxane was added dropwise to a solution of 2-{(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (from Example 18, Step 5) (70.0 g, 174.0 mmol) in anhydrous dichloromethane (700 mL). The reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under high vacuum to give a yellow gel-like 2-amino-2-[3-(trifluoromethyl)phenyl]propyl-2,2-dimethylpropionate hydrochloride (60.0 g), which could be used in the next step without further purification.
[0650] 1H NMR (400MHz, DMSO-d6:D2O) δ7.88(s,1H),7.84(d,J=8.00Hz,1H),7.79(d,J=7.60Hz,1H),7.71 (t,J=7.60Hz,1H),4.49(d,J=12.00Hz,1H),4.27(d,J=12.00Hz,1H),1.72(s,3H),1.01(s,9H);
[0651] MS: m / z 304.1 [(M+1)-HCl].
[0652] Example 18, Step 7: Preparation of 2-isothiocyano-2-[3-(trifluoromethyl)-phenyl]propyl 2,2-dimethylpropionate
[0653]
[0654] At 0°C, a 10% sodium bicarbonate solution (500 mL) was added to a solution of 2-amino-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate hydrochloride (from Example 18, step 6) (40.0 g, 118.0 mmol) in anhydrous dichloromethane (500 mL). After 15 min, phosgene (14.40 mL, d = 1.5 g / cm³) was added. 3 The mixture was stirred at the same temperature for 1 h. The reaction mixture was extracted with dichloromethane (3 × 1000 mL), the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a yellow liquid (75.0 g). It was purified by gravity column chromatography on 60-120 mesh silica gel, using 5% ethyl acetate in hexane as eluent, to give a yellow liquid 2-isothiocyano-2-[3-(trifluoromethyl)-phenyl]propyl 2,2-dimethylpropionate (44.0 g).
[0655] 1 H NMR (400MHz, DMSO-d6) δ7.85 (s, 1H), 7.81 (d, J = 7.20Hz, 1H), 7.76 (d, J = 7.60Hz, 1H),7.69(t,J=8.40Hz,1H),4.51(q,J=15.20Hz,2H),1.83(s,3H),1.35(s,9H);
[0656] MS: m / z 344.0 (M-1).
[0657] Example 18, Step 8: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0658]
[0659] Add [2-isothiocyano-2-[3-(trifluoromethyl)phenyl]propyl]2,2-dimethylpropionate (from Example 18, step 7) (1.50 g, 4.34 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (Example 1, step 5) (1.80 g, 5.29 mmol) in a dichloromethane:methanol (1:1; 50 mL) mixture, and stir at ambient temperature for 20 h. The reaction mixture was concentrated at 30°C to give a brown gel-like substance, 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (2.90 g), which can be used in the next step without further purification.
[0660] MS: m / z 550.2 (M+1).
[0661] Example 18, Step 9: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate
[0662]
[0663] Iodoacetic acid (1.47 g, 7.91 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 18, Step 8) (2.90 g, 5.28 mmol) in methanol (20 mL), and the mixture was refluxed for 1.5 h. The reaction mixture was concentrated at 30°C to obtain a brown gel (3.3 g), which was purified by preparative HPLC (TFA: acetonitrile) to obtain a brown gel 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (0.390 g), which was separated as a trifluoroacetate.
[0664] 1 H NMR(400MHz,AcOH-d4)δ7.87(s,1H),7.86(s,1H),7.72(d,J=7.76Hz,1H),7.64(t,J=7.92Hz,1H),7.60 (d,J=1.48Hz,1H),7.33-7.16(m,4H),5.41(s,2H),4.55(q,J=11.64Hz,2H),2.03(s,3H),1.17(s,9H);
[0665] MS: m / z 516.2 (M+1).
[0666] The above product was resolved into two enantiomers by chiral SFC using the following method: Chiralcel OX-H, mobile phase: 0.5% isopropylamine in isopropanol; cosolvent: 40% CO2; flow rate: 3 mL / min; pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 18-9a and 18-9b.
[0667] Examples 18-9a: 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (enantiomer A).
[0668] Enantiomer A was the first compound eluted from the column, separated as a trifluoroacetate.
[0669]
[0670] 1 H NMR(400MHz,AcOH-d4)δ7.87(s,1H),7.86(s,1H),7.72(d,J=7.76Hz,1H),7.64(t,J=7.92Hz,1H),7.60 (d,J=1.48Hz,1H),7.33-7.16(m,4H),5.41(s,2H),4.55(q,J=11.64Hz,2H),2.03(s,3H),1.17(s,9H);
[0671] MS: m / z 516.2 (M+1).
[0672] Examples 18-9b: 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (enantiomer B).
[0673] Enantiomer B was the second compound eluted from the column, separated as a trifluoroacetate.
[0674]
[0675] 1 HNMR(400MHz,AcOH-d4)δ7.87(s,1H),7.86(s,1H),7.72(d,J=7.76Hz,1H),7.64(t,J=7.92Hz,1H),7.6 0(d,J=1.48Hz,1H),7.33-7.16(m,4H),5.41(s,2H),4.55(q,J=11.64Hz,2H),2.03(s,3H),1.17(s,9H);
[0676] MS: m / z 516.2 (M+1).
[0677] Example 18: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0678]
[0679] Add 0.5N sodium hydroxide to a solution of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate trifluoroacetate (Example 18, step 9) (0.100 g, 0.159 mmol) in methanol (1.00 mL, 0.500 mmol) and stir at ambient temperature for 2 h. Quench the reaction mixture with 1.5N hydrochloric acid solution (1 mL) and concentrate under reduced pressure at 30 °C to give a brown gel (0.080 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown gel-like substance, 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol (0.030 g), which was separated as a trifluoroacetate.
[0680] 1 H NMR(400MHz,AcOH-d4)δ7.84(t,J=7.84Hz,2H),7.69(d,J=7.80Hz,1H),7.62-7.56(m,2H),7.39(d,J=7.24Hz,1H),7. 31-7.26(m,2H),7.21(s,1H),5.40(d,J=4.20Hz,2H),4.42(d,J=12.00Hz,1H),4.13(d,J=12.16Hz,1H),1.81(s,3H);
[0681] MS: m / z 432.1(M+1).
[0682] Example 18a: Preparation of (-)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol
[0683]
[0684] Add 0.5N sodium hydroxide to a solution of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate trifluoroacetate (Example 18, enantiomer A) (0.13 g, 0.0206 mmol) in methanol (1.65 mL, 0.826 mmol) and stir at ambient temperature for 2 h. Quench the reaction mixture with 1.5N hydrochloric acid solution (2 mL) and concentrate under reduced pressure at 30 °C to give a brown gel (0.11 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to obtain a colorless colloidal substance (-)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol (0.080 g), which was separated as a trifluoroacetate.
[0685] 1 H NMR(400MHz,AcOH-d4)δ7.84(t,J=8.00Hz,2H),7.68(d,J=7.68Hz,1H),7.62-7.56(m,2H),7.39(dd,J=7.36,1.60Hz,1H),7.31 -7.26(m,2H),7.20(d,J=1.64Hz,1H),5.40(q,J=15.80Hz,2H),4.42(d,J=12.04Hz,1H),4.13(d,J=12.12Hz,1H),1.81(s,3H);
[0686] MS: m / z 432.1(M+1);
[0687] SOR:[α]D 24.8 (-)8.00, (MeOH, c=0.5).
[0688] Example 18b: Preparation of (+)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol
[0689]
[0690] 0.5N sodium hydroxide was added dropwise to a solution of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate trifluoroacetate (Example 18, enantiomer B) (0.130 g, 0.0206 mmol) in methanol (1.65 mL, 0.826 mmol) and stirred at ambient temperature for 2 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (2 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.11 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a colorless gel (+)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol (0.075 g), which was separated as a trifluoroacetate.
[0691] 1 H NMR(400MHz,AcOH-d4)δ7.84(t,J=8.00Hz,2H),7.68(d,J=7.68Hz,1H),7.62-7.56(m,2H),7.39(dd,J=7.36,1.60Hz,1H),7.31 -7.26(m,2H),7.20(d,J=1.64Hz,1H),5.40(q,J=15.80Hz,2H),4.42(d,J=12.04Hz,1H),4.13(d,J=12.12Hz,1H),1.81(s,3H);
[0692] MS: m / z 432.1(M+1);
[0693] SOR:[α]D 25.0 (+)6.80, (MeOH, c=0.5).
[0694] Example 19: Preparation of 2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0695]
[0696] Example 19, Step 1: Preparation of 5-(3,4-dichlorophenyl)-5-methylimidazolidine-2,4-dione
[0697]
[0698] Ammonium carbonate (114.0 g, 1190.0 mmol) was added to a stirred solution of 1-(3,4-dichlorophenyl)ethane-1-one (commercially available) (45.0 g, 238.0 mmol) in an ethanol / water (1:1; 1000 mL) mixture, followed by potassium cyanide (18.60 g, 286.0 mmol). The mixture was stirred at 65 °C for 16 h. The reaction mixture was poured into ice-cold water (1500 mL) and stirred for 30 min. The resulting solid was filtered off and dried to give a grayish-white solid, 5-(3,4-dichlorophenyl)-5-methylimidazolidine-2,4-dione (55.0 g), which could be used in the next step without further purification.
[0699] 1 H NMR (400MHz, DMSO-d6) δ10.91(bs,1H),8.68(s,1H),7.70(s,1H),7.68(d,J=6.40Hz,1H),7.49(d,J=8.40Hz,1H),1.65(s,3H);
[0700] MS: m / z 260.1(M+1).
[0701] Example 19, Step 2: Preparation of 2-amino-2-(3,4-dichlorophenyl)propionic acid
[0702]
[0703] The solution of 5-(3,4-dichlorophenyl)-5-methylimidazolidine-2,4-dione (from Example 19, Step 1) (50.0 g, 193.0 mmol) in a 10% sodium hydroxide aqueous solution (400 mL) was refluxed for 48 h. The reaction mixture was neutralized with 6.0 N HCl (150 mL) (adjusting pH to 7), and the resulting solid was filtered and dried to give a white solid of 2-amino-2-(3,4-dichlorophenyl)propionic acid (43.0 g), which could be used in the next step without further purification.
[0704] 1 H NMR (400MHz, DMSO-d6) δ8.77(bs,2H),7.80(s,1H),7.70(d,J=8.40Hz,1H),7.52(dd,J=2.00,8.40Hz,1H),1.76(s,3H);
[0705] MS: m / z 235.1 (M+1).
[0706] Example 19, Step 3: Preparation of 2-((tert-Butoxycarbonyl)amino)-2-(3,4-dichlorophenyl)propionic acid
[0707]
[0708] Sodium bicarbonate (15.40 g, 184.0 mmol) was added to a suspension of 2-amino-2-(3,4-dichlorophenyl)propionic acid (from Example 19, Step 2) (100.0 g, 429.0 mmol) in a tetrahydrofuran:water (1:1; 900 mL) mixture, followed by di-tert-butyl dicarbonate (84.4 mL, d = 0.95 g / cm³). 3 The mixture was stirred at ambient temperature for 4 days (367.0 mmol). The reaction mixture was diluted with water (1000 mL) and extracted with ethyl acetate (4 × 2000 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a yellow gel-like substance, 2-((tert-butoxycarbonyl)amino)-2-(3,4-dichlorophenyl)propionic acid (140.0 g), which could be used in the next step without further purification.
[0709] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.45(d,J=8.40Hz,1H),7.39(s,1H),7.25(dd,J=2.00,8.40Hz,1H),1.68(s,3H),1.33(s,9H);
[0710] MS: m / z 235.1[(M+1)-Boc].
[0711] Example 19, Step 4: Preparation of tert-butyl N-[2-(3,4-dichlorophenyl)-1-hydroxypropane-2-yl]carbamate
[0712]
[0713] At 0°C, triethylamine (56.3 mL, d = 0.726 g / cm³) was added to a solution of 2-((tert-butoxycarbonyl)amino)-2-(3,4-dichlorophenyl)propionic acid (from Example 19, step 3) (45.0 g, 135.0 mmol) in anhydrous tetrahydrofuran (650 mL). 3 ,404.0 mmol), then add isobutyl chloroformate (19.40 mL, d = 1.053 g / cm). 3The mixture was stirred at the same temperature for 4 h. The solid formed was filtered off at 0 °C, and the residue was washed with anhydrous tetrahydrofuran (200 mL). The combined filtrates were added to a mixture cooled with sodium borohydride (50.9 g, 1350.0 mmol) in water (200 mL). The reaction mixture was slowly heated to ambient temperature and stirred for 72 h. The reaction mixture was quenched with ice-cold water (1000 mL), extracted with ethyl acetate (4 × 1500 mL), washed with brine (150 mL), dried over sodium sulfate, filtered, and concentrated to give a pale yellow liquid (45.0 g). It was purified by chromatography on a Grace instrument using a 200 g rapid column pre-packed with 60-120 silica gel. The product was eluted with 30-35% ethyl acetate in petroleum ether to give a grayish-white solid tert-butyl N-[2-(3,4-dichlorophenyl)-1-hydroxypropane-2-yl]carbamate (28.0 g).
[0714] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.51(d,J=8.40Hz,1H),7.43(s,1H),7.26(dd,J=2.00,8.40Hz,1H),3.46(d,J=10.80Hz,2H),1.50(s,3H),1.31(s,9H);
[0715] MS: m / z 319.2 (M-1).
[0716] Example 19, Step 5: Preparation of 2-{[(tert-butoxy)carbonyl]amino}-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate
[0717]
[0718] Under a nitrogen atmosphere and at 0°C, triethylamine (36.50 mL, d = 0.726 g / cm³) was added to a solution of tert-butyl N-[2-(3,4-dichlorophenyl)-1-hydroxypropane-2-yl]carbamate (from Example 19, step 4) (28.0 g, 87.4 mmol) in anhydrous dichloromethane (200 mL). 3 ,262.00mmol), then add neopentanoyl chloride (21.50mL, d=0.985g / cm) dropwise. 3The reaction mixture was stirred at ambient temperature for 36 h (175.0 mmol). The reaction mixture was quenched with ice-cold water (150 mL) and extracted with dichloromethane (4 × 500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a crude brown liquid (36.0 g). This was purified by chromatography on a Grace instrument using 220 g of pre-packed 60-120 silica gel, eluting the product with 20% ethyl acetate in hexane to give a colorless colloidal 2-{[(tert-butoxy)carbonyl]amino}-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate (30.0 g).
[0719] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.58(d,J=8.44Hz,1H),7.50(s,1H),7.32(dd,J=1. 76,8.42Hz,1H),4.26(q,J=10.44Hz,2H),1.55(s,3H),1.22(s,9H),1.11(s,9H);
[0720] MS: m / z 305.2[(M+1)-Boc].
[0721] Example 19, Step 6: Preparation of 2-amino-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate hydrochloride
[0722]
[0723] Under a nitrogen atmosphere and at 0°C, a 4M HCl solution (70.0 mL, 223.0 mmol) in dioxane was added dropwise to a solution of 2-{[(tert-butoxy)carbonyl]amino}-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate (from Example 19, Step 5) (30.0 g, 74.20 mmol) in anhydrous dichloromethane (300 mL), and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under high vacuum to give a yellow gel-like 2-amino-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate hydrochloride (23.0 g), which could be used in the next step without further purification.
[0724] 1H NMR(400MHz, DMSO-d6:D2O)δ7.85(s,1H),7.75(dd,J=2.88,8.52Hz,1H),7.53(dd,J=2.24 ,5.72Hz,1H),4.43(d,J=11.76Hz,1H),4.25(d,J=11.72Hz,1H),1.68(s,3H),1.11(s,9H);
[0725] MS: m / z 305.1 [(M+1)-HCl].
[0726] Example 19, Step 7: Preparation of 2-(3,4-dichlorophenyl)-2-propyl isocyanate 2,2-dimethylpropionate
[0727]
[0728] At 0°C, a 10% sodium bicarbonate aqueous solution (200 mL) was added to a solution of 2-amino-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate hydrochloride (from Example 19, step 6) (25.0 g, 73.40 mmol) in anhydrous dichloromethane (200 mL). After 15 min, phosgene (7.40 mL, d = 1.5 g / cm³) was added. 3 The mixture was stirred at the same temperature for 1 h. The reaction mixture was extracted with dichloromethane (3 × 750 mL), the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a yellow liquid (26.0 g). It was purified by gravity column chromatography on 60-120 mesh silica gel, using 25% ethyl acetate in hexane as eluent, to give a yellow liquid 2-(3,4-dichlorophenyl)-2-isocyanate propyl 2,2-dimethylpropionate (15.0 g).
[0729] 1 H NMR (400MHz, DMSO-d6) δ 7.76 (s, 1H), 7.73 (d, J = 8.40Hz, 1H), 7.51 (dd, J = 2.40, 8.40Hz, 1H), 4.45 (q, J = 11.60Hz, 2H), 1.79 (s, 3H), 1.12 (s, 9H).
[0730] Example 19, Step 8: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0731]
[0732] Add 2-(3,4-dichlorophenyl)-2-propyl isocyanate-2,2-dimethylpropionate (from Example 19, step 7) (1.50 g, 7.34 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5) (1.50 g, 7.34 mmol) in a dichloromethane:methanol (1:1; 50 mL) mixture, and stir the mixture at ambient temperature for 48 h. The reaction mixture was concentrated to give a yellow gel-like substance 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (4.00 g), which can be used in the next step without further purification.
[0733] MS: m / z 551.1(M+1).
[0734] Example 19, Step 9: Preparation of 2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate
[0735]
[0736] Iodoacetic acid (1.35 g, 7.27 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3,4-dichlorophenyl)propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (from Example 19, Step 8) (4.00 g, 7.27 mmol) in methanol (100 mL), and the mixture was stirred at 65 °C for 1 h. The reaction mixture was concentrated to remove the solvent methanol, and the residue was dissolved in a 10% sodium bicarbonate aqueous solution (100 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated to give a brown gel (4.00 g). This was purified by preparative HPLC to give a brown gel 2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (0.900 g).
[0737] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.69(s,1H),7.62(d,J=8.40Hz,2H),7.44(dd,J=2.00,8.40Hz,1H),7.29(d,J=8.00Hz,1H),7. 14(s,1H),7.05(t,J=7.20Hz,1H),7.03(d,J=7.20Hz,1H),5.11(s,2H),4.45(q,J=11.20Hz,2H),1.82(s,3H),1.05(s,9H);
[0738] MS: m / z 517.1 (M+1).
[0739] Example 19: Preparation of 2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0740]
[0741] 0.5 M sodium hydroxide was added dropwise to a solution of 2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (from Example 19, step 9) (0.750 g, 1.19 mmol) in methanol (5.95 mL, 2.97 mmol). The mixture was stirred at ambient temperature for 30 min. The reaction mixture was quenched at 0 °C with 10 mL of 1.5 N HCl aqueous solution, and then concentrated at 28 °C to give a brown gel (0.520 g). This gel was purified by preparative HPLC to give a brown gel 2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.380 g).
[0742] 1 H NMR(400MHz,AcOH-d4)δ7.72(s,1H),7.57(d,J=7.20Hz,1H),7.53(d,J=8.40H z,1H),7.48(dd,J=2.40,8.60Hz,1H),7.41(dd,J=1.20,7.40Hz,1H),7.31(t,J =7.60Hz,1H),7.27(dd,J=1.60,7.60Hz,1H),7.21(d,J=7.20Hz,1H),5.40(q,J =15.60Hz,2H),4.33(d,J=12.00Hz,1H),4.08(d,J=12.40Hz,1H),1.78(s,3H);
[0743] MS: m / z 433.1(M+1).
[0744] The above product was resolved into its two enantiomers by a chiral SFC using the following method: column: chiral Pak OX-H; flow rate: 5.0 mL / min; cosolvent: 50%; cosolvent name: 0.5% isopropylamine in isopropanol; injection volume: 7.0 μL; outlet pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 19a and 19b.
[0745] Example 19a: (-)-2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0746] (-) The enantiomer is the first compound eluted from the column.
[0747]
[0748] 1 H NMR(400MHz,AcOH-d4)δ7.72(s,1H),7.57(d,J=7.20Hz,1H),7.53(d,J=8.40H z,1H),7.48(dd,J=2.40,8.60Hz,1H),7.41(dd,J=1.20,8.40Hz,1H),7.30(t,J =7.60Hz,1H),7.27(dd,J=2.40,8.00Hz,1H),7.22(d,J=7.60Hz,1H),5.40(q,J =15.60Hz,2H),4.33(d,J=12.00Hz,1H),4.08(d,J=12.40Hz,1H),1.77(s,3H);
[0749] MS: m / z 432.1(M+1);
[0750] [α]D 25.4 (-)8.00(MeOH,c=0.5).
[0751] Example 19b: (+)-2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0752] The (+) enantiomer is the second compound eluted from the column.
[0753]
[0754] 1 H NMR(400MHz,AcOH-d4)δ7.72(s,1H),7.57(d,J=8.00Hz,1H),7.53(d,J=8.40H z,1H),7.48(dd,J=2.00,8.40Hz,1H),7.40(dd,J=1.20,7.60Hz,1H),7.30(t,J =7.60Hz,1H),7.26(dd,J=1.60,7.80Hz,1H),7.22(d,J=7.60Hz,1H),5.40(q,J =16.00Hz,2H),4.33(d,J=12.00Hz,1H),4.08(d,J=12.00Hz,1H),1.77(s,3H);
[0755] MS: m / z 432.1(M+1);
[0756] [α]D 25.5 (+)7.20(MeOH, c=0.5).
[0757] Example 20: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-4,5-dimethyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[0758]
[0759] The title compound was prepared from commercially available 4,5-dimethyloxazol-2-amine by the method described in Example 8 and isolated as a trifluoroacetate.
[0760] 1 H NMR(400MHz,AcOH-d4)δ7.68(dd,J=2.40,6.80Hz,1H),7.54-7.51(m,1H),7.35(d,J=8.00Hz,1H),7.25(dd,J=8.00,16.00Hz,2H),6.87(d, J=8.00Hz,1H),5.40(s,2H),4.32(d,J=12.00Hz,1H),4.08(d,J=12.40Hz,1H),2.28(d,J=0.80Hz,3H),2.02(d,J=1.20Hz,3H),1.78(s,3H);
[0761] MS: m / z 444.1(M+1).
[0762] Example 21: Preparation of 2-((4-(((1-methyl-1H-pyrazol-5-yl)amino)methyl)-1H-benzi[d]imidazol-2-yl)amino)-2-(3-(trifluoromethyl)phenyl)propane-1-ol)
[0763]
[0764] The title compound was prepared starting with commercially available 2-methylpyrazole-1-3-amine using the methods described in Examples 16 and 18.
[0765] 1H NMR(400MHz,AcOH-d4)δ7.85(s,1H),7.81(d,J=8.00Hz,1H),7.66(d,J=8.00Hz,1H),7.58(t,J=7.60Hz,1H),7.44(s,1H),7.36(d,J=14.80Hz,1H),7 .26(d,J=6.80Hz,2H),7.20(t,J=7.20Hz,1H),4.54(q,J=15.60Hz,2H),4. 42(d,J=12.00Hz,1H),4.13(d,J=12.00Hz,1H),3.70(s,3H),1.82(s,3H);
[0766] MS: m / z 445.2 (M+1).
[0767] Example 22: Preparation of 2-((4-(((1-methyl-1H-imidazol-2-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)-2-(3-(trifluoromethyl)phenyl)propane-1-ol)
[0768]
[0769] The title compound was prepared starting with commercially available 1-methylimidazol-2-amine, following the methods described in Examples 1 and 18.
[0770] 1 H NMR(400MHz,AcOH-d4)δ7.84(s,1H),7.81(d,J=8.00Hz,1H),7.67(d,J=7.60Hz,1 H),7.60(t,J=7.60Hz,1H),7.34(d,J=8.00Hz,1H),7.23(t,J=8.00Hz,1H),7.02(d ,J=7.60Hz,1H),6.85(d,J=2.80Hz,1H),6.78(d,J=2.40Hz,1H),5.35(d,J=7.60Hz ,2H),4.41(d,J=12.40Hz,1H),4.11(d,J=12.00Hz,1H),3.60(s,3H),1.78(s,3H);
[0771] MS: m / z 445.2 (M+1).
[0772] Example 23: Preparation of 2-(4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]-propane-1-ol
[0773]
[0774] Example 23, Step 1: Preparation of 2-[({2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0775]
[0776] Add [2-isothiocyano-2-[3-(trifluoromethyl)phenyl]propyl]2,2-dimethylpropionate (from Example 18, step 7) (1.71 g, 4.95 mmol) to a solution of 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (from Example 5, step 2) (1.8 g, 8.25 mmol) in a dichloromethane:methanol (1:1; 40 mL) mixture, and stir at ambient temperature for 72 h. The reaction mixture was concentrated at 30°C to give a brown gel-like substance 2-[({2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (3.30 g), which can be used in the next step without further purification.
[0777] MS: m / z 564.2.2(M+1).
[0778] Example 23, Step 2: Preparation of 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate
[0779]
[0780] Iodoacetic acid (1.63 g, 8.78 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 23, Step 1) (3.30 g, 5.85 mmol) in methanol (40 mL), and the mixture was refluxed for 1.5 h. The reaction mixture was concentrated at 30°C to obtain a brown gel (3.3 g), which was purified by preparative HPLC (TFA: acetonitrile) to obtain a brown gel 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (0.550 g), which was separated as a trifluoroacetate.
[0781] 1 H NMR (400MHz, AcOH-d4) δ7.88(d,J=7.52Hz,2H),7.73(d,J=8.04Hz,1H),7.65(t,J=7.92Hz,1H),7.47(d,J=1.56Hz,1H), 7.30-7.23(m,2H),6.86(d,J=0.92Hz,1H),5.48(s,2H),4.55(q,J=11.64Hz,2H),2.13(s,3H),2.05(s,3H),1.19(s,9H);
[0782] MS: m / z 530.2 (M+1).
[0783] The above product was resolved by chiral SFC using the following method: Chiralcel OX-H, mobile phase: 0.5% isopropylamine in isopropanol; cosolvent: 40% CO2; flow rate: 3 mL / min; pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 23-2a and 23-2b.
[0784] Example 23-2a: 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (enantiomer A)
[0785] Enantiomer A was the first compound eluted from the column.
[0786]
[0787] 1 H NMR (400MHz, AcOH-d4) δ7.88(d,J=7.52Hz,2H),7.73(d,J=8.04Hz,1H),7.65(t,J=7.92Hz,1H),7.47(d,J=1.56Hz,1H), 7.30-7.23(m,2H),6.86(d,J=0.92Hz,1H),5.48(s,2H),4.55(q,J=11.64Hz,2H),2.13(s,3H),2.05(s,3H),1.19(s,9H);
[0788] MS: m / z 530.2 [(M+1).
[0789] Example 23-2b: 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (enantiomer B)
[0790] Enantiomer B is the second compound eluted from the column.
[0791]
[0792] 1 H NMR (400MHz, AcOH-d4) δ7.88(d,J=7.52Hz,2H),7.73(d,J=8.04Hz,1H),7.65(t,J=7.92Hz,1H),7.47(d,J=1.56Hz,1H), 7.30-7.23(m,2H),6.86(d,J=0.92Hz,1H),5.48(s,2H),4.55(q,J=11.64Hz,2H),2.13(s,3H),2.05(s,3H),1.19(s,9H);
[0793] MS: m / z 530.2 [(M+1).
[0794] Example 23: 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0795]
[0796] Sodium hydroxide in methanol (0.600 mL, 0.311 mmol) was added dropwise to a solution of 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (Example 23, Step 2) (0.050 g, 0.077 mmol) in methanol (0.050 g, 0.077 mmol) and stirred at ambient temperature for 1.5 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (1 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.04 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown gel 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol (0.028 g), which was separated as a trifluoroacetate.
[0797] 1 H NMR (400MHz, AcOH-d4) δ7.85(t,J=8.00Hz,2H),7.69(d,J=7.84Hz,1H),7.61(t,J=7.64Hz,1H),7.44(d,J=1.52Hz,1H),7.35(d,J=7.88Hz,1 H),7.25(t,J=8.00Hz,1H),6.87(d,J=7.60Hz,1H),5.46(s,2H),4.42(d,J=12.08Hz,1H),4.14(d,J=12.12Hz,1H),2.08(s,3H),1.82(s,3H);
[0798] MS: m / z 446.1[(M+1)-TFA].
[0799] Example 23a: Preparation of (-)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0800]
[0801] Sodium hydroxide in methanol (1.86 mL, 0.932 mmol) was added dropwise to a solution of 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (Example 23-2a, enantiomer A) (0.150 g, 0.233 mmol) in methanol (20 mL), and the mixture was stirred at ambient temperature for 1.5 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (1 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.130 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a colorless gel (-)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol (0.060 g), which was separated as a trifluoroacetate.
[0802] 1 H NMR (400MHz, AcOH-d4δ7.84(t,J=8.40Hz,2H),7.68(d,J=7.60Hz,1H),7.60(t,J=8.00Hz,1H),7.43(d,J=1.20Hz,1H),7.34(d,J=8.00Hz,1H ),7.24(t,J=8.00Hz,1H),6.86(d,J=8.00Hz,1H),5.45(s,2H),4.42(d,J=12.00Hz,1H),4.13(d,J=12.00Hz,1H),2.07(s,3H),1.81(s,3H);
[0803] MS: M / z 446.1 [(M+1)];
[0804] SOR:[α]D 20.6 (-)10.16,(MeOH,c=0.5).
[0805] Example 23b: Preparation of (+)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0806]
[0807] Sodium hydroxide in methanol (1.37 mL, 0.684 mmol) was added dropwise to a solution of 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (Example 23-2b, enantiomer B) (0.11 g, 0.171 mmol) in methanol (12 mL), and the mixture was stirred at ambient temperature for 1.5 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (1 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.09 g). This gel was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a colorless gel (+)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol (0.030 g), which was separated as a trifluoroacetate.
[0808] 1 H NMR (400MHz, AcOH-d4δ7.84(t,J=8.40Hz,2H),7.68(d,J=7.60Hz,1H),7.60(t,J=8.00Hz,1H),7.43(d,J=1.20Hz,1H),7.34(d,J=8.00Hz,1H ),7.24(t,J=8.00Hz,1H),6.86(d,J=8.00Hz,1H),5.45(s,2H),4.42(d,J=12.00Hz,1H),4.13(d,J=12.00Hz,1H),2.07(s,3H),1.81(s,3H);
[0809] MS: M / z 446.1(M+1);
[0810] SOR:[α]D 20.2 (+)5.60, (MeOH, c=0.5).
[0811] Example 24: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0812]
[0813] Example 24, Step 1: Preparation of 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-5-methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide
[0814]
[0815] 5-methyloxazol-2-amine (1.03 g, 10.50 mmol) was added to a solution of 4-(bromomethyl)-2,1,3-benzothiadiazole (Example 1, Step 3) (2.00 g, 8.73 mmol) in acetonitrile (20 mL), and the mixture was stirred at ambient temperature for 60 h. The reaction mixture was concentrated to give a grayish-white gel (2.10 g), which was purified by preparative HPLC (H2O: acetonitrile), and the solution was concentrated at 40 °C to give a grayish-white solid 3-[(2,1,3-benzothiadiazole-4-yl)methyl]-5-methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide (1.60 g).
[0816] 1 H-NMR (400MHz, DMSO-d6:D2O) δ8.12(d,J=8.72Hz,1H),7.76(t,J=8.60Hz,1H),7.67(d,J=6.72Hz,1H),7.12(s,1H),5.50(s,2H),2.18(s,3H);
[0817] MS: m / z 247.1 [(M+1)-HBr].
[0818] Example 24, Step 2: Preparation of 3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine
[0819]
[0820] To a degassed solution of 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-5-methyl-2,3-dihydro-1,3-oxazol-2-imine hydrobromide (from Example 24, Step 1) (1.90 g, 7.71 mmol) in anhydrous methanol (190 mL), 5.70 g of riconene nickel (300% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was subjected to a hydrogen atmosphere and a pressure of approximately 1.5 kg / cm². 2The mixture was stirred at ambient temperature for 24 h. The reaction mixture was filtered through a diatomaceous earth bed, and the bed was washed with methanol (200 mL). The combined filtrates were concentrated at 15–20 °C to give a gray colloidal substance, 3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (1.50 g), which could be used in the next step without further purification.
[0821] MS: m / z 219.2 (M+1).
[0822] Example 24, Step 3: Preparation of 2-[({2-amino-3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0823]
[0824] Add [2-isothiocyano-2-[3-(trifluoromethyl)phenyl]propyl]2,2-dimethylpropionate (from Example 18, step 7) (1.90 g, 5.50 mmol) to a solution of 3-(((5-methyloxazol-2-yl)amino)methyl)benzene-1,2-diamine (Example 24, step 2) (1.50 g, 6.87 mmol) in a dichloromethane:methanol (1:1; 60 mL) mixture, and stir at ambient temperature for 72 h. The reaction mixture was concentrated at 30°C to give a brown gel-like substance 2-[({2-amino-3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (3.40 g), which can be used in the next step without further purification.
[0825] MS: m / z 564.2.2(M+1).
[0826] Example 24, Step 4: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate
[0827]
[0828] Iodoacetic acid (1.68 g, 9.05 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 24, Step 3) (3.40 g, 6.03 mmol) in methanol (30 mL), and the mixture was refluxed for 1.5 h. The reaction mixture was concentrated at 30°C to obtain a brown gel (3.80 g), which was purified by preparative HPLC (TFA: acetonitrile) to obtain a brown gel 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (1.00 g), which was separated as a trifluoroacetate.
[0829] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.80-7.65(m,4H),7.32(d,J=10.40Hz,1H),7.20(d,J=10.00Hz,1H),7. 06(d,J=10.40Hz,1H),6.89(s,1H),5.16(s,2H),4.48(s,2H),2.16(s,3H),1.91(s,3H),1.03(s,9H);
[0830] MS: m / z 530.2[(M+1)-TFA].
[0831] The above product was resolved into two enantiomers, Chiralcel OX-H, by chiral SFC using the following method: mobile phase: 0.5% isopropylamine in methanol; cosolvent: 30% CO2; flow rate: 3 mL / min; pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 24-4a and 24-4b.
[0832] Examples 24-4a: 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (enantiomer A)
[0833] Enantiomer A was the first compound eluted from the column.
[0834]
[0835] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.80-7.65(m,4H),7.32(d,J=10.40Hz,1H),7.20(d,J=10.00Hz,1H),7. 06(d,J=10.40Hz,1H),6.89(s,1H),5.16(s,2H),4.48(s,2H),2.16(s,3H),1.91(s,3H),1.03(s,9H);
[0836] MS: m / z 530.2 [(M+1).
[0837] Examples 24-4b: 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (enantiomer B)
[0838] Enantiomer B is the second compound eluted from the column.
[0839]
[0840] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.80-7.65(m,4H),7.32(d,J=10.40Hz,1H),7.20(d,J=10.00Hz,1H),7. 06(d,J=10.40Hz,1H),6.89(s,1H),5.16(s,2H),4.48(s,2H),2.16(s,3H),1.91(s,3H),1.03(s,9H);
[0841] MS: m / z 530.2 [(M+1).
[0842] Example 24: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol
[0843]
[0844] Add 0.5N sodium hydroxide to a solution of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate trifluoroacetate (Example 24, step 4) (0.130 g, 0.202 mmol) in methanol (1.62 mL, 0.808 mmol) and stir at ambient temperature for 1.5 h. Quench the reaction mixture with 1.5N hydrochloric acid solution (1 mL) and concentrate under reduced pressure at 30 °C to give a brown gel (0.110 g). The product was purified by preparative HPLC using acetonitrile:water with 0.1% TFA to obtain a brown gel-like substance 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol (0.055 g), which was separated as a trifluoroacetate.
[0845] 1 H NMR (400MHz, AcOH-d4) δ7.83(t,J=8.00Hz,2H),7.67(d,J=7.20Hz,1H),7.59(t,J=7.60Hz,1H),7.37(d,J=6.80Hz,1H),7.30- 7.26(m,2H),6.81(s,1H),5.32(d,J=2.80Hz,2H),4.41(d,J=12.00Hz,1H),4.12(d,J=12.00Hz,1H),2.24(s,3H),1.80(s,3H);
[0846] MS: m / z 446.1 [(M+1)].
[0847] Example 24a: Preparation of (-)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol
[0848]
[0849] Sodium hydroxide in methanol (4.36 mL, 2.18 mmol) was added dropwise to a solution of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (Examples 24-4a, enantiomer A) (0.350 g, 0.545 mmol) in methanol (40 mL, 2.18 mmol), and the mixture was stirred at ambient temperature for 2 h. The reaction mixture was quenched with 1.5 N hydrochloric acid solution (3 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.300 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to obtain a colorless colloidal substance (-)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol (0.160 g), which was separated as a trifluoroacetate.
[0850] 1 H NMR (400MHz, AcOH-d4) δ7.83(t,J=8.00Hz,2H),7.67(d,J=7.20Hz,1H),7.59(t,J=7.60Hz,1H),7.38(dd,J=6.62,2.36Hz,1H),7. 30-7.26(m,2H),6.81(s,1H),5.32(d,J=2.80Hz,2H),4.41(d,J=12.00Hz,1H),4.12(d,J=12.00Hz,1H),2.24(s,3H),1.80(s,3H);
[0851] MS: m / z 446.1(M+1);
[0852] SOR:[α]D 20.5 (-)6.80, (MeOH, c=0.5).
[0853] Example 24b: Preparation of (+)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol
[0854]
[0855] Sodium hydroxide in methanol (2.12 mL, 0.106 mmol) was added dropwise to a solution of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propyl 2,2-dimethylpropionate (Examples 24-4b, enantiomer B) (0.170 g, 0.265 mmol) in methanol (2.12 mL, 0.106 mmol) and stirred at ambient temperature for 2 h. The reaction mixture was quenched with 1.5 N hydrochloric acid solution (2 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.150 g). The mixture was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a colorless colloidal substance (+)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)-phenyl]propane-1-ol (0.120 g), which was separated as a trifluoroacetate.
[0856] 1 H NMR (400MHz, AcOH-d4) δ7.83(t,J=8.00Hz,2H),7.67(d,J=7.20Hz,1H),7.59(t,J=7.60Hz,1H),7.38(dd,J=6.62,2.36Hz,1H),7. 30-7.26(m,2H),6.81(s,1H),5.32(d,J=2.80Hz,2H),4.41(d,J=12.00Hz,1H),4.12(d,J=12.00Hz,1H),2.24(s,3H),1.80(s,3H);
[0857] MS: M / z 446.1(M+1);
[0858] SOR:[α]D 20.9 (+)7.20, (MeOH, c=0.5).
[0859] Example 25: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butane-1-ol]
[0860]
[0861] Example 25, Step 1: Preparation of 5-ethyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione
[0862]
[0863] Ammonium carbonate (107.0 g, 1110.0 mmol) was added to a stirred solution of 1-(3-(trifluoromethyl)phenyl)propane-1-one (commercially available) (45.0 g, 223.0 mmol) in a 1:1, 1000 mL ethanol / water mixture, followed by potassium cyanide (17.10 g, 263.0 mmol). The mixture was stirred at 60 °C for 16 h. The reaction mixture was then poured into ice-cold water (1500 mL) and stirred for 30 min. The resulting solid was filtered off and dried to give a grayish-white solid, 5-ethyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione (55.0 g), which could be used in the next step without further purification.
[0864] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.78(d,1H,J=7.68Hz),7.75(s,1H),7.68(d,1H,J=7.84Hz),7. 63(t,1H,J=7.76Hz), 2.08(q,1H,J=7.20Hz), 1.90(q,1H,J=7.32Hz), 0.78(t,3H,J=7.24Hz);
[0865] MS: m / z 271.1 (M-1).
[0866] Example 25, Step 2: Preparation of 2-amino-2-(3-(trifluoromethyl)phenyl)butyric acid
[0867]
[0868] 5-Ethyl-5-(3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione (from Example 25, Step 1) (55.0 g, 202.0 mmol) was dissolved in 10% sodium hydroxide aqueous solution (350 mL), and the mixture was refluxed for 48 h. The reaction mixture was neutralized with 6.0 N HCl (200 mL) (adjusting pH to 7), and the resulting solid was filtered and dried to give a white solid 2-amino-2-(3-(trifluoromethyl)phenyl)butyric acid (31.0 g), which could be used in the next step without further purification.
[0869] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.86(s,1H),7.80(d,1H,J=7.60Hz),7.62(d,1H, J=7.60Hz),7.57(t,1H,J=7.60Hz),2.14-2.08(m,2H),0.81(t,3H,J=7.60Hz);
[0870] MS: m / z 248.2 (M+1).
[0871] Example 25, Step 3: Preparation of 2-amino-2-(3-(trifluoromethyl)phenyl)butane-1-ol
[0872]
[0873] At 0°C, a solution of 2M lithium aluminum hydride in tetrahydrofuran (202.0 mL, 405.0 mmol) was added to a solution of 2-amino-2-(3-(trifluoromethyl)phenyl)butyric acid (from Example 25, Step 2) in anhydrous tetrahydrofuran (1200 mL). The reaction mixture was slowly heated to ambient temperature and stirred for 3 h. The reaction mixture was cooled to 0°C and quenched by dropwise addition of ethyl acetate solution (120 mL) and stirred for 30 min. Then, a saturated ammonium chloride solution (150 mL) was added dropwise and stirred at 0°C for 15 min. The precipitate was separated by filtration, and the filtrate was concentrated under reduced pressure to give a yellow gel (40.00 g). It was diluted with 10% sodium hydroxide solution (100 mL) and extracted with ethyl acetate (4 × 1000 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a yellow oily substance, 2-amino-2-(3-(trifluoromethyl)phenyl)butane-1-ol (18.50 g), which could be used in the next step without further purification.
[0874] 1 H NMR (400MHz, DMSO-d6) δ7.85 (s, 1H), 7.75 (d, 1H, J = 6.00Hz), 7.53 (d, 2H, J = 6.40Hz), 4.76 (t, 1H, J = 5.60Hz), 3.5 4(dd,2H,J=10.20,5.60Hz),1.84(s,2H),1.75(q,1H,J=7.60Hz),1.62(q,1H,J=6.80Hz),0.61(t,3H,J=7.60Hz);
[0875] MS: m / z 234.1(M+1).
[0876] Example 25, Step 4: Preparation of tert-butyl N-{1-hydroxy-2-[3-(trifluoromethyl)phenyl]butane-2-yl}carbamate
[0877]
[0878] At 0°C, di-tert-butyl dicarbonate (13.50 mL, d: 0.950 g / cm³) was added dropwise to a suspension of 2-amino-2-(3-(trifluoromethyl)phenyl)butane-1-ol (from Example 25, step 3) (18.50 g, 51.60 mmol) in a mixed solvent of dichloromethane:1,4-diane (4:1; 500 mL). 3 The mixture (61.90 mmol) was stirred at ambient temperature for 48 h. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (4 × 1000 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a yellow gel (18.00 g). This gel was then processed on a Grace instrument using 220 g of normal-phase silica gel. The product was purified by chromatography using a pre-packed rapid column of 40-63 μm and eluted with 25-30% ethyl acetate in hexane to obtain a colorless colloidal tert-butyl N-{1-hydroxy-2-[3-(trifluoromethyl)phenyl]butane-2-yl}carbamate (11.50 g).
[0879] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.58(s,1H),7.56(d,2H,J=2.16Hz),7.53(t,1H,J=6.32Hz ), 3.61 (t, 2H, J = 12.40Hz), 1.97 (q, 2H, J = 7.64Hz), 1.46 (s, 9H), 0.61 (t, 3H, J = 7.60Hz);
[0880] MS: m / z 234.2[(M+1)-Boc].
[0881] Example 25, Step 5: Preparation of 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate
[0882]
[0883] Under a nitrogen atmosphere and at 0°C, triethylamine (31.30 mL, d = 0.726 g / cm³) was added to a solution of tert-butyl N-{1-hydroxy-2-[3-(trifluoromethyl)phenyl]butane-2-yl}carbamate (from Example 25, step 4) (11.50 g, 34.50 mmol) in anhydrous dichloromethane (300 mL). 3 224.0 mmol), then add pentanoyl chloride (12.70 mL, d = 0.985 g / cm). 3103.00 mmol), and the reaction mixture was stirred at ambient temperature for 48 h. The reaction mixture was quenched with ice-cold water (100 mL) and extracted with dichloromethane (4 × 500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown gel (15.00 g). It was then processed on a Grace instrument using 120 g of normal-phase silica gel. The product was purified by chromatography using a pre-packed rapid column of 40-63 μm and eluted with 15-20% ethyl acetate in hexane to give a colorless colloidal 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate (10.0 g).
[0884] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.61 (s, 1H), 7.59 (d, 2H, J = 7.52Hz), 7.58 (t, 1H, J = 7.00Hz), 4.38 (q,2H,J=14.40Hz),1.95(q,2H,J=7.28Hz),1.39(s,9H),1.11(s,9H),1.09(t,3H,J=6.08Hz);
[0885] MS: m / z 318.2[(M+1)-Boc].
[0886] Example 25, Step 6: Preparation of 2-amino-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate hydrochloride
[0887]
[0888] Under a nitrogen atmosphere and at 0°C, a 4M HCl solution (15.00 mL, 59.90 mmol) in dioxane was added dropwise to a solution of 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (from Example 25, Step 5) (10.00 g, 24.00 mmol) in anhydrous dichloromethane (300 mL). The reaction mixture was stirred at ambient temperature for 16 h, then concentrated, and the residue was ground with hexane (3 × 250 mL). The supernatant was decanted, and the solid was dried to give a colorless colloidal 2-amino-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate hydrochloride (8.50 g), which could be used in the next step without further purification.
[0889] 1H NMR (400MHz, DMSO-d6:D2O) δ7.74(s,1H),7.68(d,2H,J=13.60Hz),7.56(t,1H,J=8.84Hz),4.56(d ,1H,J=12.08Hz),4.22(d,1H,J=12.12Hz),2.17-1.97(m,2H),1.02(s,9H),0.78(t,3H,J=7.36Hz);
[0890] MS: m / z 318.2 [(M+1)-HCl].
[0891] Example 25, Step 7: Preparation of 2-isothiocyano-2-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate
[0892]
[0893] At 0°C, a 10% sodium bicarbonate aqueous solution (300 mL) was added to a solution of 2-amino-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate hydrochloride (from Example 25, step 6) (8.50 g, 24.00 mmol) in anhydrous dichloromethane (300 mL). After 30 min, phosgene (11.00 mL, d = 1.5 g / cm³) was added. 3 The mixture was stirred at the same temperature for 1 h. The reaction mixture was extracted with dichloromethane (3 × 500 mL), the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give a yellow liquid (9.00 g). This was then transferred to a Grace instrument using 60.0 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm, and the product was eluted with 5-10% ethyl acetate in hexane to give a yellow liquid 2-isothiocyano-2-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate (6.50 g).
[0894] 1 H NMR (400MHz, DMSO-d6) δ7.62 (s, 1H), 7.59 (d, 2H, J = 7.16Hz), 7.56 (t, 1H, J = 7.76Hz), 4.39 (d, 2H, J=4.04Hz),2.21(q,1H,J=7.20Hz),2.07(q,1H,J=6.96Hz),1.16(s,9H),0.91(t,3H,J=7.12Hz);
[0895] Example 25, Step 8: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0896]
[0897] Add [2-isothiocyano-2-[3-(trifluoromethyl)phenyl]butyl]2,2-dimethylpropionate (from Example 25, step 7) (0.317 g, 0.880 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (Example 1, step 5) (0.300 g, 1.47 mmol) in a dichloromethane:methanol (1:1; 8 mL) mixture, and stir at ambient temperature for 72 h. The reaction mixture was concentrated in a water bath at 30°C to give a brown gel-like substance 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (0.600 g), which can be used in the next step without further purification.
[0898] MS: m / z 564.4 (M+1).
[0899] Example 25, Step 9: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate
[0900]
[0901] Iodoacetic acid (0.297 g, 1.60 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 25, Step 8) (0.600 g, 1.06 mmol) in methanol (8 mL), and the mixture was refluxed for 1.5 h. The reaction mixture was concentrated at 30 °C to remove the solvent methanol, yielding a brown gel (0.700 g). The product was purified by preparative HPLC (TFA: acetonitrile) to obtain a brown gel-like substance 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (0.090 g), which was separated as a trifluoroacetate.
[0902] 1 H NMR(400MHz,AcOH-d4)δ7.82(d,J=6.44Hz,2H),7.74(d,J=7.60Hz,1H),7.66(t,J=7.84Hz,1H),7.58(s,1H),7.32-7.30(m,3H),7.23 (s,1H),5.40(s,2H),4.94(d,J=11.84Hz,1H),4.76(d,J=11.92Hz,1H),2.35(q,J=7.08Hz,2H),1.15(s,9H),0.92(t,J=7.40Hz,3H);
[0903] MS: m / z 530.2 / 531.2(M+1).
[0904] Example 25: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butane-1-ol]
[0905]
[0906] 0.5N sodium hydroxide was added dropwise to a solution of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate trifluoroacetate (Example 25, step 9) (0.080 g, 0.124 mmol) in methanol (0.990 mL, 0.497 mmol), and the mixture was stirred at ambient temperature for 3 h. The reaction mixture was quenched with 1.5N hydrochloric acid solution (1 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.070 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to obtain a brown colloidal substance 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butane-1-ol (0.020 g), which was separated as a trifluoroacetate.
[0907] 1 H NMR(400MHz,AcOH-d4)δ7.82(s,1H),7.77(d,J=8.00Hz,1H),7.69(d,J=8.00Hz,1H ),7.61(t,J=8.00Hz,1H),7.56(d,J=1.60Hz,1H),7.38(dd,J=6.80,2.00Hz,1H),7 .31-7.26(m,2H),7.20(d,J=1.60Hz,1H),5.40(q,J=16.00Hz,2H),4.69(d,J=12.4 0Hz, 1H), 4.29 (d, J = 12.40Hz, 1H), 2.07 (q, J = 7.32Hz, 2H), 0.86 (t, J = 7.20Hz, 3H);
[0908] MS: m / z 446.1 / 447.1[(M+1)].
[0909] Example 26: Preparation of 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butane-1-ol]
[0910]
[0911] Example 26, Step 1: Preparation of (E)-2-methyl-N-(1-(3-(trifluoromethyl)phenyl)ethylidene)propane-2-sulfinamide
[0912]
[0913] Under a nitrogen atmosphere, 2-methylpropane-2-sulfinamide (80.52 g, 664.00 mmol) was added to a solution of 1-(3-(trifluoromethyl)phenyl)ethane-1-one (commercially available) (125.0 g, 664.0 mmol) in anhydrous tetrahydrofuran (1500 mL), followed by titanium ethoxide (IV) (278.60 mL, d = 1.008 gm / mL, 1328.0 mmol), and the mixture was heated to 70 °C and maintained for 17 h. The reaction mixture was diluted with a saline solution (200 mL), filtered, and the filtrate was evaporated to give a yellow gel (200.0 g). This was purified by gravity column chromatography on 60-120 mesh silica gel, eluting the product with 10% ethyl acetate in hexane to give a yellow gel (E)-2-methyl-N-(1-(3-(trifluoromethyl)phenyl)ethylene)propane-2-sulfinamide (150.0 g).
[0914] 1 H NMR (400MHz, CD3OD) δ8.25(s,1H),8.23(d,J=7.60Hz,1H),7.88(d,J=7.60Hz,1H),7.72(t,J=8.00Hz,1H),2.84(s,3H),1.35(s,9H);
[0915] MS: m / z 292.3(M+1).
[0916] Example 26, Step 2: Preparation of methyl 3-((tert-butylsulfinyl)amino)-3-(3-(trifluoromethyl)phenyl)butyrate
[0917]
[0918] Copper chloride (I) (51.0 g, 515.0 mmol) was added to a suspension of zinc powder (269.3 g, 4.120 gm, atoms) in anhydrous tetrahydrofuran (750 mL), and the mixture was stirred at 60 °C. After 30 min, a solution of methyl 2-bromoacetate (122.0 mL, d = 1.616 gm / mL, 1287.0 mmol) in anhydrous tetrahydrofuran (500 mL) was added dropwise, and the mixture was stirred at the same temperature for 30 min. A solution of (E)-2-methyl-N-(1-(3-(trifluoromethyl)phenyl)ethylidene)propane-2-sulfinamide (from Example 26, Step 1) (150.0 g, 515.0 mmol) in anhydrous tetrahydrofuran (500 mL) was added dropwise at 0–5 °C, and the mixture was stirred at the same temperature for 1 h. The reaction mixture was quenched with saturated ammonium chloride solution (200 mL), the solid formed was filtered, and the filtrate was extracted with ethyl acetate (3 × 1000 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and evaporated to give a brown gel (250.0 g). This was purified by gravity column chromatography on silica gel at 60–120 g / L, eluting the product with 70–75% ethyl acetate in hexane to give a yellow gel methyl 3-((tert-butylsulfinyl)amino)-3-(3-(trifluoromethyl)phenyl)butyrate (135.0 g).
[0919] 1 H NMR(400MHz,AcOH-d4)δ7.81(d,J=7.6Hz,1H),7.74(d,J=8.00Hz,1H),7.62(d,J=7.60Hz,1 H),7.56(t,J=8.00Hz,1H),3.62(s,3H),3.20(q,J=16.40Hz,2H),1.87(s,3H),1.35(s,9H);
[0920] MS: m / z 366.2 (M+1).
[0921] Example 26, Step 3: Preparation of N-(4-hydroxy-2-(3-(trifluoromethyl)phenyl)butane-2-yl)-2-methylpropane-2-sulfinamide
[0922]
[0923] Under a nitrogen atmosphere and at 0°C, 2M lithium aluminum hydride in tetrahydrofuran (53.00 mL, 82.10 mmol) was added to a stirred solution of methyl 3-((tert-butylsulfinyl)amino)-3-(3-(trifluoromethyl)-phenyl)butyrate (from Example 26, Step 2) (20.00 g, 54.70 mmol) in anhydrous tetrahydrofuran (300 mL), and the reaction mixture was stirred at the same temperature for 2 h. The reaction mixture was quenched at 0°C with ethyl acetate (250 mL), followed by quenching with 10% ammonium chloride aqueous solution (200 mL), the organic layer was separated, and further extracted with ethyl acetate (4 × 750 mL). The combined organic layers, dried over sodium sulfate, were filtered and concentrated to obtain a yellow oily substance, N-(4-hydroxy-2-(3-(trifluoromethyl)phenyl)butan-2-yl)-2-methylpropane-2-sulfinamide (10.00 g), which can be used in the next step without further purification.
[0924] 1 H NMR (400MHz, DMSO-d6) δ7.77(s,1H),7.75(d,J=7.60Hz,1H),7.61(t,J=7.60Hz,1H),7.57(d,J=7.60Hz,1H),5.80(s,1H),4.81(t,J=4 .80Hz,1H),3.49(q,J=4.80Hz,1H),3.31(q,J=4.00Hz,1H),2.11(q,J=7.20Hz,1H),1.89(q,J=6.00Hz,1H),1.74(s,3H),1.13(s,9H);
[0925] MS: m / z 338.2 (M+1).
[0926] Example 26, Step 4: Preparation of 3-[(2-methylpropane-2-sulfinyl)amino]-3-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate
[0927]
[0928] Under a nitrogen atmosphere and at 0°C, sodium hydride (1.77 g, 77.10 mmol) was added to a suspension of N-(4-hydroxy-2-(3-(trifluoromethyl)phenyl)butan-2-yl)-2-methylpropane-2-sulfinamide (from Example 26, step 3) (13.00 g, 38.50 mmol) in anhydrous tetrahydrofuran (300 mL), and the mixture was stirred for 30 min at the same temperature. Neopentanoyl chloride (7.10 mL, d = 0.985 g / cm³) was then added. 3The reaction mixture (57.80 mmol) was stirred at 0 °C for 3 h. The reaction mixture was quenched at 0 °C with ethyl acetate (200 mL), followed by quenching with 10% ammonium chloride aqueous solution (150 mL). The organic layer was separated and further extracted with ethyl acetate (4 × 500 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a yellow liquid (17.0 g). This liquid was then processed on a Grace instrument using 220.00 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm. The product was eluted with 35% ethyl acetate in hexane to give a yellow oily compound 3-[(2-methylpropane-2-sulfinyl)amino]-3-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate (15.0 g).
[0929] 1 H NMR (400MHz, DMSO-d6) δ7.78(s,1H),7.76(d,J=7.60Hz,1H),7.59(t,J=7.32Hz,1H),7.56(d,J=7.60Hz, 1H),5.51(s,1H),3.91(t,J=8.80Hz,2H),2.27(t,J=8.40Hz,2H),1.71(s,3H),1.13(s,9H),1.01(s,9H);
[0930] MS: m / z 422.1(M+1).
[0931] Example 26, Step 5: Preparation of 3-amino-3-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate hydrochloride
[0932]
[0933] At 0°C, 4M HCl in dioxane (4.50 mL, 178.0 mmol) was added to a stirred solution of 3-[(2-methylpropane-2-sulfinyl)amino]-3-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (from Example 26, Step 4) (15.00 g, 35.60 mmol) in dichloromethane (200 mL), and the mixture was stirred at ambient temperature for 12 h. The reaction mixture was concentrated to give a yellow gel-like 3-amino-3-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate hydrochloride (12.0 g), which could be used in the next step without further purification.
[0934] 1H NMR (400MHz, DMSO-d6) δ8.90(bs,3H),7.95(s,1H),7.91(d,J=7.60Hz,1H),7.78(d,J=8.00Hz,1H ),7.72(t,J=8.00Hz,1H),3.97-3.88(m,2H),2.39(t,J=6.80Hz,2H),1.76(s,3H),0.097(s,9H);
[0935] MS: m / z 318.2 [(M+1)-HCl].
[0936] Example 26, Step 6: Preparation of 3-isothiocyano-3-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate
[0937]
[0938] At 0°C, sulfur phosgene (3.90 mL, d = 1.50 g / cm³) was added to a stirred solution of 3-amino-3-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate hydrochloride (from Example 26, step 5) (12.00 g, 33.90 mmol) in a two-phase mixture of dichloromethane (50 mL) and 10% sodium bicarbonate aqueous solution (50 mL). 3 The mixture was stirred for 30 min. The organic layer was separated and further extracted with dichloromethane (2 × 250 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to give a yellow oily substance, 3-isothiocyano-3-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate (7.50 g), which could be used in the next step without further purification.
[0939] 1 H NMR (400MHz, DMSO-d6) δ7.81(s,1H),7.78(s,1H),7.72(t,J=7.20Hz,1H),7.67(d,J=8.80Hz,1H), 3.95(t,J=7.60Hz,2H),2.51(d,J=8.80Hz,1H),2.44(d,J=8.40Hz,1H),1.87(s,3H),1.01(s,9H);
[0940] Example 26, Step 7: Preparation of 3-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-3-[3-(trifluoromethyl)-phenyl]butyl 2,2-dimethylpropionate and 3-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-3-[3-(trifluoromethyl)-phenyl]butyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0941]
[0942] 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (from Example 1, Step 5) (0.273 g, 1.34 mmol) was added to a stirred solution of [3-isothiocyano-3-[3-(trifluoromethyl)phenyl]butyl]2,2-dimethylpropionate (from Example 26, Step 6) (0.400 g, 1.11 mmol) in dichloromethane (10 mL), and the reaction mixture was stirred at ambient temperature for 48 h. The reaction mixture was concentrated to give a brown gel-like substance, 3-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-3-[3-(trifluoromethyl)-phenyl]butyl 2,2-dimethylpropionate and 3-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-3-[3-(trifluoromethyl)-phenyl]butyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (0.600 g), which can be used in the next step without further purification.
[0943] MS: m / z 564.3 (M+1).
[0944] Example 26, Step 8: Preparation of 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butyl-2,2-dimethylpropionate
[0945]
[0946] Ioiodoacetic acid (0.198 g, 1.06 mmol) was added to a solution of 3-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-3-[3-(trifluoromethyl)-phenyl]butyl 2,2-dimethylpropionate and 3-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-3-[3-(trifluoromethyl)-phenyl]butyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (from Example 26, step 7) (0.600 g, 1.06 mmol) in methanol (20 mL), and the reaction mixture was stirred at ambient temperature for 3 h. The reaction mixture was concentrated to obtain a brown gel (0.400 g), which was purified by preparative HPLC using the TFA method to obtain a brown gel 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate (0.300 g), which was separated as a trifluoroacetate.
[0947] 1 H NMR(400MHz,AcOH-d4)δ7.91(s,1H),7.85(d,J=9.20Hz,1H),7.70(d,J=7.60Hz,1H),7.62(t,J=7.60Hz,1H),7.59(d,J=1.60Hz,1H),7.34(t,J=4.8 0Hz,1H),7.29(d,J=4.80Hz,2H),7.25(d,J=1.60Hz,1H),5.44(d,J=14.0 0Hz,2H),4.27-4.10(m,2H),2.63-2.53(m,2H),2.02(s,3H),1.11(s,9H);
[0948] MS: m / z 530.6 (M+1).
[0949] Example 26: Preparation of 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butane-1-ol]
[0950]
[0951] At 0°C, 0.5 M sodium hydroxide was added dropwise to a solution of 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butyl 2,2-dimethylpropionate trifluoroacetate (from Example 26, step 8) (0.300 g, 0.466 mmol) in methanol (4.66 mL, 2.33 mmol), and the mixture was stirred at 28°C for 4 h. The reaction mixture was quenched with 1.5 N HCl aqueous solution (10 mL) and concentrated at 25°C to give a brown gel (0.100 g). The product was purified by preparative HPLC using the TFA method to obtain a white solid 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butane-1-ol (0.040 g), which was then separated as a trifluoroacetate.
[0952] 1 H NMR (400MHz, AcOH-d4) δ7.91 (s, 1H), 7.88 (dd, J=8.80, 17.80Hz, 1H), 7.68 (dd, J= 10.00,17.20Hz,1H),7.62(t,J=7.60Hz,1H),7.47-7.39(m,1H),7.27(d,J=1.60H z,1H),7.24(t,J=7.20Hz,1H),6.56(dd,J=2.80Hz,1H),6.50(dd,J=0.80,3.00Hz ,1H),4.88(d,J=14.80Hz,2H),3.88-3.80(m,2H),2.51-2.41(m,2H),2.04(s,3H);
[0953] MS: m / z 446.2 (M+1).
[0954] Example 27: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol
[0955]
[0956] Example 27, Step 1: Preparation of 5-methyl-5-(3-(trifluoromethoxy)phenyl)imidazolidine-2,4-dione
[0957]
[0958] Ammonium carbonate (106.0 g, 1100.0 mmol) was added to a stirred solution of 1-(3-(trifluoromethoxy)phenyl)ethane-1-one (commercially available) (45.0 g, 220.0 mmol) in a 1:1, 1000 mL ethanol / water mixture, followed by potassium cyanide (17.20 g, 265.0 mmol). The mixture was stirred at 60 °C for 16 h. The reaction mixture was then poured into ice-cold water (1500 mL) and stirred for 30 min. The resulting solid was filtered off and dried to give a grayish-white solid, 5-methyl-5-(3-(trifluoromethoxy)phenyl)imidazolidine-2,4-dione (56.0 g), which could be used in the next step without further purification.
[0959] 1 H NMR (400MHz, DMSO-d6) δ10.88(bs,1H),8.67(s,1H),7.56(t,1H,J=8.00Hz),7.53(d,1H,J=7.60Hz),7.42(s,1H),7.35(d,1H,J=6.80Hz),1.66(s,3H);
[0960] MS: m / z 273.1 (M-1).
[0961] Example 27, Step 2: Preparation of 2-amino-2-(3-(trifluoromethoxy)phenyl)propionic acid
[0962]
[0963] 60.0 g (219.0 mmol) of 5-methyl-5-(3-(trifluoromethoxy)phenyl)imidazolidine-2,4-dione (from Example 27, Step 1) was added to a 10% aqueous sodium hydroxide solution (600 mL), and the mixture was stirred at 120 °C for 5 days. The reaction mixture was neutralized with 6.0 N HCl (300 mL) (adjusting pH to 7), filtered, and the resulting solid was dried to give a white solid of 2-amino-2-(3-(trifluoromethoxy)phenyl)propionic acid (51.0 g), which could be used in the next step without further purification.
[0964] 1 H NMR (400MHz, DMSO-d6) δ8.07 (bs, 3H), 7.52 (t, 1H, J = 8.00Hz), 7.51 (s, 1H), 7.47 (d, 1H, J = 7.64Hz), 7.28 (d, 1H, J = 8.00Hz), 1.64 (s, 3H);
[0965] MS: m / z 250.1 (M+1).
[0966] Example 27, Step 3: Preparation of 2-amino-2-(3-(trifluoromethoxy)-phenyl)propane-1-ol
[0967]
[0968] At 0°C, a solution of 2M lithium aluminum hydride in tetrahydrofuran (120.00 mL, 241.0 mmol) was added to a solution of 2-amino-2-(3-(trifluoromethoxy)phenyl)propionic acid (from Example 27, Step 2) (40.00 g, 161.00 mmol) in anhydrous tetrahydrofuran (1000 mL), and the reaction mixture was slowly heated to ambient temperature and stirred for 3 h. The reaction mixture was cooled to 0°C and quenched by dropwise addition of ethyl acetate solution (120 mL) and stirred for 30 min. Then, it was treated with dropwise addition of saturated ammonium chloride solution (150 mL) and stirred at 0°C for 15 min. The precipitate obtained was separated by filtration, and the filtrate was concentrated under reduced pressure to give a yellow gel (38.0 g). It was diluted with 10% sodium hydroxide solution (100 mL) and extracted with ethyl acetate (4 × 1000 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a yellow oily substance, 2-amino-2-(3-(trifluoromethoxy)-phenyl)propane-1-ol (23.0 g), which could be used in the next step without further purification.
[0969] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.47(d,1H,J=7.84Hz),7.44(s,1H),7.41(t,1H,J=9.00Hz),7.15(d,1H,J=7.80Hz),3.41(q,2H,J=10.48Hz),1.33(s,3H);
[0970] MS: m / z 236.1 (M+1).
[0971] Example 27, Step 4: Preparation of tert-butyl N-{1-hydroxy-2-[3-(trifluoromethoxy)phenyl]propane-2-yl}carbamate
[0972]
[0973] At 0°C, di-tert-butyl dicarbonate (44.50 mL, d: 0.950 g / cm³) was added dropwise to a suspension of 2-amino-2-(3-(trifluoromethoxy)phenyl)propane-1-ol (from Example 27, step 3) (38.0 g, 162.0 mmol) in a mixed solvent of dichloromethane:1,4-dioxane (4:1; 500 mL). 3The mixture was stirred at ambient temperature for 72 h (194.00 mmol). The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (4 × 1000 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a yellow gel (55.0 g). This gel was then processed on a Grace instrument using 220.0 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm, and the product was eluted with 30-40% ethyl acetate in hexane to obtain a colorless colloidal tert-butyl N-{1-hydroxy-2-[3-(trifluoromethoxy)phenyl]propane-2-yl}carbamate (36.0 g).
[0974] 1 H NMR (400MHz, DMSO-d6) δ7.44(d,1H,J=7.40Hz),7.40(s,1H),7.32(d,1H,J=11.20Hz),7.20(t,1H,J =9.60Hz), 6.85 (bs, 1H), 4.96 (t, 1H, J = 7.20Hz), 4.03 (q, 2H, J = 9.60Hz), 1.56 (s, 3H), 1.37 (s, 9H);
[0975] MS: m / z 336.2 (M+1).
[0976] Example 27, Step 5: Preparation of 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate
[0977]
[0978] Under a nitrogen atmosphere and at 0°C, triethylamine (41.54 mL, d = 0.726 g / cm³) was added to a solution of tert-butyl N-{1-hydroxy-2-[3-(trifluoromethoxy)phenyl]propane-2-yl}carbamate (from Example 27, step 4) (25.00 g, 74.60 mmol) in anhydrous dichloromethane (500 mL). 3 298.0 mmol), then add pentanoyl chloride (18.24 mL, d = 0.985 g / cm). 3 149.0 mmol), and the reaction mixture was stirred at ambient temperature for 48 h. The reaction mixture was quenched with ice-cold water (150 mL) and extracted with dichloromethane (4 × 750 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown gel (32.0 g). It was then processed on a Grace instrument using 120.0 g of normal-phase silica gel. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm. The product was eluted with 15-20% ethyl acetate in hexane to give a yellow liquid 2-{[(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (20.0 g).
[0979] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.47(t,1H,J=10.80Hz),7.37(d,1H,J=10.80Hz),7.27(s,1H) ,7.23(d,1H,J=10.40Hz),4.26(q,2H,J=14.00Hz),1.55(s,3H),1.40(s,9H),1.11(s,9H);
[0980] MS: m / z 320.2[(M+1)-Boc].
[0981] Example 27, Step 6: Preparation of 2-amino-2-[3-(trifluoromethoxy)-phenyl]propyl 2,2-dimethylpropionate hydrochloride
[0982]
[0983] Under a nitrogen atmosphere and at 0°C, a 4M HCl solution (95.40 mL, 381.00 mmol) in dioxane was added dropwise to a solution of 2-{(tert-butoxy)carbonyl]amino}-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (from Example 27, Step 5) (32.00 g, 76.30 mmol) in anhydrous dichloromethane (400 mL). The reaction mixture was stirred at ambient temperature for 16 h, then concentrated, and the residue was ground with hexane (3 × 250 mL). The supernatant was decanted, and the solid was dried to give a yellow gel-like substance, 2-amino-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate hydrochloride (20.0 g), which could be used in the next step without further purification.
[0984] 1 H NMR (400MHz, DMSO-d6) δ8.98 (s, 3H), 7.61 (t, 1H, J = 7.48Hz), 7.57 (d, 2H, J = 7.50Hz), 7. 43(s,1H),4.46(d,1H,J=11.60Hz),4.28(d,1H,J=12.12Hz),1.70(s,3H),1.04(s,9H);
[0985] MS: m / z 320.1 [(M+1)-HCl].
[0986] Example 27, Step 7: Preparation of 2-isothiocyano-2-[3-(trifluoromethoxy)-phenyl]propyl 2,2-dimethylpropionate
[0987]
[0988] At 0°C, a 10% sodium bicarbonate aqueous solution (50 mL) was added to a solution of 2-amino-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate hydrochloride (from Example 27, step 6) (3.80 g, 12.00 mmol) in anhydrous dichloromethane (50 mL). After 30 min, phosgene (1.82 mL, d = 1.5 g / cm³) was added. 3 The mixture was stirred at the same temperature for 1 h. The reaction mixture was extracted with dichloromethane (3 × 200 mL), the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give a yellow liquid (4.30 g). This liquid was then subjected to a 60.0 g positive silica gel packing process on a Grace instrument. Chromatographic purification was performed using a pre-packed rapid column of 40-63 μm, and the product was eluted with 8-10% ethyl acetate in hexane to give a colorless liquid 2-isothiocyano-2-[3-(trifluoromethoxy)-phenyl]propyl 2,2-dimethylpropionate (2.00 g).
[0989] 1 H NMR (400MHz, DMSO-d6) δ7.59 (d, 1H, J = 7.90Hz), 7.56 (t, 1H, J = 4.60Hz), 7.47 (s, 1H), 7.38 (d, 1H, J = 7.70Hz), 4.47 (q, 2H, J = 11.32Hz), 1.79 (s, 3H), 1.05 (s, 9H).
[0990] Example 27, Step 8: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[0991]
[0992] Add [2-isothiocyano-2-[3-(trifluoromethoxy)phenyl]propyl]2,2-dimethylpropionate (from Example 27, step 7) (3.89 g, 1.08 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (from Example 1, step 5) (2.20 g, 1.08 mmol) in a dichloromethane:methanol (4:1; 10 mL) mixture, and stir the mixture at ambient temperature for 48 h. The reaction mixture was concentrated in a water bath at 30°C to give a brown gel-like substance 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (6.00 g), which can be used in the next step without further purification.
[0993] MS: m / z 566.0 (M+1).
[0994] Example 27, Step 9: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate
[0995]
[0996] Iodoacetic acid (2.96 g, 15.90 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (from Example 27, step 8) (6.00 g, 1.06 mmol) in methanol (50 mL), and the mixture was stirred at ambient temperature for 2 h. The reaction mixture was concentrated at 30°C to remove the solvent methanol, yielding a brown gel-like substance, 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (5.50 g), which could be used in the next step without further purification.
[0997] MS: m / z 532.2 [(M+1)].
[0998] Example 27: Preparation of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol
[0999]
[1000] To a solution of 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (from Example 27, step 9) (4.0 g, 7.53 mmol) in methanol (45.2 mL, 22.6 mmol), 0.5 M sodium hydroxide was added dropwise. The mixture was stirred at ambient temperature for 30 min. The reaction mixture was quenched with 10 mL of 1.5 N HCl aqueous solution at 0 °C and concentrated at 28 °C to give a brown gel (0.520 g). The mixture was purified by preparative HPLC to obtain a yellow gelatinous substance, 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol (2.2 g), which was then separated as a trifluoroacetate.
[1001] 1 H NMR(400MHz,AcOH-d4)δ7.57-7.50(m,3H),7.45(s,1H),7.41(dd,J=2.40,6.80Hz,1H),7.30(d,J=6.40Hz,3H), 7.21(d,J=1.60Hz,1H),5.41(d,J=4.80Hz,2H),4.39(d,J=12.00Hz,1H),4.11(d,J=12.00Hz,1H),1.79(s,3H);
[1002] MS: m / z 448.1 [(M+1)].
[1003] The above product was resolved into its two enantiomers by chiral SFC using the following method: column: (R,R)-Whelk-01; flow rate: 3.0 mL / min; cosolvent: 30%; cosolvent name: 0.5% isopropylamine in isopropanol; injection volume: 3.0 μL; outlet pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 27a and 27b.
[1004] Example 27a: (+)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol
[1005] The (+) enantiomer was the first compound eluted from the column.
[1006]
[1007] 1 H NMR(400MHz,AcOH-d4)δ7.56-7.52(m,3H),7.45(s,1H),7.41(d,J=8.00Hz,1H),7.30-7.27(m,3H),7.20( d,J=1.60Hz,1H),5.41(d,J=6.40Hz,2H),4.39(d,J=12.40Hz,1H),4.11(d,J=12.00Hz,1H),1.78(s,3H);
[1008] MS: M / z 448.2(M+1);
[1009] [α]D 25.4 (+)9.20(MeOH,c=1.0).
[1010] Example 27b: (-)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol
[1011] (-) The enantiomer is the second compound eluted from the column.
[1012]
[1013] 1 H NMR(400MHz,AcOH-d4)δ7.57-7.49(m,3H),7.45(s,1H),7.41(d,J=8.40Hz,1H),7.30-7.24(m,3H),7.20( d,J=1.20Hz,1H),5.41(d,J=6.40Hz,2H),4.39(d,J=12.00Hz,1H),4.11(d,J=12.00Hz,1H),1.78(s,3H);
[1014] MS: m / z 448.0 (M+1);
[1015] [α]D 25.5 (-)8.6(MeOH,c=1.0).
[1016] Example 28: Preparation of 2-({4-[(2-imino-4,5-dimethyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]-propane-1-ol
[1017]
[1018] The title compound was prepared by the method described in Example 18, starting with commercially available 4,5-dimethyloxazol-2-amine and then using [2-isothiocyano-2-[3-(trifluoromethyl)phenyl]propyl]2,2-dimethylpropionate (from Example 18, step 7), and isolated as a trifluoroacetate.
[1019] 1H NMR(400MHz,AcOH-d4)δ7.87(s,1H),7.84(d,J=8.00Hz,1H),7.69(d,J=8.0 0Hz,1H),7.61(t,J=8.00Hz,1H),7.34(d,J=8.00Hz,1H),7.24(t,J=8.00Hz, 1H),6.87(d,J=7.60Hz,1H),5.41(s,2H),4.42(d,J=12.00Hz,1H),4.14(d,J =12.00Hz,1H),2.28(d,J=0.80Hz,3H),2.01(d,J=0.80Hz,3H),1.82(s,3H);
[1020] MS: m / z 460(M+1).
[1021] Example 29: Preparation of 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol)
[1022]
[1023] The title compound was prepared by the method described in Example 27, starting with 3-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 5, step 2) and [2-isothiocyano-2-[3-(trifluoromethoxy)phenyl]propyl]2,2-dimethylpropionate (from Example 27, step 7), and isolated as a trifluoroacetate.
[1024] 1 H NMR(400MHz,AcOH-d4)δ7.59-7.50(m,2H),7.44(d,J=1.56Hz,2H),7.37(d,J=8.00Hz,1H),7.31-7.24(m,2H),6 .88(d,J=7.84Hz,1H),5.47(s,2H),4.39(d,J=12.04Hz,1H),4.12(d,J=12.12Hz,1H),2.02(s,3H),1.80(s,3H);
[1025] MS: m / z 462.2(M+1).
[1026] Example 30: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]-propane-1-ol]
[1027]
[1028] Example 30, Step 1: Preparation of 2-[({2-amino-3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[1029]
[1030] Add [2-isothiocyano-2-[3-(trifluoromethoxy)phenyl]propyl]2,2-dimethylpropionate (from step 7 of Example 27) (0.300 g, 0.830 mmol) to a solution of 3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl-1,2-diamine (Example 24, step 2) (0.280 g, 1.28 mmol) in a dichloromethane:methanol (2:1; 9 mL) mixed solvent, and stir at ambient temperature for 48 h. The reaction mixture was concentrated in a water bath at 30°C to give a brown gel-like substance 2-[({2-amino-3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (0.580 g), which can be used in the next step without further purification.
[1031] MS: m / z 580.4 (M+1).
[1032] Example 30, Step 2: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propyl 2,2-dimethylpropionate
[1033]
[1034] Iodoacetic acid (0.265 g, 1.42 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]phenyl}carbamoylthio)amino]-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (as a mixture of inseparable regioisomers) (Example 30, Step 1) (0.550 g, 0.949 mmol) in methanol (8 mL), and the mixture was refluxed for 1.5 h. The reaction mixture was concentrated at 30°C to remove the solvent methanol, yielding a brown gel (0.600 g), which was purified by preparative HPLC (TFA: acetonitrile) to obtain a brown gel 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propyl 2,2-dimethylpropionate (0.200 g), which was separated as a trifluoroacetate.
[1035] 1 H-NMR (400MHz, AcOH-d4): δ7.58-7.53(m,2H),7.48(s,1H),7.37-7.29(m,4H),6.86(d,J=1.20Hz,1H), 5.34(s,2H),4.61(d,J=11.60Hz,1H),4.50(d,J=11.60Hz,1H),2.26(s,3H),2.01(s,3H),1.17(s,9H);
[1036] MS: m / z 546.1 (M+1).
[1037] The above product was resolved into two enantiomers, Chiralcel OX-H, by chiral SFC using the following method: mobile phase: 0.5% isopropylamine in isopropanol; cosolvent: 40% CO2; flow rate: 4 mL / min; pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 30-2a and 30-2b.
[1038] Example 30-2a: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propyl 2,2-dimethylpropionate (enantiomer A).
[1039] Enantiomer A was the first compound eluted from the column, separated as a trifluoroacetate.
[1040]
[1041] 1 H-NMR (400MHz, AcOH-d4): δ7.58-7.53(m,2H),7.48(s,1H),7.37-7.29(m,4H),6.86(d,J=1.20Hz,1H), 5.34(s,2H),4.61(d,J=11.60Hz,1H),4.50(d,J=11.60Hz,1H),2.26(s,3H),2.01(s,3H),1.17(s,9H);
[1042] MS: m / z 546.1 (M+1).
[1043] Example 30-2b: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]-propyl-2,2-dimethylpropionate (enantiomer B).
[1044] Enantiomer B is the second compound eluted from the column, separated as a trifluoroacetate.
[1045]
[1046] 1H-NMR (400MHz, AcOH-d4): δ7.58-7.53(m,2H),7.48(s,1H),7.37-7.29(m,4H),6.86(d,J=1.20Hz,1H), 5.34(s,2H),4.61(d,J=11.60Hz,1H),4.50(d,J=11.60Hz,1H),2.26(s,3H),2.01(s,3H),1.17(s,9H);
[1047] MS: m / z 546.1 (M+1).
[1048] Example 30: Preparation of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]-propane-1-ol]
[1049]
[1050] To a solution of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate trifluoroacetate (from Example 30, step 2) (0.200 g, 0.303 mmol) in methanol (6.0 mL, 3.03 mmol), the mixture was stirred at ambient temperature for 5 h. The reaction mixture was quenched with 1.5 N hydrochloric acid solution (3 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.170 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to obtain a brown gel-like substance 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol (0.080 g), which was separated as a trifluoroacetate.
[1051] 1H NMR(400MHz,AcOH-d4)δ7.58-7.50(m,2H),7.45(s,1H),7.41(dd,J=2.52,6.56Hz,1H),7.32-7.27(m,3H),6.82(d, J=1.40Hz,1H),5.33(d,J=3.76Hz,2H),4.39(d,J=12.08Hz,1H),4.11(d,J=12.12Hz,1H),2.25(s,3H),1.79(s,3H);
[1052] MS: m / z 462.3(M+1).
[1053] Example 30a: Preparation of (-)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propane-1-ol
[1054]
[1055] Sodium hydroxide in methanol (7.28 mL, 3.64 mmol) was added dropwise to a solution of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (Example 30-2a, enantiomer A) (0.480 g, 0.728 mmol) in methanol (7.28 mL, 3.64 mmol). The mixture was stirred at ambient temperature for 5 h. The reaction mixture was quenched with 1.5 N hydrochloric acid solution (4 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.410 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown colloidal substance (-)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propane-1-ol (0.165 g), which was separated as a trifluoroacetate.
[1056] 1H NMR(400MHz,AcOH-d4)δ7.58-7.50(m,2H),7.45(s,1H),7.41(dd,J=2.52,6.56Hz,1H),7.32-7.27(m,3H),6.82(d, J=1.40Hz,1H),5.33(d,J=3.76Hz,2H),4.39(d,J=12.08Hz,1H),4.11(d,J=12.12Hz,1H),2.25(s,3H),1.79(s,3H);
[1057] MS: m / z 462.4(M+1);
[1058] SOR:[α]D 24.9 (-)9.20,(MeOH,c=0.5).
[1059] Example 30b: Preparation of (+)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propane-1-ol
[1060]
[1061] Sodium hydroxide in methanol (8.34 mL, 4.17 mmol) was added dropwise to a solution of 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propyl 2,2-dimethylpropionate (Example 30-2b, enantiomer B) (0.550 g, 0.834 mmol). The mixture was stirred at ambient temperature for 5 h. The reaction mixture was quenched with 1.5 N hydrochloric acid solution (4 mL) and concentrated under reduced pressure at 30 °C to give a brown gel (0.48 g). The product was purified by preparative HPLC using 0.1% TFA in acetonitrile:water to give a brown colloidal substance (+)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol (0.150 g), which was separated as a trifluoroacetate.
[1062] 1H NMR(400MHz,AcOH-d4)δ7.58-7.50(m,2H),7.45(s,1H),7.41(dd,J=2.52,6.56Hz,1H),7.32-7.27(m,3H),6.82(d, J=1.40Hz,1H),5.33(d,J=3.76Hz,2H),4.39(d,J=12.08Hz,1H),4.11(d,J=12.12Hz,1H),2.25(s,3H),1.79(s,3H);
[1063] MS: m / z 462.3(M+1);
[1064] SOR:[α]D 24.9 (+)7.20, (MeOH, c=0.5).
[1065] Example 31: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1066]
[1067] Example 31, Step 1: Preparation of N-methoxy-N-methyl-2,1,3-benzothiadiazole-4-carboxamide
[1068]
[1069] Triethylamine (18.6 mL, 133 mmol) and propylphosphonic anhydride (50%, in EtOAc) (63.6 g, 200 mmol) were added to a solution of 2,1,3-benzothiadiazole-4-carboxylic acid (6 g, 33.3 mmol) and N,O-dimethylhydroxylamine hydrochloride (8.12 g, 83.2 mmol) in tetrahydrofuran (75 mL). The reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture was washed with water (250 mL), extracted with ethyl acetate (3 × 100 mL), and the combined organic layers were washed with a brine solution (100 mL). The mixture was dried over sodium sulfate, filtered, and concentrated to give a crude product (13 g) as a brown solid. This crude product was purified by column chromatography and eluted with 40% ethyl acetate in petroleum ether to give a grayish-white solid N-methoxy-N-methyl-2,1,3-benzothiadiazole-4-carboxamide (7 g).
[1070] 1 H NMR (400MHz, DMSO-d6) δ8.21-8.17(m,1H),7.79-7.77(m,2H),3.50(s,3H),3.33(s,3H);
[1071] MS: m / z 224.1(M+1).
[1072] Example 31, Step 2: Preparation of 1-(2,1,3-benzothiadiazol-4-yl)ethane-1-one
[1073]
[1074] A solution of N-methoxy-N-methyl-2,1,3-benzothiadiazole-4-carboxamide (from Example 31, Step 1) (4 g, 17.9 mmol) in tetrahydrofuran:diethyl ether (1:1, 80 mL) was cooled to 0 °C, and methyl magnesium bromide (2 M, in THF) (53.7 mL, 107 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was quenched with an aqueous solution of ammonium chloride (100 mL), extracted with ethyl acetate (3 × 50 mL), washed with an aqueous brine solution (100 mL), dried over sodium sulfate, filtered, and concentrated to give a crude product (5.2 g) of brown gelatinous substance. This product was purified by silica gel column chromatography, eluting with 10% ethyl acetate in petroleum ether, to give a pale yellow solid 1-(2,1,3-benzothiadiazole-4-yl)ethane-1-one (1.2 g).
[1075] 1 H NMR (400MHz, DMSO-d6) δ8.31-8.25(m,2H),7.76-7.72(m,1H),3.07(s,3H);
[1076] MS: m / z 179.0 (M+1).
[1077] Example 31, Step 3: Preparation of N-[1-(2,1,3-benzothiadiazol-4-yl)ethyl]-1,3-oxazol-2-amine
[1078]
[1079] To a solution of 1-(2,1,3-benzothiadiazol-4-yl)ethane-1-one (from Example 31, Step 2) (1.2 g, 6.73 mmol) and 1,3-oxazol-2-amine (2.26 g, 26.9 mmol) in ethanol (40 mL) cooled to 0 °C, titanium isopropoxide (IV) (34.1 mL, 114 mmol) was added, and the reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture was then cooled to 0 °C, and sodium borohydride (0.764 g, 20.2 mmol) was added in portions, and the reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture was quenched with ice water (75 mL), filtered through a diatomaceous earth bed, and washed with ethyl acetate. The filtrate was concentrated, diluted with water (100 mL), extracted with ethyl acetate (3 × 50 mL), and the combined organic layers were washed with a brine solution (50 mL). The mixture was dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (1.3 g). The sample was purified by silica gel column chromatography and eluted with 30% ethyl acetate in petroleum ether to give a pale yellow solid N-[1-(2,1,3-benzothiadiazol-4-yl)ethyl]-1,3-oxazol-2-amine (0.320 g).
[1080] 1 H NMR(400MHz, DMSO-d6)δ7.98-7.95(m,2H),7.70(t,J=6.80Hz,1H),7.61(d,J=7.20Hz,1H), 7.40(d,J=0.80Hz,1H),6.65(d,J=0.80Hz,1H),5.56-5.49(m,1H),1.58(d,J=6.80Hz,3H);
[1081] MS: m / z 247.1 (M+1).
[1082] Example 31, Step 4: Preparation of 3-{1-[(1,3-oxazol-2-yl)amino]ethyl}phenyl-1,2-diamine
[1083]
[1084] Raunene nickel (1.82 g, 300 wt / wt) was added to a solution of N-[1-(2,1,3-benzothiadiazol-4-yl)ethyl]-1,3-oxazol-2-amine (from Example 31, Step 3) (0.400 g, 1.62 mmol) in methanol (30 mL), and the reaction mixture was incubated at ambient temperature at 1.5 kg / cm². 2 Hydrogenation was carried out for 16 hours. The reaction mixture was filtered through a diatomaceous earth bed, and the filtrate was concentrated to obtain a brown liquid product (0.295 g), which could be used in the next step without further purification.
[1085] MS: m / z 219.2 (M+1).
[1086] Example 31, Step 5: Preparation of 2-{[(2-amino-3-{1-[(1,3-oxazol-2-yl)amino]ethyl}-phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{1-[(1,3-oxazol-2-yl)amino]ethyl}phenyl)carbamoylthio]-amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate]
[1087]
[1088] [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7) (0.446 g, 1.35 mmol) was added to a solution of 3-(1-(1,3-oxazol-2-ylamino)ethyl)phenyl-1,2-diamine (from Example 31, step 4) (0.295 g, 1.35 mmol) in a dichloromethane:methanol (1:1, 8 mL) mixture, and the mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated to give a brown, gelatinous crude product (0.700 g), which could be used in the next step without further purification.
[1089] MS: m / z 548.1 (M+1).
[1090] Example 31, Step 6: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate
[1091]
[1092] To a solution of 2-{[(2-amino-3-{1-[(1,3-oxazol-2-yl)amino]ethyl}-phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{1-[(1,3-oxazol-2-yl)amino]ethyl}phenyl)carbamoylthio]-amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers) (from Example 31, step 5) (0.700 g, 1.28 mmol)) in methanol (10 mL), iodoacetic acid (0.237 g, 1.28 mmol) was added, and the reaction mixture was stirred at ambient temperature for 5 h. The reaction mixture was concentrated and diluted with ice-cold water (50 mL). The aqueous layer was extracted with dichloromethane (3 × 50 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (50 mL), then washed with brine solution (50 mL), dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (0.530 g). This was purified by preparative HPLC (0.1% TFA in acetonitrile:water) to give a brown gelatinous product 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (0.340 g).
[1093] 1 H NMR(400MHz,DMSO-d6)δ12.18(bs,1H),10.18(bs,1H),8.48(bs,1H),7.80-7.78(m,1H),7.50-7.42(m,3H),7.19-7.16(m,3H), 6.86(d,J=6.00Hz,1H),5.11(t,J=4.00Hz,1H),4.52-4.37(m,2H),1.87(d,J=6.80Hz,3H),1.48(d,J=9.20Hz,3H),1.06(s,9H);
[1094] MS: m / z 514.1 (M+1).
[1095] Example 31, Step 7: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1096]
[1097] To a solution of 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (from Example 31, Step 6) (0.240 g, 0.46 mmol) in methanol (3.7 mL, 1.87 mmol), 0.5 N sodium hydroxide in methanol was added, and the reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated, and the residue was diluted with water (10 mL). The aqueous layer was extracted with dichloromethane (3 × 15 mL), the combined organic layers were washed with water (10 mL), then with a brine solution (10 mL), dried over sodium sulfate, filtered, and concentrated to give a crude product (0.180 g). The sample was purified by preparative HPLC (method: 0.1% TFA in acetonitrile:water) to obtain a grayish-white solid 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol (0.060 g).
[1098] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.58-7.41(m,1H),7.41-7.30(m,3H),7.28-6.94(m,1H),6.87-6.79(m,2H),6.77-6.65(m,1 H),4.94-4.89(m,1H),3.83-3.48(m,2H),1.69(d,J=4.40Hz,3H),1.49(d,J=6.80Hz,1H),1.28(dd,J=6.80,21.20Hz,2H);
[1099] MS: m / z 430.2 (M+1).
[1100] Example 32: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1101]
[1102] Example 32, Step 1: Preparation of 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-2,3-dihydro-1,3-thiazolyl-2-imine hydrobromide
[1103]
[1104] 1,3-Thiazol-2-amine (commercially available) (10.50 g, 105.0 mmol) was added to a solution of 4-bromomethyl-2,1,3-benzothiadiazole (from Example 1, Step 3) (12.0 g, 52.4 mmol) in acetonitrile (120 mL), and the mixture was stirred at 60 °C for 16 h. The solid formed in the reaction mixture was filtered and dried to give a crude product (13 g) of brown solid. This was stirred with water (6 × 50 mL), the solid was filtered, and dried under high vacuum at 40 °C to give a grayish-white solid 3-[(2,1,3-benzothiadiazole-4-yl)methyl]-2,3-dihydro-1,3-thiazol-2-imine hydrobromide (9.0 g).
[1105] 1 H NMR (400MHz, DMSO-d6) δ9.75 (s, 2H), 8.12 (t, J = 0.40Hz, 1H), 7.76 (q, J = 6.80Hz, 1H), 7.49-7.43 (m, 2H), 7.10 (d, J = 4.80Hz, 1H), 5.81 (s, 2H);
[1106] MS: m / z 249.1 [(M+1)-HBr].
[1107] Example 32, Step 2: Preparation of 3-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-phenyl-1,2-diamine
[1108]
[1109] To a degassed solution of 3-[(2,1,3-benzothiadiazol-4-yl)methyl]-2,3-dihydro-1,3-thiazolyl-2-imine hydrobromide (from Example 32, Step 1) (2.5 g, 10.1 mmol) in anhydrous methanol (450 mL), 7.5 g of Ramanel (300% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was subjected to a hydrogen atmosphere and a pressure (approximately 1.5 kg / cm²). 2 The mixture was stirred at ambient temperature for 24 h. The reaction mixture was filtered through a diatomaceous earth bed, and the bed was washed with methanol (250 mL). The combined filtrates were concentrated at 20 °C to give a gray colloidal substance, 3-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-phenyl-1,2-diamine (2.0 g), which could be used in the next step without further purification.
[1110] 1 H NMR(400MHz, DMSO-d6)δ6.84(s,1H),6.56-6.41(m,4H),4.79(s,2H);
[1111] MS: m / z 221.1(M+1).
[1112] Example 32, Step 3: Preparation of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-thiazolyl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl-2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-thiazolyl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl-2,2-dimethylpropionate (a mixture of regioisomers)
[1113]
[1114] Add [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7) (3.0 g, 9.15 mmol) to a solution of 3-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]benzene-1,2-diamine (from Example 32, step 2) (4 g, 18.157 mmol) in a dichloromethane:methanol (1:1, 80 mL) mixture, and stir the mixture at room temperature for 72 h. The reaction mixture was concentrated in a water bath at 30°C to give a yellow gel-like substance 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl-2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl-2,2-dimethylpropionate (a mixture of regioisomers) (7.00 g), which can be used in the next step without further purification.
[1115] MS: m / z 550.1 (M+1).
[1116] Example 32, Step 4: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate
[1117]
[1118] Iodoacetic acid (3.55 g, 19.10 mmol) was added to a solution of 2-[({2-amino-3-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl-2,2-dimethylpropionate and 2-[({2-amino-6-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl-2,2-dimethylpropionate (a mixture of regioisomers) (from Example 32, Step 3) (7.00 g, 12.70 mmol) in methanol (110 mL), and the mixture was refluxed for 1 h. The reaction mixture was concentrated at 30 °C to remove the solvent methanol, giving a crude product (8.0 g) as a red gel. The product was purified by preparative HPLC (0.1% TFA in acetonitrile:water) to obtain a brown gel-like substance, 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (2.5 g), which was separated as a trifluoroacetate.
[1119] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.67(q,J=2.00Hz,1H),7.39-7.49(m,2H),7.32(d,J=8.00Hz,1H),7.19(q,J=8.40Hz,2 H),6.98(d,J=4.80Hz,1H),6.87(d,J=7.60Hz,1H),5.36(s,2H),4.41(q,J=11.20Hz,2H),1.84(s,3H),1.05(s,9H);
[1120] MS: m / z 516.1 [(M+1)].
[1121] Example 32, Step 5: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1122]
[1123] To a solution of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate trifluoroacetate (from Example 32, Step 4) (1.6 g, 2.54 mmol) in dioxane, 4.0 M HCl (3.81 mL, 15.20 mmol) was added dropwise, and the mixture was heated at 80 °C for 48 h. The reaction mixture was concentrated under reduced pressure at 30 °C to give a brown, gelatinous crude product (1.2 g). The product was purified by preparative HPLC (method: 0.1% TFA in acetonitrile:water) to obtain a brown gelatinous substance 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (0.9 g), which was separated as a trifluoroacetate.
[1124] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.59(t,J=2.00Hz,1H),7.39-7.33(m,3H),7.23-7.18(m,2H),7.0 0(d,J=4.40Hz,1H),6.84(d,J=7.60Hz,1H),5.37(s,2H),3.72(q,J=11.20Hz,2H),1.74(s,3H);
[1125] MS: m / z 432.0 [(M+1)].
[1126] The above product was separated into its two enantiomers by chiral SFC using the following method: column: Chiral pakOX-H; mobile phase: 0.5% isopropylamine in isopropanol; cosolvent: 50% CO2; flow rate: 5 mL / min; pressure: 100 bar; temperature: 35 °C, to obtain two enantiomers 32a and 32b.
[1127] Example 32a: (-)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1128] (-) The enantiomer is the first compound eluted from the column, separated as a hydrochloride salt.
[1129] 1H NMR(400MHz, DMSO-d6:D2O)δ7.54(d,J=6.80Hz,1H),7.30-7.21(m,2H),7.22(t,J=4.40Hz,2H),7.02 -6.95(m,2H),6.83(d,J=4.00Hz,1H),5.15(q,J=14.80Hz,2H),3.66(q,J=10.80Hz,2H),1.72(s,3H);
[1130] MS: m / z 432.1 [(M+1)-HCl];
[1131] SOR:[α]D 23.3 (-)22.40,(MeOH,c=0.5).
[1132] Example 32b: (+)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1133] The (+) enantiomer is the second compound eluted from the column and separated as a hydrochloride salt.
[1134] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.61(d,J=5.60Hz,1H),7.42-7.36(m,2H),7.30(d,J=7.60Hz,1H),7.24( d,J=4.40Hz,1H),7.10(bs,1H),6.94-6.92(m,2H),5.29(bs,2H)3.71(q,J=11.20Hz,2H),1.72(s,3H);
[1135] MS: m / z 432.1 [(M+1)-HCl];
[1136] SOR:[α]D 23.4 (+)22.80, (MeOH, c=0.5).
[1137] Example 33: Preparation of 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one]
[1138]
[1139] Example 33, Step 1: Preparation of 1-[(2,1,3-benzothiadiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one
[1140]
[1141] At 0°C, 60% sodium hydride (0.911 g, 23.8 mmol) was added to a solution of 2,3-dihydro-1H-imidazol-2-one (commercially available) (2.0 g, 23.80 mmol) in DMSO (200 mL), and the mixture was stirred for 30 min. 4-(bromomethyl)-2,1,3-benzothiadiazole (from Example 1, step 3) (4.36 g, 19.0 mmol) was added at 0°C, and the mixture was stirred at ambient temperature for 3 h. The reaction mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and concentrated to give a brown gel. The solid was filtered and dried to obtain a brown crude product (1.2 g), which was purified by silica gel column chromatography using 10% methanol in DCM as eluent to obtain a grayish-white solid 1-[(2,1,3-benzothiadiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one (0.4 g).
[1142] 1 H NMR (400MHz, DMSO-d6) δ10.09 (s, 1H), 8.03 (d, J = 8.00Hz, 1H), 7.70 (q, J = 6.80Hz, 1H) ,7.27(q,J=1.20Hz,1H),6.54(q,J=2.00Hz,1H),6.42(t,J=2.80Hz,1H),5.19(s,2H);
[1143] MS: m / z 232.9 (M+1).
[1144] Example 33, Step 2: Preparation of 1-[(2,3-diaminophenyl)methyl]-2,3-dihydro-1H-imidazol-2-one
[1145]
[1146] To a degassed solution of 1-[(2,1,3-benzothiadiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one (from Example 33, Step 1) (0.6 g, 2.58 mmol) in anhydrous methanol (43 mL), 1.8 g of riconene nickel (300% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was subjected to a hydrogen atmosphere and a pressure of approximately 1.5 kg / cm². 2The mixture was stirred at ambient temperature for 24 h. The reaction mixture was filtered through a diatomaceous earth bed, which was then washed with methanol (150 mL). The combined filtrates were concentrated at 20 °C to give a brown gel-like substance, 1-[(2,3-diaminophenyl)methyl]-2,3-dihydro-1H-imidazol-2-one (0.22 g), which could be used in the next step without further purification.
[1147] MS: m / z 205.1 (M+1).
[1148] Example 33, Step 3: Preparation of 2-[({2-amino-3-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[1149]
[1150] Add [2-(3-chloro-4-fluoro-phenyl)-2-isothiocyanopropyl]2,2-dimethylpropionate (from Example 8, step 7) (0.42 g, 1.29 mmol) to a solution of 1-[(2,3-diaminophenyl)methyl]-2,3-dihydro-1H-imidazol-2-one (from Example 33, step 2) (0.22 g, 1.08 mmol) in acetonitrile (5 mL) and stir at room temperature for 48 h. The reaction mixture was concentrated at 30°C to give a colorless gel-like product 2-[({2-amino-3-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers) (0.35 g), which can be used in the next step without further purification.
[1151] MS: m / z 534.2 (M+1).
[1152] Example 33, Step 4: Preparation of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate
[1153]
[1154] Iodoacetic acid (0.183 g, 0.983 mmol) was added to a solution of 2-[({2-amino-3-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-[({2-amino-6-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]phenyl}carbamoylthio)amino]-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers) (from Example 33, Step 3) (0.35 g) in methanol (10 mL), and the mixture was refluxed for 2 h. The reaction mixture was concentrated at 30°C to remove the solvent methanol, yielding a crude product, which was purified by preparative HPLC (0.1% TFA in acetonitrile:water) to give a yellow solid 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate (0.07 g), which was separated as a trifluoroacetate.
[1155] MS: m / z 500.1 (M+1).
[1156] Example 33, Step 5: Preparation of 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one]
[1157]
[1158] 0.5N sodium hydroxide was added dropwise to a solution of 2-(3-chloro-4-fluorophenyl)-2-({4-[(2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propyl 2,2-dimethylpropionate trifluoroacetic acid hydrochloride (from Example 33, Step 4) (0.07 g, 0.140 mmol) in methanol (2.8 mL, 1.40 mmol), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated to obtain a brown gel, which was purified by preparative HPLC (0.1% FA in acetonitrile:water) to give a colorless gel 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one (0.025 g).
[1159] 1 H NMR (400MHz, AcOH-d4) δ7.67 (dd, J=2.40, 6.80Hz, 1H), 7.53-7.49 (m, 1H), 7.42 (d, J=7.60Hz, 1H), 7.24-7. 20(m,3H),6.50(s,2H),5.00-4.89(m,2H),4.20(d,J=12.00Hz,1H),4.01(d,J=12.00Hz,1H),1.84(s,3H);
[1160] MS: m / z 416.1 (M+1).
[1161] Example 34: Preparation of 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]imidazolidine-2-one]
[1162]
[1163] Starting with imidazolidine-2-one (commercially available) (1.0 g, 11.615 mmol), 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]imidazolidine-2-one (0.100 g) was prepared using the method described in Example 33, and isolated as a white solid.
[1164] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.50(d,J=6.80Hz,1H),7.36(s,1H),7.27(t,J=8.80Hz,1H),7.08(d,J=7.20Hz,1H),7.01(d,J= 7.60Hz,1H),6.87(d,J=7.60Hz,1H),4.31(s,1H),4.20(s,1H),3.65(d,J=10.80Hz,2H),2.99(t,J=7.20Hz,4H),1.64(s,3H);
[1165] MS: m / z 418.0 (M+1).
[1166] Example 35: Preparation of 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-3-methylimidazolium-2-one]
[1167]
[1168] Starting with 1-methylimidazolidine-2-one (commercially available) (1.0 g, 9.988 mmol), instead of 2,3-dihydro-1H-imidazolidine-2-one, 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-3-methylimidazolidine-2-one (0.150 g) was prepared using the method described in Example 33 and separated as a gray solid.
[1169] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.63(t,J=2.00Hz,1H),7.40-7.38(m,3H),7.22-7.14(m,2H),4.35(d ,J=10.40Hz,2H),3.72(t,J=6.40Hz,2H),3.24-3.16(m,4H),2.66(d,J=12.40Hz,3H),1.75(s,3H);
[1170] MS: m / z 432.0 (M+1).
[1171] Example 36: Preparation of 3-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-1,3-thiazolidin-2-one]
[1172]
[1173] Starting with 1,3-thiazolidin-2-one (commercially available) (0.5 g, 4.85 mmol), instead of 2,3-dihydro-1H-imidazol-2-one, 3-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-1,3-thiazolidin-2-one (0.2 g) was prepared using the method described in Example 33 and separated as a colorless gel.
[1174] 1 H NMR (400MHz, AcOH-d4) δ7.67(dd,J=2.40,6.80Hz,1H),7.66-7.47(m,2H),7.29-0.22(m,2H),7.18(d,J=6.80Hz,1H),4.67(d,J=15.20 Hz,1H),4.50(d,J=15.20Hz,1H),4.27(d,J=12.00Hz,1H),4.03(d,J=12.00Hz,1H),3.64-3.55(m,2H),3.31-3.18(m,2H),1.81(s,3H);
[1175] MS: m / z 435.0 [(M+1)-TFA].
[1176] Example 37: Preparation of 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]pyrrolidone
[1177]
[1178] Starting with pyrrolidone-2-one (commercially available) (1.0 g, 11.750 mmol), instead of 2,3-dihydro-1H-imidazol-2-one, 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]pyrrolidone-2-one (0.130 g) was prepared using the method described in Example 33. It was isolated as a trifluoroacetate salt and was a grayish-white solid.
[1179] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.63-7.61(m,1H),7.41-7.37(m,2H),7.35-7.30(m,1H),7.23-7.14(m,2H),4.45(q ,J=14.80Hz,2H),3.71(t,J=11.60Hz,2H),3.27(t,J=7.20Hz,2H),2.26-2.21(m,2H),1.92(s,2H),1.80(s,3H);
[1180] MS: m / z 417.1 (M+1).
[1181] Example 38: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]-methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1182]
[1183] Example 38, Step 1: Preparation of N-[(2,1,3-benzothiadiazol-4-yl)methyl]-1,3-oxazol-2-amine
[1184]
[1185] Titanium isopropoxide (IV) (17.4 mL, 58.5 mmol) was added to a solution of 2,1,3-benzothiadiazole-4-carboxaldehyde (from Example 9, Step 2) (0.8 g, 4.87 mmol) in ethanol (50 mL) cooled to 0 °C, and the reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture was cooled to 0 °C, and sodium borohydride (0.368 g, 9.75 mmol) was added in portions, and the reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture was quenched with ice-cold water (50 mL), filtered through a diatomaceous earth bed, and washed with ethyl acetate (50 mL). The filtrate was concentrated, the crude mixture was diluted with water (50 mL), and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with a brine solution (50 mL), dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (1.1 g). The sample was purified by silica gel column chromatography and eluted with 38% ethyl acetate in petroleum ether to give a grayish-white solid N-[(2,1,3-benzothiadiazol-4-yl)methyl]-1,3-oxazol-2-amine (0.450 g).
[1186] 1 H NMR(400MHz, DMSO-d6)7.99(d,J=8.80Hz,1H),7.86(m,1H),7.70(t,J=6.80Hz,1H),7.6 0-7.58(m,1H),7.45(d,J=0.80Hz,1H),6.75(d,J=0.40Hz,1H),4.88(d,J=2.00Hz,2H);
[1187] MS: m / z 233.1(M+1).
[1188] Example 38, Step 2: Preparation of 3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl-1,2-diamine
[1189]
[1190] To a degassed solution of N-[(2,1,3-benzothiadiazol-4-yl)methyl]-1,3-oxazol-2-amine (from Example 38, Step 1) (0.400 g, 1.72 mmol) in methanol (40 mL), 1.5 g of riconene nickel (300% w / w, pre-washed five times with anhydrous methanol) was added, and the resulting reaction mixture was subjected to hydrogen pressure (approximately 1.5 kg / cm²). 2The mixture was stirred at ambient temperature for 16 hours. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under high vacuum to obtain a brown liquid 3-{[(1,3-oxazol-2-yl)amino]methyl}benzene-1,2-diamine (0.285 g), which could be used in the next step without further purification.
[1191] MS: m / z 205.2(M+1).
[1192] Example 38, Step 3: Preparation of 2-{[(2-amino-3-{[(1,3-oxazol-2-yl)amino]methyl}-phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[1193]
[1194] To a solution of 3-{[(1,3-oxazol-2-yl)amino]methyl}benzene-1,2-diamine (from Example 38, step 2) (0.275 g, 1.25 mmol) in a dichloromethane:methanol (1:1, 8 mL) mixture, 2-(3-chloro-4-fluorophenyl)-2-isothiocyanopropyl-2,2-dimethylpropionate (from Example 8, step 7) (0.453 g, 1.37 mmol) was added, and the mixture was stirred at ambient temperature for 40 h. The reaction mixture was concentrated to give a brown, gelatinous crude product (0.620 g), which could be used in the next step without further purification.
[1195] MS: m / z 534.1 (M+1).
[1196] Example 38, Step 4: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate
[1197]
[1198] Iodoacetic acid (0.259 g, 1.39 mmol) was added to a solution of 2-{[(2-amino-3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)-carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(3-chloro-4-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers) (from Example 38, Step 3) (0.620 g, 1.16 mmol) in methanol (15 mL). The reaction mixture was stirred at ambient temperature for 5 h, concentrated, and diluted with ice-cold water (50 mL). The aqueous layer was extracted with dichloromethane (3 × 50 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (50 mL), then washed with brine solution (50 mL), dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (0.260 g). This was purified by preparative HPLC (0.1% TFA in acetonitrile:water) to give a brown solid 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (0.125 g).
[1199] 1 H NMR(400MHz,DMSO-d6)δ11.93(s,1H),8.51(s,2H),7.71-7.62(m,2H),7.47-7.23(m,3 H),7.01-6.96(m,1H),6.80-6.72(m,2H),4.54-4.45(m,4H),1.82(s,3H),1.06(s,9H);
[1200] MS: m / z 500.2(M+1).
[1201] Example 38: Preparation of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1202]
[1203] To a solution of 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (from Example 38, Step 4) (0.085 g, 0.17 mmol) in methanol (0.68 mL, 0.34 mmol), 0.5 N sodium hydroxide in methanol was added, and the reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated, and the residue was diluted with water (10 mL). The aqueous layer was extracted with dichloromethane (3 × 15 mL). The combined organic layers were washed with water (10 mL), then washed with a brine solution (10 mL), dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (120 mg). The product was purified by preparative HPLC (method: 10 mmol ammonium acetate in water: acetonitrile) to obtain a grayish-white solid 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol (0.028 g).
[1204] 1 H NMR (400MHz, CD3OD) δ7.61-7.58(m,1H),7.46-7.42(m,1H),7.29(m,1H),7.19(t,J=8.80Hz,1H),7.13-7.11(m,1 H),6.97-6.95(m,2H),6.78(s,1H),4.60(s,2H),3.95(d,J=11.60Hz,1H),3.81(d,J=11.60Hz,1H),1.31(s,3H);
[1205] MS: m / z 416.1 (M+1).
[1206] Example 39: Preparation of 2-(4-chloro-3-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1207]
[1208] Using commercially available 1-(4-chloro-3-fluorophenyl)ethane-1-one and 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5), the desired product was obtained according to the method described in Example 18, and its two enantiomers were separated.
[1209] Example 39a: 2-(4-chloro-3-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (enantiomer a)
[1210] 1 H NMR (400MHz, DMSO-d6:D2O): δ7.77(d,J=10.40Hz,1H),7.57(t,J=8.00Hz,1H),7.46(d,J=10.80Hz,1H),7.37-7 .21(m,3H),7.18(d,J=7.60Hz,1H),7.10(t,J=5.60Hz,1H),5.27(d,J=10.80Hz,2H),3.59(m,2H),1.76(s,3H);
[1211] MS: m / z 416.0 [(M+1)-HCl].
[1212] Example 39b: 2-(4-chloro-3-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol (enantiomer b)
[1213] 1 H NMR(400MHz, DMSO-d6:D2O)δ7.76(s,1H),7.56(t,J=8.00Hz,1H),7.45(dd,J=2.00,11.20Hz,1H),7 .35(d,J=8.00Hz,1H),7.23(m,3H),7.09(d,J=7.60Hz,1H),5.26(s,2H),3.69(m,2H),1.75(s,3H);
[1214] MS: m / z 416.1 [(M+1)-HCl].
[1215] Example 40: Preparation of 2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]-methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1216]
[1217] Example 40, Step 1: Preparation of 2-{[(2-amino-3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(4-chloro-3-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(4-chloro-3-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers)
[1218]
[1219] Add 2-(4-chloro-3-fluorophenyl)-2-isothiocyanopropyl 2,2-dimethylpropionate (1.63 g, 4.94 mmol) (prepared from commercially available 1-(4-chloro-3-fluorophenyl)ethane-1-one by the method described in steps 1 to 7 of Example 3) to a solution of 3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl-1,2-diamine (from Example 38, step 2) (1.2 g, 4.94 mmol) in a dichloromethane:methanol (1:1, 24 mL) mixed solvent. The reaction mixture was stirred at room temperature for 24 h, and then concentrated in a water bath at 30 °C to give a yellow gel-like substance 2-{[(2-amino-3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(4-chloro-3-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(4-chloro-3-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers) (2.80 g), which can be used in the next step without further purification.
[1220] MS: m / z 534.0 (M+1).
[1221] Example 40, Step 2: Preparation of 2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate
[1222]
[1223] Iodoacetic acid (0.975 g, 5.24 mmol) was added to a solution of 2-{[(2-amino-3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(4-chloro-3-fluorophenyl)propyl 2,2-dimethylpropionate and 2-{[(2-amino-6-{[(1,3-oxazol-2-yl)amino]methyl}phenyl)carbamoylthio]amino}-2-(4-chloro-3-fluorophenyl)propyl 2,2-dimethylpropionate (a mixture of regioisomers) (from Example 40, Step 1) (2.80 g, 5.24 mmol) in methanol (30 mL), and the mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated at 30 °C to remove the solvent methanol, yielding a crude product, which was dissolved in DCM, washed with 10% NaHCO3 solution, and then washed with brine solution. The organic layer was dried over sodium sulfate and concentrated to give a brown gelatinous product (2.1 g). This was purified by preparative HPLC (method: 10 mmol ammonium acetate in water: acetonitrile) to give a white solid 2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (1.3 g).
[1224] 1 H NMR (400MHz, DMSO-d6:D2O) δ7.54-7.35(m,4H),7.01(t,J=5.60Hz,1H),6.82-6.71(m,3H),4.54-4.44(m,4H),1.81(s,3H),1.05(s,9H);
[1225] MS: m / z 500.1 (M+1).
[1226] The product from step 2 was separated into two enantiomers by a chiral SFC using the following method: column: Chiral pakOX-H; mobile phase: 0.5% isopropylamine in isopropanol; cosolvent: 40% CO2; flow rate: 5 mL / min; pressure: 100 bar; temperature: 35 °C, yielding two enantiomers, 40a and 40b.
[1227] Example 40, Step 3a: (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]-methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate
[1228] The (+) enantiomer was the first compound eluted from the column.
[1229]
[1230] 1 H NMR(AcOH-d4)δ7.55-7.47(m,2H),7.42-7.40(m,2H),7.29(dd,J=1.60,6.80Hz,1H),7.25-7.19(m,2H),7.16 (d,J=1.60Hz,1H),4.80(s,2H),4.58(d,J=11.60Hz,1H),4.49(d,J=11.60Hz,1H),1.95(s,3H),1.18(s,9H);
[1231] MS: m / z 500.2(M+1);
[1232] SOR:[α]D 23.5 (+)12.80, (MeOH, c=0.5).
[1233] Example 40, Step 3b: (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl-2,2-dimethylpropionate
[1234] (-) The enantiomer is the second compound eluted from the column.
[1235]
[1236] 1 H NMR(400MHz,AcOH-d4)δ7.53-7.47(m,2H),7.43-7.40(m,2H),7.30(dd,J=1.60,6.80Hz,1H),7 .25-0.21(m,2H),7.17(d,J=1.60Hz,1H),4.81(s,2H),4.53(m,2H),1.96(s,3H),1.21(s,9H);
[1237] MS: m / z 500.1(M+1);
[1238] SOR:[α]D 23.2 (-)11.60,(MeOH,c=0.5).
[1239] Example 40a: Preparation of (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1240]
[1241] A solution of 0.5 N sodium hydroxide in methanol (8 mL, 4.00 mmol) was added to a stirred solution of (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]-methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl 2,2-dimethylpropionate (from Example 40, Step 3a) (0.5 g, 1.00 mmol). The reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated, and the residue was diluted with water (5 mL). The aqueous layer was extracted with DCM (3 × 75 mL), the combined organic layers were washed with a brine solution (10 mL), dried over sodium sulfate, filtered, and concentrated to give a crude product (0.36 g) of a grayish-white solid. It was purified by preparative HPLC (method: 10 mmol ammonium acetate in water: acetonitrile) to give a white solid (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol (0.22 g).
[1242] 1 H NMR(400MHz,AcOH-d4)δ7.50-7.40(m,3H),5.60(dd,J=28.02,14.08Hz,1H),7.30-7.21(m,3H),7. 15(d,J=1.20Hz,1H),4.78(s,2H),4.30(d,J=12.00Hz,1H),4.08(d,J=12.00Hz,1H),1.76(s,3H);
[1243] MS: m / z 416.1(M+1);
[1244] SOR:[α]D 23.4 (-)5.60, (MeOH, c=0.5).
[1245] Example 40b: Preparation of (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1246]
[1247] A solution of 0.5 N sodium hydroxide in methanol (7.20 mL, 3.600 mmol) was added to a stirred solution of (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propyl-2,2-dimethylpropionate (from Example 40, step 3b) (0.45 g, 0.900 mmol), and the reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated, and the residue was diluted with water (5 mL). The aqueous layer was extracted with DCM (3 × 75 mL), the combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and concentrated to give a crude product (0.33 g) of a grayish-white solid. It was purified by preparative HPLC (method: 10 mmol ammonium acetate in water: acetonitrile) to give a white solid (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol (0.14 g).
[1248] 1 H NMR(400MHz,AcOH-d4)δ7.49-7.40(m,3H),7.36(d,J=8.40Hz,1H),7.30-7.21(m,3H),7 .15(s,1H),4.79(s,2H),4.30(d,J=12.00Hz,1H),4.08(d,J=12.00Hz,1H),1.76(s,3H);
[1249] MS: m / z 416.1(M+1);
[1250] SOR:[α]D 23.2 (+)4.80, (MeOH, c=0.5).
[1251] Example 41: Preparation of 2-(3-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1252]
[1253] Using commercially available 1-(3-chloro-2-fluorophenyl)ethane-1-one and 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5), the desired product was obtained according to the method described in Example 18, and then separated into two enantiomers.
[1254] Example 41a: (-)-2-(3-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1255] It is separated from its hydrochloride form, which is a grayish-white solid.
[1256] 1 H NMR (400MHz, AcOH-d4) δ7.54-7.41(m,4H),7.33-7.18(m,4H),5.68-5.57(m,2H),4.51(d,J=12.40Hz,1H),4.17(d,J=12.00Hz,1H),1.89(s,3H);
[1257] MS: m / z 416.0 (M+1);
[1258] [α]D 23.0 (-)1.60(MeOH,c=0.5).
[1259] Example 41b: (+)-2-(3-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1260] It is separated from its hydrochloride form, which is a grayish-white solid.
[1261] 1 H NMR(400MHz,AcOH-d4)δ7.57(d,J=1.60Hz,1H),7.48-7.44(m,3H),7.32-7.27(m,2H),7.22-7.1 7(m,2H),5.41(d,J=5.20Hz,2H),4.52(d,J=12.40Hz,1H),4.15(d,J=12.00Hz,1H),1.83(s,3H);
[1262] MS: m / z 416.0 (M+1);
[1263] [α]D 22.5 (+)6.0 (MeOH, c=0.5).
[1264] Example 42: Preparation of 2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1265]
[1266] Using 3-{[(1,3-oxazol-2-yl)amino]methyl}phenyl-1,2-diamine (from Example 38, step 2) and 2-(3-chloro-2-fluorophenyl)-2-isothiocyanopropyl-2,2-dimethylpropionate (prepared from commercially available 1-(3-chloro-2-fluorophenyl)ethane-1-one by the method described in steps 1 to 7 of Example 3), the desired product was obtained according to the method described in Example 40, and then separated into its two enantiomers.
[1267] Example 42a: (+)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1268] It separates into a grayish-white solid.
[1269] 1 H NMR(400MHz,AcOH-d4)δ7.48-7.46(m,2H),7.37-7.34(m,2H),7.28-7.21(m,2H),7.17-7.13(m ,2H),4.78(t,J=16.00Hz,2H),4.52(d,J=13.20Hz,1H),4.17(d,J=12.40Hz,1H),1.81(s,3H);
[1270] MS: m / z 416.0 (M+1);
[1271] [α]D 23.7 (+)39.6 (MeOH, c=0.5).
[1272] Example 42b: (+)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1273] It separates into a grayish-white solid.
[1274] 1 H NMR(400MHz,AcOH-d4)δ7.48-7.44(m,2H),7.36-7.34(m,2H),7.28-7.21(m,2H),7.17-7.13(m ,2H),4.78(t,J=16.00Hz,2H),4.52(d,J=13.20Hz,1H),4.17(d,J=12.80Hz,1H),1.81(s,3H);
[1275] MS: m / z 416.1(M+1);
[1276] [α]D 23.6 (-)37.6 (MeOH, c=0.5).
[1277] Example 43: Preparation of 2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1278]
[1279] Example 43, Step 1: Preparation of (2,1,3-benzothiadiazole-4-yl)methanol
[1280]
[1281] Potassium carbonate (151 g, 1091 mmol) was added to a solution of 4-(bromomethyl)-2,1,3-benzothiadiazole (from Example 1, Step 3) (50 g, 218 mmol) in 1,4-dioxane:water (1:1, 1000 mL), and the reaction mixture was stirred at 100 °C for 20 h. The reaction mixture was cooled to ambient temperature, washed with water (500 mL), and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were washed with a brine solution (300 mL), dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (36 g). This product was purified by silica gel column chromatography, eluting with 25% ethyl acetate in petroleum ether, to give a grayish-white solid (2,1,3-benzothiadiazole-4-yl)methanol (27 g).
[1282] 1 H NMR (400MHz, DMSO-d6) δ7.98-7.96(m,1H),7.75-7.68(m,2H),5.51(t,J=4.00Hz,1H),5.03(d,J=5.60Hz,2H);
[1283] Example 43, Step 2: Preparation of 2,1,3-benzothiadiazole-4-carboxaldehyde
[1284]
[1285] Dess-Martin periodinane (51 g, 120 mmol) was added in portions to a solution of (2,1,3-benzothiadiazole-4-yl)methanol (from Example 43, Step 1) in dichloromethane (400 mL) cooled to 0 °C, and the reaction mixture was stirred at ambient temperature for 1 h. The reaction was quenched with an aqueous sodium bicarbonate solution (300 mL), filtered through a diatomaceous earth bed, and washed with dichloromethane. The filtrate was separated into an aqueous layer and an organic layer. The organic layer was washed with a brine solution (150 mL), dried over sodium sulfate, filtered, and concentrated to give a crude product (12 g) of yellow solid. It was purified by silica gel column chromatography, eluting with 30% ethyl acetate in petroleum ether, to give a grayish-white solid 2,1,3-benzothiadiazole-4-carboxaldehyde (8.0 g).
[1286] 1 H NMR (400MHz, DMSO-d6) δ10.64(s,1H),8.47(dd,J=1.20,8.80Hz,1H),8.31(dd,J=1.20,7.00Hz,1H),7.98-7.94(m,1H);
[1287] MS: m / z 165.1 (M+1).
[1288] Example 43, Step 3: Preparation of N-[(2,1,3-benzothiadiazol-4-yl)methyl]-1,2-oxazol-3-amine
[1289]
[1290] To a solution of 2,1,3-benzothiadiazole-4-carboxaldehyde (from Example 43, Step 2) (4 g, 24.4 mmol) and 1,2-oxazol-3-amine (commercially available, 4.1 g, 48.7 mmol) in ethanol (250 mL) cooled to 0 °C, titanium isopropoxide (IV) (87 mL, 292 mmol) was added, and the reaction mixture was stirred at ambient temperature for 20 h. The reaction mixture was cooled to 0 °C, and sodium borohydride (0.922 g, 24.4 mmol) was added in portions. The reaction mixture was stirred at ambient temperature for 20 h, then quenched with ice water (100 mL), filtered through a diatomaceous earth bed, and washed with ethyl acetate. The filtrate was concentrated, the crude product was diluted with water (100 mL), extracted with ethyl acetate (2 × 100 mL), the combined organic layers were washed with a brine solution (50 mL), dried over sodium sulfate, filtered, and concentrated to give a brown, gelatinous crude product (6.5 g). The sample was purified by silica gel column chromatography and eluted with 42% ethyl acetate in petroleum ether to give a pale yellow solid N-[(2,1,3-benzothiadiazol-4-yl)methyl]-1,2-oxazol-3-amine (3.5 g).
[1291] 1 H NMR(400MHz, DMSO-d6)δ8.40(d,J=2.00Hz,1H),7.98(d,J=8.80Hz,1H),7.72-7.68(m,1H), 7.61-7.59(m,1H),6.86(t,J=6.00Hz,1H),6.06(d,J=1.60Hz,1H),4.80(d,J=6.00Hz,2H);
[1292] MS: m / z 233.1(M+1).
[1293] Example 43, Step 4: Preparation of 3-{[(1,2-oxazol-3-yl)amino]methyl}phenyl-1,2-diamine
[1294]
[1295] Zinc powder (2.82 g, 43.1 mmol) was added to a solution of N-[(2,1,3-benzothiadiazol-4-yl)methyl]-1,2-oxazol-3-amine (from Example 43, Step 3) (2 g, 8.61 mmol) in acetic acid:water (1:1, 40 mL), and the reaction mixture was stirred at room temperature for 20 h. The reaction mixture was washed with water (100 mL), extracted with ethyl acetate (2 × 100 mL), and the combined organic layers were washed with a saline solution (50 mL). The organic layers were dried over sodium sulfate, filtered, and concentrated to give a brown gel-like substance 3-{[(1,2-oxazol-3-yl)amino]methyl}phenyl-1,2-diamine (1.6 g), which could be used in the next step without further purification.
[1296] MS: m / z 205.2(M+1).
[1297] Example 43: Preparation of 2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1298]
[1299] Using 3-{[(1,2-oxazol-3-yl)amino]methyl}phenyl-1,2-diamine (from Example 43, step 4) and 2-(3-chloro-2-fluorophenyl)-2-isothiocyanopropyl 2,2-dimethylpropionate (prepared from commercially available 1-(3-chloro-2-fluorophenyl)ethane-1-one by the method described in steps 1 to 7 of Example 3), the desired product was obtained according to the method described in Example 40, and then separated into its two enantiomers.
[1300] Example 43a: (-)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1301] It separates into a white solid.
[1302] 1 H NMR(400MHz,AcOH-d4)δ8.13(d,J=1.60Hz,1H),7.47-7.42(m,2H),7.36-7.34(m,1H),7.22-7.21(m,2H),7.11(t,J =8.00Hz,1H),5.95(d,J=2.00Hz,1H),4.56(s,2H),4.46(d,J=12.80Hz,1H),4.14(d,J=12.40Hz,1H),1.82(s,3H);
[1303] MS: m / z 416.1(M+1);
[1304] [α]D 23.7 (-)39.84(MeOH,c=0.5).
[1305] Example 43b: (+)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1306] It separates into a white solid.
[1307] 1 H NMR(400MHz,AcOH-d4)δ8.13(d,J=2.00Hz,1H),7.46-7.42(m,2H),7.36-7.33(m,1H),7.23-7.19(m,2H),7.11(t,J =8.00Hz,1H),5.95(d,J=1.60Hz,1H),4.56(s,2H),4.46(d,J=12.80Hz,1H),4.14(d,J=12.40Hz,1H),1.82(s,3H);
[1308] MS: m / z 416.0 (M+1);
[1309] [α]D 23.4 (+)37.68 (MeOH, c=0.5).
[1310] Example 44: Preparation of 2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1311]
[1312] Using 3-{[(1,2-oxazol-3-yl)amino]methyl}phenyl-1,2-diamine (from Example 43, step 4) and 2-(4-chloro-3-fluorophenyl)-2-isothiocyanopropyl 2,2-dimethylpropionate (prepared from commercially available 1-(4-chloro-3-fluorophenyl)ethane-1-one by the method described in steps 1 to 7 of Example 3), the desired product was obtained according to the method described in Example 40, and then separated into its two enantiomers.
[1313] Example 44a: (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1314] It separates into a white solid.
[1315] 1 H NMR (400MHz, AcOH-d4): δ8.16(d,J=1.60Hz,1H),7.48-7.43(m,2H),7.37-7.34(m,1H),7.31-7.28(m,1H),7.22- 7.18(m,2H),5.97(d,J=1.60Hz,1H),4.55(s,2H),4.24(d,J=12.00Hz,1H),4.05(d,J=11.60Hz,1H),1.77(s,3H);
[1316] MS: m / z 416.1(M+1);
[1317] SOR:[α]D 23.7 (-)4.00,(MeOH,c=0.5).
[1318] Example 44b: (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1319] It separates into a white solid.
[1320] 1H NMR (400MHz, AcOH-d4): δ8.16 (d, J=1.60Hz, 1H), 7.48-7.43 (m, 2H), 7.35 (dd, J=2.00, 8.60Hz, 1H), 7.32-7.30 (m, 1H), 7.22-7.19(m,2H),5.97(d,J=1.60Hz,1H),4.55(s,2H),4.24(d,J=12.00Hz,1H),4.05(d,J=12.00Hz,1H),1.77(s,3H);
[1321] MS: m / z 416.1(M+1);
[1322] SOR:[α]D 23.7 (+)3.20, (MeOH, c=0.5).
[1323] Example 45: Preparation of 2-(3-chloro-5-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1324]
[1325] Using commercially available 1-(3-chloro-5-fluorophenyl)ethane-1-one and 3-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]benzene-1,2-diamine (from Example 1, step 5), the desired product was obtained according to the method described in Example 18, and its two enantiomers were separated.
[1326] Example 45a: (-)-2-(3-chloro-5-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1327] It is separated as a hydrochloride salt, which is a grayish-white solid.
[1328] 1 H NMR (400MHz, DMSO-d6) δ10.01(s,2H),7.85(s,1H),7.38(t,J=6.40Hz,5H),7.28(d,J =10.00Hz,1H),7.16(d,J=6.40Hz,2H),5.39(s,2H),3.78-3.71(m,2H),1.81(s,3H);
[1329] MS: m / z 416.1(M+1);
[1330] [α]D 23.2 (-)8.0(MeOH,c=0.5).
[1331] Example 45b: (+)-2-(3-chloro-5-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol
[1332] It is separated as a hydrochloride salt, which is a grayish-white solid.
[1333] 1 H NMR (400MHz, DMSO-d6) δ10.01(s,2H),7.85(s,1H),7.48-7.37(m,4H),7.30-7.15(m,4H),5.40(s,2H),3.78-3.68(m,2H),1.78(d,J=18.80Hz,3H);
[1334] MS: m / z 416.1(M+1);
[1335] [α]D 23.1 (+)7.6 (MeOH, c=0.5).
[1336] Example 46: Preparation of 2-(3-chloro-5-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1337]
[1338] Using 3-{[(1,2-oxazol-3-yl)amino]methyl}phenyl-1,2-diamine (from Example 43, step 4) and 2-(3-chloro-5-fluorophenyl)-2-isothiocyanopropyl 2,2-dimethylpropionate (prepared from commercially available 1-(3-chloro-5-fluorophenyl)ethane-1-one by the method described in steps 1 to 7 of Example 3), the desired product was obtained according to the method described in Example 40, and its two enantiomers were separated.
[1339] Example 46a: (-)-2-(3-chloro-5-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1340] It separates into a white solid.
[1341] 1H NMR(400MHz,AcOH-d4)δ8.17(d,J=2.00Hz,1H),7.42(d,J=1.20Hz,1H),7.32-7.27(m,2H),7.23-7.15(m,2H),7.14 -7.13(m,1H),5.98(d,J=2.00Hz,1H),4.56(s,2H),4.25(d,J=20.00Hz,1H),4.06(d,J=12.00Hz,1H),1.78(s,3H);
[1342] MS: m / z 416.2(M+1);
[1343] [α]D 23.2 (-)9.20(MeOH,c=0.5).
[1344] Example 46b: (+)-2-(3-chloro-5-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol
[1345] It separates into a white solid.
[1346] 1 H NMR(400MHz,AcOH-d4)δ8.17(d,J=1.60Hz,1H),7.42(d,J=1.20Hz,1H),7.32-7.27(m,2H),7.23-7.15(m,2H),7.14 -7.13(m,1H),5.98(d,J=2.00Hz,1H),4.56(s,2H),4.26(d,J=11.60Hz,1H),4.0...
Claims
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof; in A is a 5- or 6-membered aromatic heterocycle containing at least one nitrogen atom and optionally one sulfur atom and optionally one oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 Substitution of at least one group selected from alkylthio and cyano; R1 is selected from hydrogen and C. 1-6 alkyl; Alternatively, A and R1 together with the nitrogen atom to which they are attached form a 5-6 membered aromatic or non-aromatic heterocycle comprising 1-2 nitrogen atoms, optionally 1 oxygen atom, and optionally 1 sulfur atom, optionally selected from halogens, C 1-6 Alkyl groups, halogenated C 1-6 Alkyl, C 1-6 Alkoxy groups, halogenated C 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio, =NH, =O, -OH and cyano groups; R2-R3 are independently selected from hydrogen and C. 1-6 Alkyl groups; R4-R6 are independently selected from hydrogen, halogens, and C. 1-4 Alkyl groups; R7-R8 are independently selected from hydrogen, C 1-4 Alkyl group, C substituted with an OH group 1-4 Alkyl group, with an OC 1-3 Alkyl-substituted C 1-4 Alkyl groups, C substituted with at least one halogen 1-4 alkyl groups, Or R7 and R8 together with the carbon atoms they are attached to form C 3-4 cycloalkyl; R9-R13 are independently selected from hydrogen, halogens, and C atoms substituted with at least one halogen. 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 Alkyl thiols and cyano groups.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein A is a 5-membered aromatic heterocycle comprising 1-3 nitrogen atoms and optionally 1 oxygen atom, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 Substitution of groups in alkylthio and cyano groups.
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein A is a 6-membered aromatic heterocycle comprising 1-3 nitrogen atoms, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 At least one of the groups selected from alkylthio and cyano is substituted.
4. The compound according to claim 2 or 3, or a pharmaceutically acceptable salt thereof, wherein A is selected from imidazole, pyrazol, oxazol, isoxazol, oxadiazol, and pyrimidinyl, optionally selected from halogens, C 1-6 Alkyl groups, C substituted with at least one halogen 1-6 Alkyl, C 1-6 Alkoxy groups, C substituted with at least one halogen 1-6 Alkoxy, C 1-6 At least one of the groups selected from alkylthio and cyano is substituted.
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from hydrogen (H) and methyl.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is H.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein A and R1 together with the nitrogen atom to which they are attached form a 5-membered non-aromatic heterocycle comprising 1-2 nitrogen atoms and 1 oxygen atom, said 5-membered non-aromatic heterocycle being substituted with one, two or three groups selected from methyl and =NH.
8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R2-R3 are independently selected from H and C. 1-3 Alkyl groups.
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2-R3 are all H.
10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4-R6 are independently selected from H, F, Cl and methyl groups.
11. The compound of claim 10 or a pharmaceutically acceptable salt thereof, wherein R4-R6 are all H.
12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R7 is selected from H and C. 1-3 Alkyl groups.
13. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R8 is selected from C 1-4 Alkyl group, C substituted with an OH group 1-4 Alkyl groups, and those with an OC 1-3 Alkyl-substituted C 1-4 Alkyl groups.
14. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R7 and R8 together with the carbon atoms to which they are attached form a cyclopropyl group.
15. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R9-R13 are independently selected from H, halogens, and C substituted with at least one halogen. 1-6 Alkyl groups and C groups substituted with at least one halogen 1-6 The group in alkoxy.
16. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R9, R12, and R13 are all H, and R10-R11 are independently selected from H, halogens, and C substituted with at least one halogen. 1-6 Alkyl groups and C groups substituted with at least one halogen 1-6 The group in the alkoxy group; the condition is that R10 and R11 are not both H.
17. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R9, R10, R11 and R12 are each selected from H and halogen groups, and R13 is H.
18. The compound according to claim 1, wherein the compound is selected from any one of the following: N-[1-(3-chlorophenyl)cyclopropyl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazole-2-amine N-[2-(3-chlorophenyl)propane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-amine, 2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(3-Chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3-chlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-N-{1-[3-(trifluoromethyl)phenyl]ethyl}-1H-1,3-benzodiazole-2-amine, 2-(3-Chlorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-amine, 4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-N-{2-[3-(trifluoromethyl)phenyl]propane-2-yl}-1H-1,3-benzodiazol-2-amine, 2-(3-Chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, N-[2-(3-chlorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-amine 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(pyrimidin-4-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(3-chloro-4-fluorophenyl)-2-((4-((((5-methylisoxazol-3-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol, (+)-2-(3-chloro-4-fluorophenyl)-2-((4-((((5-methylisoxazol-3-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol, 2-(3-Chloro-4-fluorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3-Chloro-4-fluorophenyl)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, N-[2-(3-chloro-4-fluorophenyl)-1-methoxypropane-2-yl]-4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-amine, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(5-methyl-1,2,4-oxadiazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(3-chloro-4-fluorophenyl)-2-((4-(((5-methyl-1,3,4-oxadiazol-2-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)propane-1-ol, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(3-methyl-1,2,4-oxadiazol-5-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, (-)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, (+)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, 2-(3,4-Dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(3,4-Dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3,4-dichlorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-(3-Chloro-4-fluorophenyl)-2-({4-[(2-imino-4,5-dimethyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-((4-(((1-methyl-1H-pyrazol-5-yl)amino)methyl)-1H-benzi[d]imidazol-2-yl)amino)-2-(3-(trifluoromethyl)phenyl)propane-1-ol, 2-((4-(((1-methyl-1H-imidazol-2-yl)amino)methyl)-1H-benzo[d]imidazol-2-yl)amino)-2-(3-(trifluoromethyl)phenyl)propane-1-ol, 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, (-)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, (+)-2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, (-)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, (+)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]propane-1-ol, 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]butane-1-ol, 3-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-3-[3-(trifluoromethyl)phenyl]butane-1-ol, 2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol, (+)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol, (-)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol, 2-({4-[(2-imino-4,5-dimethyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethyl)phenyl]-propane-1-ol, 2-({4-[(2-imino-4-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]propane-1-ol, 2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)phenyl]-propane-1-ol, (-)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propane-1-ol, (+)-2-({4-[(2-imino-5-methyl-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)-2-[3-(trifluoromethoxy)-phenyl]propane-1-ol, 2-(3-chloro-4-fluorophenyl)-2-[(4-{1-[(1,3-oxazol-2-yl)amino]ethyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(3-Chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazolyl-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3-chloro-4-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-thiazo-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-2,3-dihydro-1H-imidazol-2-one, 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]imidazolidine-2-one, 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-3-methylimidazolidine-2-one, 3-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]-1,3-thiazolidin-2-one, 1-[(2-{[2-(3-chloro-4-fluorophenyl)-1-hydroxypropane-2-yl]amino}-1H-1,3-benzodiazol-4-yl)methyl]pyrrolidone-2-one, 2-(3-chloro-4-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]-methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(4-chloro-3-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(4-chloro-3-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(4-chloro-3-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]-methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(3-Chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(3-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3-Chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(3-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(4-chloro-3-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(3-chloro-5-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(3-chloro-5-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(3-chloro-5-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-(3-chloro-5-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(3-chloro-5-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(3-chloro-5-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(5-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (-)-2-(5-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, (+)-2-(5-chloro-2-fluorophenyl)-2-({4-[(2-imino-2,3-dihydro-1,3-oxazol-3-yl)methyl]-1H-1,3-benzodiazol-2-yl}amino)propane-1-ol, 2-(5-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(5-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(5-chloro-2-fluorophenyl)-2-[(4-{[(1,3-oxazol-2-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, 2-(5-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (+)-2-(5-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, (-)-2-(5-chloro-2-fluorophenyl)-2-[(4-{[(1,2-oxazol-3-yl)amino]methyl}-1H-1,3-benzodiazol-2-yl)amino]propane-1-ol, Or its pharmaceutically acceptable salt.
19. A pharmaceutical composition comprising the compound of any one of claims 1-18 and a pharmaceutically acceptable additive.
Citation Information
Patent Citations
2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
WO2006013210A2
Novel potassium channel inhibitors
CN109153667A
Substituted benzimidazoles as potassium channel inhibitors
CN111344281A
